






CHEMICAL BIOLOGY OF METALLOPROTEASES 


































CHEMICAL BIOLOGY OF METALLOPROTEASES 












A THESIS SUBMITTED 
FOR THE DEGREE OF DOCTOR OF PHILOSOPHY 
 
DEPARTMENT OF CHEMISTRY 







I would like to express my sincere gratitude to my supervisor Professor Yao Shao 
Qin for his guidance, encouragement and continuous support throughout my Ph.D 
studies. The extensive knowledge, vision, and creative thinking of Prof. Yao have 
been the source of inspiration for me throughout my studies. Under his supervision 
and training, I have learnt a lot about the research field of Chemical biology, and have 
made great improvement on my mental discipline, leadership skills, and planning 
ability. I would like to take this opportunity to extend my best wishes to him and hope 
his research group will attain greater success in the future.  
Next, I am very thankful to a number of my senior lab-mates in both Chemistry 
and DBS labs: Wang Jun, Mahesh, Li Junqi, Rajavel Srinivisan, Sun Hongyan, Resmi 
C. Panicker, Dr. Sun Liping, Ng Su Ling, Chattopadhaya Souvik, Huang Xuan, Tan 
Lay Pheng, Candy Lu, Wei Lin. They gave me a lot of help and support during my 
first 1-2 years study, which was probably the hardest time for me. Besides, I also have 
many thanks to those junior lab-mates such as Kalesh, Wu Hao, Yang Pengyu, Shi 
Haibin, Liu Kai, Liqian, Ge Jingyan, Dr. Li Lin, Zhang Chongjing, Cheng Xiamin, Na 
Zhenkun, Su Ying, Tan Ching Tian, Lee Jiexun, Zhang Xiaohua, Tan Mei Xuan, Lee 
Mei Ying, Wendy Leong, Ong Li Bing, David Ng, Derek Sim, Low Joo Leng, 
Shuyun, Yuhui, Tan Choon Meng, Liang Xian, Kaijia, Wee Liang, Farhana, Kitty, 
Cindy, Wang Jigang, Dr. Li Zhengqiu and Wu Xiaoyuan. Working with all of them 
has been a great experience and happy time for me. 
II 
 
I appreciate the support of the service laboratory staff –– Ms Ler Peggy and Mdm 
Han Yanhui from the NMR lab, Mdm Lai Hui Ngee and Mdm Wong Lai Kwai from 
the Mass Spectrometry lab, Mdm Tong Yan and Dr. Xiao Yong from DBS confocal 
Lab –– in providing training and technical expertise.  
I would like to express my greatest thanks to my parents for their understanding 
and supports over these years. This thesis will be dedicated to them. 
Last but not least, I am also grateful to the National University of Singapore, for 
providing me the opportunity and scholarship for my research study. 
 
 
I greatly acknowledge the following who had helped in part of the work 
described in this thesis: 
1. In Chapter 2, the PTP probes 2-P5 and 2-P6 were synthesized and characterized 
by Su Ying. The two-photon dye 2-24 was designed and synthesized by Dr. Li 
Lin and he also participated in the two-photon image experiment. The bacteria 
lysates and transfected HeLa cells were provided by Wu Hao. Mass Spectrometry 
analysis was carried out by Wang Jigang in A/P Lin Qingsong’s lab. 
2. In Chapter 4 and 5, a proportionate amount of work was done by my senior 
lab-mate Mr Wang Jun. My major contribution is the synthesis of eight warheads. 





Table of Contents 
Page 
Summary                    VIII 
List of Publications                 IX 
List of Figures                  XI 
List of Tables                   XIV 
List of Schemes                        XV 
List of Abbreviations and Symbols              XVI 
List of 20 Natural Amino Acids                XX 
 
Chapter 1.  Introduction             1 
1.1  Summary                1 
 1.2  Chemical Biology of Metalloproteases        2 
  1.2.1  The Nature of Matrix Metalloproteases       2 
  1.2.2  Development of MMP Inhibitors        4 
   1.2.2.1  Hydroxamic acid-based MMP Inhibitors     5 
   1.2.2.2  Non-Hydroxamic acid-based MMP Inhibitors    9 
 1.3  Chemical Biology of Cysteine Proteases        14 
  1.3.1  The Nature of Caspases          14 
  1.3.2  Activity-based protein profiling        17 
  1.3.3  Fluorescent Probes for Bioimaging Applications     18 
 1.4  Project Objective             20 
IV 
 
Chapter 2.  Multicolor, One- and Two-Photon Imaging of Enzymatic  
Activities in Live Cells with Fluorescently Quenched  
Activity-Based Probes (qABPs)         22 
 2.1  Summary               22 
 2.2  Introduction              23 
 2.3  Results and Discussion            28 
  2.3.1  Design Principle of Quinone (or Quinolimine) Methide- 
Based qABPs             28 
  2.3.2  Chemical Synthesis of the Probes        29 
  2.3.3  Mechanistic Studies of the Probes with Recombinant Enzymes 32 
  2.3.4  In-Cell Bioimaging of Apoptosis Using qABPs     36 
  2.3.5  One- and Two-Photon qABPs for Tyrosine Phosphatases   39 
  2.3.6  Live Cell Imaging with CPP-Containing Probe (2-P7)   43 
 2.4  Conclusion               45 
Chapter 3.  In Situ “Click” Assembly of Small Molecule Matrix 
Metalloprotease Inhibitors Containing Zinc-Chelating  
Groups              47 
 3.1  Summary               47 
 3.2  Introduction              47 
3.3  Results and Discussion            49 
3.3.1  Design and synthesis of our new small molecule MMPIs   49 
3.3.2  Inhibitor Fingerprinting with MMPs        51 
V 
 
3.3.3  Docking Simulations            54 
3.4  Conclusion               55 
Chapter 4.  Rapid Assembly of Matrix Metalloprotease Inhibitors  
Using Click Chemistry           56 
4.1  Summary               56 
4.2  Introduction              57 
4.3  Results and Discussion            58 
4.3.1  Design and synthesis of alkyne and azide building blocks   58 
4.3.2  Rapid assembly and in situ screening of metalloprotease  
inhibitors              61 
4.3.3  Docking Simulations           64 
4.4  Conclusion               65 
Chapter 5.  “Click” Synthesis of Small Molecule Probes for Activity-based 
Fingerprinting of Matrix Metalloproteases      66 
5.1  Summary               66 
5.2  Introduction              66 
5.3  Results and Discussion            68 
5.3.1  Chemical design of the activity-based MMP probes    68 
5.3.2  Activity based fingerprinting of metalloproteases    69 
5.4  Conclusion               72 
Chapter 6.  Experimental Procedures          73 
6.1  General Information            73 
VI 
 
6.2  Solution Phase Synthesis           75 
6.2.1  General Procedure for Synthesis of Dabcyl-containing linker  75 
6.2.2  General Procedure for Synthesis of probe 2-P1 to 2-P4   77 
6.2.3  General Procedure for Synthesis of 2-P5 (1-P PTP) and  
2-P6 (2-P PTP)            89 
6.2.4  General Procedure for Synthesis of Alkyne building blocks  
(3-D and 3-E)             97 
6.2.5  General Procedure for Synthesis of Azide building blocks (3-C) 99 
6.2.6  Synthesis of succinyl hydroxamate-based alkyne-containing 
warheads (4-8)            105 
6.2.7  Synthesis of succinyl hydroxamate-based warheads with P1’ 
substitution             123 
6.2.8  General Procedure of in situ Click Chemistry      129 
6.3  Solid Phase Synthesis            131 
6.3.1  Loading of Fmoc-Lys(Biotin)-OH onto Rink Amide AM Resin 131 
6.3.2  General procedure for Fmoc deprotection      131 
6.3.3  General procedure for coupling of Fmoc-amino acids   132 
6.3.4  Procedure for coupling of compound 2-17      132 
6.3.5  Procedure for coupling of Fluorescein(OAc)2-NHS    132 
6.3.6  Cleavage of peptide from resin         133 
6.3.7  Purification of the peptides         133 
6.4  Microplate-Based Enzyme Profiling Procedures      134 
VII 
 
6.4.1  Caspase activity assay on microplate       134 
6.4.2  High-Throughput Inhibitor Screening against MMPs    135 
6.4.3  IC50 Measurements against MMPs        137 
6.4.4  Ki
 
Measurements against MMPs        138 
6.5  Gel-Based Labeling Experiments with 2-P1 and 2-P5     138 
6.6  Western Blot              140 
6.7  Mass Spectrometry             140 
6.8  Cell Culture               141 
6.9  Transfection Experiment           141 
6.10  Live Cell Imaging             142 
6.11  Docking Simulations            143 
Chapter 7.  Conclusion Remarks           144 
7.1 Conclusion               144 
Chapter 8.  References              145 
Chapter 9.  Appendix              160 
9.1  Supplemental Tables            160 
9.2  Supplemental Figures            162 







Proteases are known to recognize a larger number of different substrates and are 
involved in almost every process in the cells. Abnormal proteases activities are linked 
to many serious diseases, such as cancer, inflammation, arteriosclerosis, 
neurodegeneration and infection. Due to their essential roles in physiological and 
pathological events, proteases are very important targets for drug development. 
Therefore, it will be interesting to establish a chemical biology platform to study and 
understand the activities, localizations and functions of different enzymes. In this 
thesis, we report a high-throughput strategy for assembling and in-situ screening of 
small molecule-based MMP inhibitors. A “one-pot” click chemistry protocol was 
developed for this application (Chapter 3). Furthermore, we also successfully 
developed fluorescent quenched activity-based probes suitable for biomedical 
applications (Chapter 2). This approach provides real-time imaging of endogenous 
Caspase-3/7 activities in the apoptotic cells and could potentially target different 
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Recent evidence suggests that 18-29% of eukaryotic genomes encode enzymes.
1
 
The different classes of enzymes each have different roles to play. For example, the 
phosphorylation/dephosphorylation of biomolecules, are performed by phosphatases 
and kinases, and this intricate control forms the basis of cell cycle regulation, signal 
transduction and cellular communication. Another major class of enzymes is the 
proteases, which participate in numerous physiological processes such as cell growth 
and differentiation, metabolism and cell death. The different classes of proteases are 
distinguished by the mode of proteolysis and the relevant residues in the enzyme 
active site. Aspartate and metalloproteases are able to polarize a water molecule that 
acts as the nucleophile in proteolysis, while serine, threonine and cysteine proteases 
cleave their substrates through a nucleophilic amino acid side chain in the enzyme 
active site.
2
 However, the number of these enzymes that have been characterized are 
limited, and even less is understood about the physiological roles, substrate specificity 
and downstream targets of the vast majority of these important proteins. Consequently, 
a lot of efforts have been put in to establish the chemical biology platform for better 
understanding of the activity, biochemistry and cellular pathways controlled by 
enzymes, as well as in seeking novel pharmaceutical leads to modulate their activities. 
2 
 
1.2 Chemical Biology of Metalloproteases 
Metalloproteases, together with serine, threonine, cysteine, aspartate and glutamic 
acid proteases, represent the six major classes of proteolytic enzymes which mediate 
the hydrolysis of the scissile amide bond. These proteases have been found to be 
involved in a variety of cell functions such as DNA replication, cell-cycle 
progression, cell proliferation, differentiation, migration. Deregulations of protease 
activities are known to cause many diseases such as cancer, HIV, malaria, 
Alzheimer’s diseases，inflammation and arthritis.3-4 Thus, around 5-10% of overall 




1.2.1 The Nature of Matrix Metalloproteases 
Matrix metalloproteases (MMPs), also known as Matrixins, constitute a family of 
zinc-dependent endoproteinases which are involved in tissue remodeling and 
degradation of all components of the extracellular matrix (ECM), angiogenesis and 
cell motility. MMPs are expressed by a variety of connective tissue and 
pro-inflammatory cells as inactive zymogens, which are subsequently processed by 
other proteolytic enzymes (serine proteases, furin, plasmin and others) to generate the 
active forms.
7
 Tissue inhibitors of metalloproteases (TIMPs) are the endogenous 
inhibitors of MMPs but, in cancer or in other degenerative pathologies, their 
misregulation leads to an ‘overexpression’ of some of these proteases.8-9 Abnormal 
MMP activities are linked to many serious diseases such as cancer, HIV, malaria, 
3 
 
Alzheimer’s diseases. Therefore, the design of selective MMP inhibitors (MMPIs) is 
desired. 
Currently, at least 26 human MMPs are known, and they may be subdivided into 










Certain studies have been made to delineate the reaction mechanism for 
proteolysis by MMPs.
10-11
 In Figure 1-1, the reaction mechanism for proteolysis by 
MMPs can be clearly seen. It is proposed that the scissile amide carbonyl coordinates 
to the active-site zinc(II) ion. This carbonyl is attacked by a water molecule, which is 
hydrogen bonded to a conserved glutamic acid (Glu-198 in MMP-8) and at the same 
time coordinated to the zinc(II) ion. The water donates a proton to the Glu residue 
which transfers it to the nitrogen of the scissile amide. This is followed by the Glu 
residue shuttling the remaining proton from the water molecule to the nitrogen of the 
scissile amide with resultant peptide bond cleavage. During this process the positively 
charged zinc(II) ion helps to stabilize the negative charge at the carbon of the scissile 
4 
 
amide and a conserved alanine (Ala-161 in MMP-8) helps to stabilize the positive 
charge at the nitrogen of the scissile amide.
11
 
The active site of MMPs consists of two distinct regions: a groove near the 
protein surface which is centered on the catalytic zinc ion and an S1’ specificity site 
that varies considerably among members of the family. The S1’ subsite apparently 
plays a significant role in determining the substrate specificity in the active enzymes. 
From X-ray crystallographic analysis and homology modeling the MMPs may be 
classified as falling into two broad structural classes dependent on the depth of the S1’ 
pocket. This “selectivity pocket” is relatively deep for the majority of the enzymes 
(e.g., MMP-2, MMP-9, MMP-3, MMP-8, MMP-13, etc.), but for certain enzymes 
(e.g., MMP-1, MMP-7, and MMP-11) it is partially or completely occluded due to an 
increase in the size of the side chain of the amino acid which form the S1’ pocket.
12
 
Since the structural differences between MMP families occur mainly in the S1’ 
subsite, modifications of the P1’ group have been utilized to introduce inhibitor 
selectivity. 
 
1.2.2 Developing MMP Inhibitors 
Much efforts have been put on the developing the inhibitors of Matrix 
metalloproteases. To be an effective inhibitors of the MMP class of enzymes, a 
molecule need contain at least three parts: i) a functional group (e.g. carboxylic acid, 
hydroxamic acid and sulfhydryl etc.) capable of chelating the active site zinc (II) ion 
(this will be referred to as the zinc binding group or ZBG), ii) at least one functional 
5 
 
group which provides a hydrogen bond interaction with the enzyme backbone and iii) 
one or more side chains which undergo effective van der Waals interactions with the 
enzyme subsites.
3
 To develop potent MMP inhibitors, two general methods have been 
applied: one method is the substrate-based design of pseudopeptide derivatives; 
another approach is the random screening of nature compound libraries as well as 
synthetic small molecule libraries.
13
 However, such random screening of large 
libraries usually takes a lot of time and efforts but only achieves limited results with 
only a few compounds found to be potent and selective MMP inhibitors.
14
 Thus, most 
researchers still prefer to devote their efforts to the design of peptide-based MMP 
inhibitors. Based on the selection of ZBGs, the corresponding peptide sequence could 
be positioned either on the left-hand side (LHS) or the right-hand side (RHS), or on 
both sides of the cleavage site. Among all the ZBGs developed so far, the hydroxamic 




1.2.2.1 Hydroxamic acid-based MMP Inhibitors 
A lot of research has been done on developing potent MMP inhibitors that 
contain the hydroxamic acid functional group. With the hydroxamic acid functionality 
as the ZBG, inhibitors that are designed to target the enzyme subpockets on the 
right-hand side of the active site exhibit particularly potent inhibition, in contrast, the 
corresponding left-hand side inhibitors were reported to possess only modest 
inhibitory potency.
16-17
 Factors that contribute to the high binding affinity includes the 
hydroxamate acts as a bidentate ligand with each oxygen at an optimal distance 
6 
 
(1.9-2.3 Å) from the active-site zinc(II) ion; and the position of the hydroxamate 
nitrogen suggests that it is protonated and forms a hydrogen bond with a carbonyl 
oxygen of the enzyme backbone (As shown in Figure 1-2).
4
 Another factor critical to 
achieving potent inhibition is the length between the hydroxamic acid and the carbon 
bearing P1’ substitution. As firstly reported by Johnson and co-workers in 1987, 
succinyl hydroxamic acid derivatives were more potent inhibitors of MMP-1 than 
either the corresponding malonyl or glutaryl derivatives.
18
 Afterwards, the 
peptide-based succinyl hydroxamate has became one of the most widely exploited 
scaffolds of MMP inhibitors. 
 
 
Figure 1-2 Binding of a hydroxamate inhibitor to MMP-7 
 
As described previously, the S1’ pocket is considered to be the most important 
selectivity pocket for MMP inhibitors. It was firstly reported by Porter, Morphy, and 
co-workers, through their previously obtained structural data on the MMPs, that the S1’ 
subsite is a deep pocket for the majority of the MMPs (e.g., MMP-2, MMP-3, 





This seminal discovery was supported by their SAR data which shows that certain 
MMPs tolerate large hydrophobic P1’ side chains. For example, the small molecule 
with 3-phenylpropyl group at P1’ position, one of the first deep pocket selective MMP 
inhibitors provides selective inhibition of MMP-2 over MMP-1 and MMP-3 for 
succinyl hydroxamates (as shown in Figure 1-3, compound 1-1).
19
 Another example 
is a C9 alkyl chain at P1’, as shown in compound 1-2, gives reduced in vitro inhibition 
of MMP-1 while maintaining potent inhibitory activity against MMP-2, MMP-3, and 
MMP-9.
20
 As reported by Miller and co-workers, extending the P1’ substituent to C10 
(compound 1-3) results in potent inhibition of MMP-1, however, further increasing 
the length of P1’ side chain to C16 will cause a loss of activity against MMP-1.
21
 
When succinyl hydroxamate MMP inhibitors with extended P1’ substituents were 
subjected to modifications with heteroatoms, a similar switch in the inhibition of 
MMP-1 was also observed.
22-24
 These results indicated that the incorporation of 
extended P1’ substituents can generate potent deep pocket selective MMP inhibitors.  
SAR analysis of P2’ group modification indicates that changes made at that 
position have, in general, a modest effect on in vitro activity. This view is reinforced 
by X-ray crystallographic analysis of MMP-inhibitor complexes, which reveals that 
the P2’ group of peptidyl succinyl hydroxamic acid based MMP inhibitors points out 
of the enzyme, making few contacts with the S2’ cleft.
4
 However, the group at P2’ can 
have an effect on the pharmacokinetic properties of the inhibitors. Take GM6001 
(compound 1-4) as an example, introducing tryptophan at P2’ position yields more 
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potent inhibitor than other amino acid side chains.
25
 It is one the of the most potent 
MMP inhibitors commercial available.  
The S3’ region of the MMP enzymes is a relatively open area and a wide range of 
groups can be introduced at P3’ position.
3
 Heteroaryl and aryl groups appear to 
enhance MMP-3 and TACE (TNF-α converting enzyme, a transmembrane 
metalloprotease) inhibitory activity. Moreover, introduction of a benzhydryl group at 
P3’ position, e.g. compound 1-5, leads to compounds that are selective for MMP-7 





Figure 1-3. Examples of hydroxamic acid-based MMP inhibitors. 
 
Although inhibitors based on hydroxamic acid constantly show low nanomolar or 
even subnanomolar potencies towards MMPs in vitro, however, these inhibitors are 
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generally not exclusively specific towards the MMPs under physiological conditions. 
In addition, no hydroxamic acid-based MMPIs have successfully completed the 
clinical trials.
28-30
 Low oral availability, poor in vivo stability, and undesirable side 
effects associated with hydroxamate compounds are cited as reasons for the inability 




1.2.2.2 Non-Hydroxamic acid-based MMP Inhibitors 
Due to the limitations of hydroxamic acid-based MMP inhibitors as mentioned 
above, there has been considerable interest in compounds that contain (1) Carboxylic 
acids ZBGs, (2) Thiol ZBGs, (3) Phosphorus-based ZBGs as well as (4) Novel zinc 
binding groups. 
 
(1) Carboxylic Acids ZBGs 
As the synthetic precursor to the corresponding hydroxamate-based MMPIs, the 
carboxylate compounds are the most commonly studied inhibitors after 
hydroxamates.
31
 Many carboxylates have been shown to be effective MMP inhibitors 
and some appear to be promising clinical candidates despite the fact that the 
carboxylate group is a less effective binding group toward zinc. An early lead 
AG3067 (1-6) was used as a starting point for further investigation of potential 
inhibitors. Selectivity for the deep pocket MMPs was provided by the P1’ 
biphenylpropyl group, and the addition a cyano group to the biphenyl group at the 4’ 
position slightly improved inhibition against MMP-2 and also prevented potential 
10 
 
enzymatic oxidation. The inclusion of a tert-leucine N-methylamide moiety at the 
P2’/P3’position aided in both activity and solubility. Replacement of the propyl group 
at P1’ with five-membered heterocycles dramatically improved the activity of these 
inhibitors. AG3365 (1-7) was found to be a potent and selective inhibitor. To reduce 
the peptidic character, the P2’/P3’ fragment was replaced with aminopantolactone, and 
together with reorientation of the P1’ pyrrole ring, the orally bioavailable compound 
AG3433 (1-8) was produced. This compound is currently under preclinical 
investigation. 
 
Figure 1-4. Examples of carboxylic acid-based MMP inhibitors. 
 
(2) Thiol ZBGs 
Among monodentate ligands, thiols appear to be the most attractive ZBG for 
incorporation in MMP inhibitors. Although the intrinsic affinity of a monodentate 
thiol ZBG is less than that of a bidentate groups such as carboxylate or hydroxamate, 
Babine and Bender have suggested that ease of solubility and ionization tend to make 





 However, the fact that thiols are oxidatively unstable, and can potentially 
form disulfide bonds in vivo, significantly limits their overall clinical prospects.  
 
(3) Phosphorus-Based ZBG 
Aside from hydroxamate- and thiol-based compounds, inhibitors based on 
phosphorus ZBGs are also actively being investigated.
32
 Many different 
phosphorus-based functionalities have been exploited to generate potent inhibitors 
against a range of MMPs, although so far none are potent enough to be in clinical 
trials. ZBGs based on the phosphonamidate moiety can complex to the enzyme in two 
different modes where either one or both of the oxygen atoms care coordinated to 
active site zinc ion. The biggest advantage of using Phosphonamidates as a ZBG is 
the facile chemical synthesis to developing full length of inhibitors against MMPs. By 
interacting with both S1’-S3’ and S1-S3 binding pockets, the inhibitors with full length 
at both sides may improve the potency and selectivity accordingly compared to the 
one side compounds. The inhibitor 1-9 is a typical example which showed improved 










(4) Novel Zinc Binding Groups 
Although the succinyl hydroxamate-based inhibitors are extremely potent, their 
selectivities towards a particular MMP are still very poor. Besides, no 
hydroxamate-based MMP inhibitors have successfully completed the clinical trials. In 
an attempt to find alternatives to the hydroxamic acid group, lots of work has been 
done by Cohen’s group, who developed bioinorganic model complexes able to mimic 
the binding mode of ligands to the MMP active site. As they had early shown, a series 
of cyclic compounds were identified as ligands for use in MPIs (Figure 1-6).
34
 
Comparing to acetohydroxamic acid (AHA, 1-10), these cyclic compounds exhibit 
their superior properties including: a) better hydrolytic stability originating from 
cyclic structures, b) potentially improved biological tolerance and c) proposed 
increased affinity for the MMP zinc(II) ion due to ligand rigidity and zinc 
thiophilicity.
35
 In addition, some sulfur-containing donor ligands appeared more 
potent interaction than their oxygen analogues. Using these pyrone-based cyclic 
compounds as a ZBG, Puerta and co-workers designed and synthesized a series of 
new MMP inhibitors. Further evaluated by fluorimetric assay, compounds 1-22 and 
1-23 shown in Table 1-1 resulted to be the best inhibitors among them (in the 
nanomolar range on MMP-3), and also showed more potent over their hydroxamate 
analogues.
36
 Afterwards, they also tested this new family of heterocyclic inhibitors in 
a cell culture assay on neonatal rat cardiac fibroblasts.
37
 The results suggested that 
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these new ZBGs are potent, non-toxic and biocompatible chelating portions to be used 
for the construction of new non-hydroxamate MMPIs. In 2007, Johnson and his 
co-workers also reported a first series of anthrax lethal factor (LF) metalloprotease 
inhibitors with low-micromolar to submicromolar activity using rhodanine-based 
ZBG.
38
 It would also be interesting to test all the derived compounds against other 
related human metalloproteases such as MMPs. Overall, these novel ZBGs proved to 
be a valid alternative to the hydroxamate moiety to be exploited in the synthesis of 
new MMP inhibitors. 
 
Figure 1-6. Structures of AHA and new ZBGs examined by Cohen’s group 
 
 




1.3 Chemical Biology of Cysteine Proteases 
As one of the six major classes of proteases, cysteine proteases contain a catalytic 
cysteine residue at the enzyme active site. According to their structures, functions and 
localizations, these protease can be further subdivided into three classes called: clans 
CA (papain-like proteases), clans CD (caspases and other related enzymes) and clans 
PA (picornaviral proteases).
4, 39
 With recent progress in investigation of this class of 
enzymes, it has become more clear that these cysteine proteases fulfill specific 
functions in a myriad of biological processes like extracellular matrix turnover, 
antigen presentation and processing events.
40
 Moreover, they are also involved in 
many diseases and represent promising drug targets for osteoporosis, arthritis, cancer 
and Alzheimer’s disease.41-42   
 
1.3.1 The Nature of Caspases 
Caspases play important roles in both the cytokine maturation/inflammation and 
programmed cell death, also known as apoptosis.
43-45
 To date, at least twelve different 
human caspases have been identified. According to their sequence homology and 
substrate specificity, caspases also can be further divided into three subfamilies: 1) 
inflammatory caspases (caspase-1, -4, -5 and -13), is known to be instrumental in 
inflammatory responses and generally favours substrates bearing a W/L-E-H-D 
tetrapeptide sequence. 2) initiator caspases (caspase-2, -8, -9, -10), is responsible for 
the activation of effector caspases to initiate apoptosis and they proteolyze after the 
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L/V-E-V-D sequence. And 3) effector caspases (caspase-3, -6, -7), which carry out 
apoptosis and recognise the D-E-V-D sequence.
44, 46
  
The catalytic diad of the caspases consists of a nucleophilic cysteine and histidine 
imidazole ring. These enzymes recognize a tetrapeptide motif and are well known to 
cleave after an aspartic acid at the P1 position of its substrates due to the extensive 
hydrogen bonding between the P1 aspartate and the surrounding amino acid residues 
at S1 pocket of the caspase active site.
5, 47
 Therefore, the aspartic acid group is 
essential at P1 position. Aside for the S1 pocket, Thornberry’s studies have shown that 
the S4 subsite is very crucial in conferring the caspase specificity, however, S2 and S3 
pockets display less stringent requirements for residues of their substrates.
48
  
As the name implies, the cysteine protease contains a catalytic cysteine residue at 
the enzyme active site. Take papain as a example, the catalytic mechanism of this 
class of enzymes is as shown in Figure 1-7.
5
 The thiol functionality of the active site 
cysteine (Cys 25) and the imidazole ring of histidine (His 159) exist as a 
thiolate/imidazolium ion pair. This results in the thiolate anion being highly 
nucleophilic and the scissile peptide bond is readily attacked to form a tetrahedral 
alkoxide intermediate, which is stabilized by the oxyanion hole. This alkoxide 
intermediate collapses to form a thioester upon protonation by the imidazole ring of 
the neighbouring His 159 residue, in tandem with the release of the C-terminal 
substrate fragment. Finally, hydrolysis of the thioester intermediate by a molecule of 
water generates a second alkoxide tetrahedral intermediate. The breakdown of this 
16 
 




Figure 1-7. Catalytic mechanism of cysteine proteases. 
 
The caspases are of medical interest as research studies have indicated that 
upregulation of these enzymes are often associated with many diseases. As such, 
excessive apoptosis can lead to ischemic damage and neurodegenerative diseases, 
whereas conditions such as cancer and autoimmune diseases can result from 
insufficient apoptosis.
49
 Therefore, studying the dynamics of caspases (especially 
Caspase-3/-7) activation in living cells would provide valuable information about the 
apoptotic mechanism and signaling pathway. Despite the increasing attention given to 




1.3.2 Activity-based protein profiling 
Recently, activity-based protein profiling (ABPP) has proven to be a powerful 
tool in proteomic studies. ABPPs use active site-directed, small molecule-based 
covalent probes to report on the functional state of enzyme activities directly in native 
biological systems.
50-51
 The design or selection of ABPP probes to target a subset of 
the proteome or a specific class of enzymes is based on a common binding motif 
and/or reactivity of a particular group of enzymes. This principle has been 



















general design of activity-based probes (ABPs) will include three parts: 1) a reactive 
group, so-called ‘warhead’, which will specifically target and react with the active site 
of one particular class of enzymes and consequently form the covalent linkage with 
target enzyme; 2) a reporter unit, which is typically a fluorophore or biotin tag for the 
direct read out of the protein’s activity; and 3) a linker, which forms a bridge between 
the reactive group and the reporter unit and minimizes the possible disruption from 
the reporter tag in the protein recognition process. For the affinity-based probes 
(AfBPs), targeting the non-covalent hydrolytic maechanism proteins such as 
cysteine/serine proteases, a photoreactive molecule (e.g. benzophenone or diazirine) 
will be introduced. After engaged with target protein, the UV-mediated cross-linking 
reaction will occur at a suitable proximal residue near the active-site. These 
photo-AfBPs typically label the target protein in an activity-dependant manner like 
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the traditional ABPs. More recently, ABPP has been combined with high-resolution 
mass spectrometry (MS) analytical platforms and facilitated the identification of 
conserved catalytic residues in enzyme active sites.
67-69
 Moreover, ABPP also 





1.3.3 Fluorescent Probes for Bioimaging Applications 
Fluorescent imaging has recently emerged as a powerful tool in modern chemical 
biology and physiology fields. Compared with other technologies, such as 
radioisotope labeling, MRI, ESR and electrochemical detection, fluorescence imaging 
offers many advantages including high level of sensitivity, being non-invasive and 
provides safe detection as well as drastic modulation of fluorescence signal.
72
 
Furthermore, this method allows real-time visualization and tracking of enzymatic 
activities in intact cells or whole organisms with high spatial and temporal resolution 
and thus will provide a much better understanding of the biochemical and 
physiological processes. Currently, the progress in the field of cellular imaging is 
becoming more dependent on the development of novel fluorescent probes. One of 
the most widely used approaches is the genetically encoded fluorescent biosensors 
utilizing green fluorescent protein (GFP) and its variants.
73-74
 The last two decades 
have witnessed the remarkable contribution of GFP and its variants for imaging and 
















 This approach is extremely 
powerful for tracking the expression and localization of proteins in a wide variety of 
tissues and organisms with less photodynamic toxicity and photobleaching. However, 
it also has few disadvantages: 1) using macromolecules which are difficult to make 
modifications without significantly affecting the fluorescence property, 2) need of 
genetic engineering of the samples, 3) lack of ability to covalently trap the target of 
interest for further analysis and identification. 
Recently, small molecule-based approaches have been comprehensively 
described to report enzymatic activities both in vitro and in vivo. One of the 
traditional methods is developing the fluorogenic substrates which are composed of 
synthetic peptides attached to a fluorogenic or colorimetric molecule. The enzyme 
activity can be visualized by detecting the fluorochrome or dye molecule that is 
released after substrate cleavage.
84
 Furthermore, fluorescence resonance energy 
transfer (FRET) is also widely utilized to develop imaging probes. In the FRET-based 
probe, enzymatic cleavage of the linker between two fluorochromes changes the 
fluorescence intensity, which can be monitored and used as an indirect readout of 
enzyme activity.
85-86
 However, the rapid diffusion problem facing by all these 
substrate-based imaging probes may limit their usage in high spatial resolution studies 
of enzymes regulation and localization.  
Activity-based fluorescent probes as another small molecule-based approach have 
the potential to address the above problem due to their ability to form covalent bonds 





 However, the major limitation to this approach is that they 
produce a fluorescencene signal both when bound to a target enzyme and when they 
are free in solution, which means that the normal version of ABPs are unsuitable for 
live-cell imaging. To overcome this problem and enable direct real-time studies of 
protease activity in live cells, quenched activity-based probes (qABPs) have been 
designed by Bogyo’s group.89 These acyloxymethyl ketone-based probes emit a 
fluorescent signal only after specific binding to the protease target. This method 
couples imaging and trapping together within the same design and achieves great 






Figure 1-8. Activity-dependent labeling of cysteine protease by qABP 
 
1.4 Project Objective 
One of the greatest challenges is achieving selectivity targeting specifically one 
particular MMP member while having no or little effect on other MMP members. 
Since MMP family members share the main structural characteristics, the design of 
selective MMP inhibitors is a difficult task. In order to achieve this difficult task, 
solid-phase combinatorial chemistry and rapid inhibitor assembly using “click 
chemistry” have been utilized to develop thousands of peptide-based or small 
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molecule-based MMP inhibitors. Based on the huge number of different inhibitors, 
structure-activity relationship (SAR) studies can be carried out easily. 
On the other hand, in order to study the Caspase-3/-7 activities in its cellular 
environment, we also intend to design and synthesize a novel fluorescently quenched 
activity-based probe which is hoped to be capable of imaging the caspase activity 







Multicolor, One- and Two-Photon Imaging of Enzymatic 
Activities in Live Cells with Fluorescently Quenched 





Fluorescence imaging provides an indispensable way to locate and monitor 
biological targets within complex and dynamic intracellular environments. Of the 
various imaging agents currently available, small molecule-based probes provide a 
powerful tool for live cell imaging, primarily due to their desirable properties, 
including cell permeability (as a result of their smaller sizes), chemical tractability 
(e.g., different molecular structures/designs can be installed), and amenability to 
imaging a wide variety of biological events. With a few exceptions, most existing 
small molecule probes are however not suitable for in vivo bioimaging experiments in 
which high-resolution studies of enzyme activity and localization are necessary. In 







(qABPs) which are highly modular, and can sensitively image (through multiple 
enzyme turnovers leading to fluorescence signal amplification) different types of 
enzyme activities in live mammalian cells with good spatial and temporal resolution. 
We have also incorporated two-photon dyes into our modular probe design, enabling 
for the first time activity-based, fluorogenic two-photon imaging of enzyme activities. 
This, hence, expands the repertoire of ‘smart’, responsive probes currently available 
for live cell Bioimaging experiments. 
 
2.2 Introduction 
Fluorescence imaging provides an indispensable way to locate and monitor 
biological targets within complex and dynamic intracellular environments.
72, 74, 91-94
 
The breadth of imaging experiments is arguably limited by the variety of detection 
probes available. Such imaging probes can report, in real-time, points within cells or 
tissues that exhibit intended interactions or activities, providing a detailed picture of 
biological processes that occur in vivo. In general, there are three classes of probes 





 and small molecules.
72, 94
 Fluorescent 
proteins are genetically encoded; hence do not require external application and 
delivery. As macromolecular imaging probes, however, they have numerous 
shortcomings for intracellular applications.
73
 For example, they may not distribute 
evenly in cells, provide sufficient handles for rational modification/design or deliver 
required sensitivities or specificities. Nanomaterials such as quantum dots obviate 
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some of these problems by offering much improved sensitivities and other chemical 
and physical properties, but themselves are macromolecular in nature, therefore, 
offering limited solutions.
72, 94
 Small molecule-based probes provide a powerful tool 
for live cell imaging, primarily due to their desirable properties, including cell 
permeability (as a result of their smaller sizes), chemical tractability (e.g., different 
molecular structures/designs can be installed), and amenability to imaging a wide 
variety of biological events.
73
 In recent years, many research groups have successfully 
developed and deployed small molecule imaging probes for intracellular detection of 
ions, metabolites, proteins (including enzymes), organelles, and different types of 
cells/tissues.
72, 88-90, 94-101
 Of particular importance are small molecule-based probes 
capable of reporting in vivo enzymatic activities,
88-90, 97-101
 as few FP-based, 
enzyme-detecting biosensors are currently available and they suffer from limited 
dynamic range of detection and many other problems.
102
 Most small molecule 
approaches make use of a cell-permeable reporter substrate that, upon being processed 
by an endogenous enzyme target, produces a fluorescence signal that can be 
visualized microscopically.
88, 98-100
 These probes, however, normally diffuse away 
from the site of reaction rapidly, thus, providing limited utilities in high-resolution 







Figure 2-1. Two existing small molecule approaches for spatially resolved imaging of 
enzymatic activities in vivo. (A) ELF 97™ phosphatase substrate.97 (B) Acyloxymethyl 
ketone (AOMK)-based quenched activity-based probes (qABPs) liberate fluorescence upon 




Several probe designs have begun to address this challenge of enabling smart, 
precise sensing of enzymatic activity in vivo (Figure 2-1).
89-90, 97
 The commercial 
product ELF 97 acts as a substrate for both acid and alkaline phosphatases, a group of 
highly regulated enzymes critical in modulating signal transduction pathways.
97
 Upon 
enzymatic removal of the phosphate residue, the water-soluble substrate forms a 
bright yellow-green fluorescent product which precipitates at the site of enzymatic 
activity. This enables good spatial resolution of phosphatase activities in cells (Figure 
2-1A). The strategy, however, is in general applicable to phosphatases, although 
recent studies have indicated that, when coupled with clever linker design, it may be 
adaptable to the detection of proteases as well.
103
 Bogyo and co-workers recently 
developed the so-called fluorescently quenched activity-based probes (qABPs) to 
monitor real-time protease activities in live human cells (Figure 2-1B).
50-51, 89-90, 104
 
By using acyloxymethyl ketone (AOMK)-based probes which emit a strong 
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fluorescent signal only after proteolysis by a cysteine protease target, with the 
simultaneous formation of a covalent probe-enzyme adduct, this strategy couples 
imaging and suicide inhibition within the same design to achieve the intended 
“turn-on” imaging capability for cysteine proteases in vivo with good spatial 
resolution. While highly elegant, this approach may suffer from some limitations. For 
example, the method was based on a suicide inhibitor which, unlike ELF 97, provided 
no signal amplification, thus, potentially obscuring the probe‘s ability to truly monitor 
enzyme activity and limiting its sensitivity when screening low-abundance targets. 
We would like to point out, however, in a recent study carried out to directly compare 
fluorescent ABPs and commercially available polymer-based substrates of proteases 
as imaging reagents, Bogyo and co-workers showed that their ABPs might offer 




Herein, based on the well-established quinone methide chemistry,
106-114
 we have 
successfully developed a new class of fluorescently qABPs which are highly modular, 
and can sensitively image (through multiple enzyme turnovers leading to fluorescence 
signal amplification) different types of enzyme activities in live mammalian cells with 
good spatial and temporal resolution (Figure 2-2). We have also incorporated 
two-photon dyes into our modular probe design (vide infra),
95-96
 enabling for the first 
time activity-based, fluorogenic two-photon imaging of enzyme activities. This, hence, 











Figure 2-2. (A) Overall design principle of our quenched activity-based probes (qABPs). The 
probe includes three elements (or modules), specifically the fluorophore (in red), the quencher 
(and/or a tag like biotin), and an enzyme recognition warhead (WH; in blue) that surround a 
mandelic acid core. These modules are interchangeable, allowing the strategy to be broadly 
applicable to different types of enzymes. Upon cleavage of WH by the enzyme, the probe 
released the quencher, producing a reactive quinone (or quinolimine) methide intermediate (in 
bracket). In an intracellular environment, three pathways of this reactive intermediate are 
possible: A) it is hydrated/quenched with bulk water; B) it binds a nucleophile within the 
enzyme of interest but does not necessarily inactivate the enzyme; C) it reacts with a nearby 
nucleophile and accumulates in same organelle where the enzymatic reaction occurs. (B) 
Structures of probes (2-P1 to 2-P6) used in the current study. The strategy is demonstrated 
with, but not limited to, cysteine proteases (top) and phosphatases (bottom). Both one- and 
two-photon fluorophores were incorporated. Detailed synthetic schemes and procedures are 






2.3 Results and Discussion 
2.3.1 Design Principle of Quinone (or Quinolimine) Methide-Based qABPs 
Quinone (or quinolimine) methide-based small molecule probes were previously 
used for in vitro labeling of enzymes either in their purified form, in cell extracts or 
recombinantly expressed inside bacterial cells.
27, 108-112
 It has been well-established 
that the diffusible nature of these probes causes the labeling to occur away from 
catalytic active site of the target enzyme.
113-114
 Recent studies have further shown that 
release of the quinine methide intermediate from the active site of the target occurs at 
a rate competitive with the subsequent labeling process (i.e., Pathways A-C in Figure 
2-2), causing nonspecific labeling of other proteins (and thus making them ill-suited 




 We exploited this unique feature to 
design the new class of qABPs suitable for in vivo Bioimaging (Figure 2-2); these 
probes contained modular components, including an enzyme substrate warhead (WH), 
a fluorescence reporter and a quencher, strategically built around a mandelic acid core. 
Other tags such as biotin or CPP (cell-penetrating peptide) may be introduced as well, 
when needed.
116-120
 The resulting fluorogenic probes were normally in the “off” state 
in which the reporter fluorescence was effectively quenched by the proximal Dabcyl 
quencher. Upon introduction into cells and enzymatic cleavage of the WH, an 
1,6-elimination reaction led to the release of the quencher group, liberating 
fluorescence and a quinone/quinolimine methide intermediate. By taking advantage of 
the reactive yet diffusible nature of this intermediate, we were able to achieve both 
sufficient spatial resolution to “image” enzyme localization, and fluorescence signal 
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amplification to sensitively report endogenous multiturnover enzyme activity. We 
envisioned in a typical live cell imaging experiment, of the three pathways possible 
for the intermediate, Pathway C was the most productive (Figure 2-2A); a substantial 
amount of the quencher-released, highly fluorescent intermediate had a long enough 
half-life to diffuse out of the enzyme active site (thus keeping the bulk of the enzyme 
target unmodified for multiple catalytic conversions), and label available nucleophiles 
within its immediate vicinity (e.g., proteins residing in the same subcellular organelle 
as the intended target). Taking advantage of this property, fluorescence would be 
accumulated at the site of activity in situ, magnifying overall readouts. Furthermore, 
the design enabled different dyes (e.g., 1-P/2-P dyes), and substrate elements to be 
introduced as desired, in a modular fashion. 
 
2.3.2 Chemical Synthesis of the Probes 
To validate our new qABP design, six model probes (2-P1 to 2-P6) were 
synthesized and used to study two different classes of enzymes, namely, caspases (a 
clan CD cysteine protease subclass) and protein tyrosine phosphatases (PTPs) (Figure 
2-2B). Two additional control probes, 2-C1 and 2-C2, were also synthesized (Figure 
2-3). It should be noted that the modularity of our probe design should enable this 
strategy to be readily applicable to most other hydrolytic enzymes (e.g., all four major 
classes of proteases
109-110
). The synthesis of caspase probes 2-P1 to 2-P4 involved 
both solution- and solid-phase chemistry (Scheme 6-2 in Chapter 6); from a 
commercially available starting material, compound 2-17a was synthesized in 12 
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solution-phase steps. Briefly, the first three steps were modified from published 
procedures.
110
 Selective protection of the tert-butyl group thereafter yielded acid 2-9b 
which was coupled with allyl-protected glycine to produce compound 2-11. After 
hydrolysis of the acetyl group, the nitro group was reduced to amine and coupled with 
first amino acid, aspartic acid, to afford product 2-14. The secondary alcohol was 
activated by p-nitrophenyl chloroformate and coupled with Dabcyl-containing amino 
linker to form the carbamate adduct 2-16. The building block 2-17 was obtained by 
deprotection of allyl group using palladium catalyst. Finally, 2-P1 to 2-P4 (each 
containing a different substrate WH - DEVD, YVAD, LEVD, and VEID, respectively, 
targeting different classes of caspases
48
) were assembled by solid-phase peptide 
synthesis. A biotin tag was introduced for future pull-down/target identification 
purposes, but may be replaced with a CPP when needed (vide infra).
117-120
 After 
cleavage from resin, the crude products were further purified and fully characterized. 
The amenability of our synthetic strategy to solid-phase synthesis should allow easy 
access to other probes in the future. The PTP probes, 2-P5 and 2-P6, were similarly 
synthesized on the mandelic acid core structure with solution-phase chemistry 
(Scheme 6-3 in Chapter 6). Instead of peptide-based substrates, a “caged” phosphate 
group was incorporated, followed by a two-step carbamation reaction to yield 
compound 2-34. After deprotection of the allyl group, fluorescein and dye 2-22 (a 
two-photon dye) were directly coupled to give the final probes 2-P5 and 2-P6, 
respectively. The “caging” of the phosphate in the two probes enabled temporal 
31 
 
control of “imaging” PTP activities in live cells.121-122 To minimize the size of these 
probes, biotin tag was omitted. 
 
Figure 2-3. Structures of the two control probes 2-C1 and 2-C2. Similar to Figure 2-2, of the 
three modular components in each probe that surround the mandelic acid core, the 
fluorophore and the enzyme recognition warhead (WH) were highlighted in red and blue, 
respectively. WH in 2-C1 and 2-C2 are acetylated Asp and Glu, respectively. 
 
In previous studies by Bogyo and co-workers, where AOMK-containing 
activity-based probes were developed to target a variety of cysteine proteases 
including caspases, cathepsins, and legumain, the authors found that Asp-AOMK, a 
probe which contains a single aspartic acid residue at the P1 position and was intended 
for caspases, cross-reacted readily with human legumain.
56
 Legumain is a CD-clan 
lysosomal cysteine protease that plays a pivotal role in the endosomal/lysosomal 
degradation system. It specifically cleaves peptide bonds with Asn or Asp at the P1 
position.
123
 To unambiguously confirm that our caspases detecting probes, 2-P1 to 
2-P4, did not cross-react with other endogenous cysteine proteases especially 
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legumain, 2-C1 and 2-C2 control probes, each containing a single acetylated Asp and 
Glu residue at the P1 position, respectively, to make up the WH of the probes, were 
also designed (Figure 2-3). These two probes were similarly synthesized from the 
corresponding key intermediates, 2-17a and 2-17b, respectively. 
 
2.3.3 Mechanistic Studies of the Probes with Recombinant Enzymes 
The caspase probes 2-P1 to 2-P4, together with the two control probes 2-C1 and 
2-C2, were first tested in vitro with several recombinant cysteine proteases, namely, 
caspases (1, 3, 4, 6, 7, 8 and 9), cathepsins (B, L and S), and legumain. The standard 
microplate-based enzymatic assay was adopted, and the fluorescence results after an 
1-h incubation were plotted in Figure 2-4A. 2-P1 (Ac-DEVD) exhibited strong 
fluorescence readouts with caspase-3 and -7, with some cross-reactivity with 
caspase-6 and -8. 2-P2 (Ac-YVAD) was only recognized by caspase-1 and -4 which 
are both potential regulators of inflammation. 2-P3 (Ac-LEVD) and 2-P4 (Ac-VEID) 
mainly targeted caspase-1 and -4, and caspase-4 and -6, respectively. As intended, 
none of the four probes showed any cross-reactivity with recombinant cathepsins, the 
most abundant cysteine proteases in mammalian cells, nor did they cross-react with 
legumain. Interestingly, the two control probes, 2-C1 and 2-C2, also showed no 
reactivity in our assay conditions against all enzymes tested, including legumain. This 
is in sharp contrast to previous findings using the Asp-AOMK probe where significant 
cross-reactivity was observed.
56
 While the exact reason for the discrepancy is still 




Figure 2-4. Mechanistic studies of 2-P1 to 2-P4, together with control probes 2-C1 and 2-C2, 
against recombinant enzymes. (A) Substrate specificities of all six probes (bottom to top: 
2-P1, 2-P2, 2-P3, 2-P4, 2-C1, 2-C2) toward recombinant caspases, cathepsins, and legumain 
in a microplate-based enzyme assay. Left to right: legumain, cathepsins (L, B and S), and 
caspases (-1, -4, -8, -9, -6, -3 and -7). RF values were obtained after a 1-h incubation. Kinetic 
studies of 2-P1 against caspase-3 and -7 are shown as inset. (B) In vitro labeling of 2-P1 
against purified capase-3 and -7. Free probe was observed in the dye front at the bottom of the 
gel. A small amount of the enzyme was labeled. (C) Comparison of caspase-7 activity before 
and after labeling (red bars). Upon Neutravidin affinity pull down, the probe-labeled 
caspase-7 was shown to retain most of its original activity (blue bars), indicating, even with 
covalent labeling, the enzyme still retained its catalytic activity. Wash-through fractions 
contained substantial caspase-7 activity, indicating most of the enzyme was not covalently 
modified. (D) QTOF MS determination of caspase-7 before and after labeling, indicating a 
majority of the protein was not covalently modified. 
 
Table 2-1. Kinetic Data of 2-P1 with Caspase-3 and Caspase-7 
 Caspase-3 Caspase-7 













Ac-DEVD-AFC 9.09 ± 0.09 10.8 ± 0.1 1.19 ± 0.03 8.26 ± 0.08 6.8 ± 0.5 0.82 ± 0.05 
2-P1 31.99 ± 0.13 7.1 ± 0.1 0.22 ± 0.05 69.83 ± 0.11 5.0 ± 0.3 0.07 ± 0.01 
 
design of these two qABP systems and chemical structures of the probes. Our new 
qABPs thus worked as expected in vitro, and showed excellent substrate specificity 
toward intended enzyme targets (i.e., caspases).
48
 Owing to the essential roles of 
caspase-3 and -7 in cellular apoptosis, 2-P1 was selected as a candidate for further in 
vitro and in vivo studies. At optimized conditions (25 μM of 2-P1 with 1:20 
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caspase/2-P1 ratio), the enzymatic reaction between 2-P1 and purified caspase-3/-7 
was monitored in a time-dependent manner (Figure 2-4A); typical saturation kinetics 
of enzymatic activity was observed. This demonstrated that fluorescence was 
dependent on catalytic cleavage of the substrate WH, Ac-DEVD, in 2-P1, which 
spontaneously released the quencher. The fact that 2-P1 was acting like a typical 
fluorogenic protease substrate indicated that Pathway A (Figure 2-2A) was in 
operation and the majority of the released quinone methide intermediate was 
quenched by the bulk medium, that is, H2O, and/or other nucleophiles present in the 
solution, such as DTT.
114
 We further determined the kinetic values of 2-P1 against 
caspase-3/-7 (KM = 31.99±0.13 μM and kcat = 7.1±0.1 s
-1
 for caspase-3; KM = 69.83
±0.11 μM and kcat = 5.0±0.3 s
-1
 for caspase-7). In general, our probe has greater KM 
and smaller kcat values when compared to the commercial coumarin-based caspase-3/7 
substrate Ac-DEVD-AFC (Table 2-1), giving approximately 10-fold lower catalytic 
efficiency (kcat/KM). This indicates our probe was multiply turned over and should 
serve as a reasonably efficient substrate for the enzymes. After reaching maximum 
fluorescence, the reaction mixtures were analyzed on a 20% SDS-PAGE gel followed 
by in-gel fluorescence scanning and staining with Coomassie blue (Figure 2-4B); two 
fluorescently labeled bands were observed, representing both the large (p17/p19) and 
small (p12/p11) subunits of active caspase-3/-7. This is presumably caused by 
covalent modification of the quinine methide intermediate (Pathway B in Figure 
2-2A), a phenomenon often observed in previous studies.
108-112
 Another significantly 
stronger fluorescent band, which co-migrated with the dye front, was also observed, 
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but did not appear in the Coomassie gel. This band was subsequently identified to be 
the adduct of quinine methide-H2O reaction (Pathway A). On the basis of the 
fluorescence/Coomassie gels, the labeled proteins were estimated to be <10% of total 
protein amount present in the reaction, thus, explaining the reason 2-P1/caspase 
microplate assay followed typical enzyme kinetics. The microplate and labeling 
experiments were repeated with heat- and inhibitor-inactivated caspase-3/-7; neither 
fluorescence release nor protein labeling was observed, indicating both the substrate 
cleavage and enzyme labeling were activity-dependent. To more quantitatively assess 
the amount of labeled caspase and whether the labeled caspase still retains its 
enzymatic activity, one portion of the completed caspase-7/2-P1 (1:20 ratio) reaction, 
as described above, was tested with Ac-DEVD-AFC (red bars in Figure 2-4C, and 
Figure 2-5); no significant decrease of caspase-7 activity was observed when 
compared with the untreated caspase-7 alone. The same reaction mixture was 
subjected to mass spectrometric (MS) analysis (Figure 2-4D); results indicated that 
most of the caspase-7 (> 90%) in the reaction was not covalently labeled and showed 
an identical MS spectrum as the unmodified caspase-7. To further assess whether 
2-P1-labeled caspase-7 still retains its catalytic activity, the labeling mixture was 
affinity-enriched with Neutravidin beads, and washed until the flowthroughs were 
free of any caspase activity. Subsequent testing of the bead-bound (therefore 
covalently modified with 2-P1) caspase-7 showed the enzyme still retained most of its 
catalytic activity (Figure 2-4C, blue bars). It is promising to observe that even 
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probe-labeled protein adducts retained most of the enzymatic activity, enabling 
multiple turnovers of our qABP strategy. 
 





























































Figure 2-5. Comparison of enzyme’s activity with and without probe labeling indicates that, 
no significant decrease of activity was observed. 
 
2.3.4 In-Cell Bioimaging of Apoptosis Using qABPs 
Next, we determined whether the strategy could be used for “imaging” enzyme 
localization in cells with sufficient sensitivity and spatial resolution. 2-P1 was again 
used as an example and its in situ labeling profiles against cellular lysates were 
analyzed by in-gel fluorescence scanning (Figure 2-6A). In both bacterial and 
apoptotic mammalian cell lysates, where caspase-3/-7 activities were overexpressed,  
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the fluorescence labeling of caspase-3/-7 by 2-P1 was greatly diminished, while a 
wide number of nontarget proteins were clearly labeled (lanes 3, 4 and 7; compared to 
lanes 1 and 2). Some highly fluorescent free dye (e.g., the quinone methide-H2O 
adduct) was also evident in these lanes but readily washed away with buffer (data not 
Figure 2-6. (A) In vitro labeling of 2-P1 in bacterial and mammalian lysates (free probe 
released from the reaction moved at the gel front and was not shown). Lanes 1 and 2, 
purified caspase-3 and -7; lanes 3 and 4, bacterial lysates overexpressing caspase-3 and -7; 
lane 5, bacterial lysate without inducing the overexpression of caspase-3/7; lane 6, normal 
HeLa cell lysate; lane 7, apoptotic HeLa cell lysate. (B) Confocal microscope images of 
caspase-3/-7 activities using 2-P1 in apoptotic HeLa cells and confirmed with 
immunofluorescence staining. Panel i: 488 nm channel (pseudocolored in green) detecting 
cellular localization of 2-P1. (Inset) Normal HeLa cells incubated with 2-P1. Panel ii: 
immunofluorescence staining at 543 nm channel (pseudocolored in red) using anti-caspase-3 
primary antibody and anti-rabbit IgG-TR secondary antibody. Panel iii: merged images of 
panels i and ii, together with stained nuclei (with Hoechest; pseudocolored in blue). Panel iv: 
DIC image of the same cells. All images were acquired under the same settings. Scale bar = 




shown). Lysates of normal bacteria (nor expressing caspase-3/7) and HeLa cells did 
not show any significant fluorescent band upon incubation with 2-P1 (i.e., lane 5 and 
6), nor did they release the free dye. These results demonstrate that Pathway C was 
indeed in operation as originally anticipated (Figure 2-2A); 2-P1, upon activation by 
caspase-3/-7 in the cell lysates, released the reactive quinone methide intermediate 
which diffused away from the active site of the target (while keeping the enzyme 
active) and was subsequently “trapped” by other proteins in the vicinity. It should be 
pointed out that the very concept of using “reactive” chemical handles in a small 
molecule reporter to achieve localization near the site/organelle of the reaction is in 
fact not new, and has been extensively exploited in other commercial probes, that is, 
Mitotracker.
97
 To determine whether these resultant, fluorescently labeled proteins 
could provide sufficient spatial resolution to accurately report localization of the 
enzyme target, confocal fluorescence microscopy was next used to image normal and 
apoptotic HeLa cells treated with 2-P1 (Figure 2-6B and Figure 9-5 in Chapter 9). 
Owing to the relatively large size of our current probes (MW > 1000), they were not 
cell-permeable, but may be made so in the future by introducing a cell-penetrating 
peptide (vide infra).
116-120
 So for most live cell experiments reported in this article, 
cells were first permeabilized by treatment of 1% digitonin (10% DMSO) for 1 min. 
Normal, un-induced cells showed an extremely low fluorescence signal (inset in Panel 
i, Figure 2-6B), indicative of little or no capase-3/-7 activity. Upon the addition of 
staurosporine (STS, an apoptosis trigger), an exponential increase of fluorescence 
signals was detected and spread throughout the cells. After washing off free dye and 
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fixing the cells, strong green fluorescence signals were retained, which perfectly 
merged with Immunofluorescence (IF) signals generated from anti-caspase-3 primary 
antibody, which specifically detects both the large (17 kDa) and small (12 kDa) 
subunits of active Caspase-3, and a fluorescently labeled secondary antibody (Panels 
ii and iii). In contrast, no obvious fluorescence was detected when STS-induced cells 
were pretreated with a commercial caspase-3/-7 inhibitor, then 2-P1 (Figure 9-5 in 
Chapter 9), again highlighting that bioimaging of caspase-3/-7 activity in live 
mammalian cells with our probe was activity-dependent. The two control probes, 
2-C1 and 2-C2, were also used to image apoptotic HeLa cells under identical 
conditions (Figure 9-7 in Chapter 9); no significant fluorescence was observed for 
both probes. Taken together, we concluded that our qABPs were indeed suitable 
probes for live cell imaging of enzyme localization. 
 
2.3.5 One- and Two-Photon qABPs for Tyrosine Phosphatases 
To further expand the utility of our qABP strategy for in vivo imaging 
applications, two additional probes (2-P5 and 2-P6) with different dyes (one-photon 
and two-photon) were synthesized to target protein tyrosine phosphatases (PTPs) 
(Figure 2-2). Two-photon microscopy (TPM) provides key advantages over the usual 
one-photon imaging techniques, namely, increased penetration depth, lower tissue 
autofluorescence and self-absorption, and reduced photodamage and 
photobleaching.
95-96, 124-126
 The caged phosphate group was introduced to temporally 





214 nm 1 
2 
the current study, we chose a simple photolabile 2-nitrobenzyloxy group as the caging 
molecule for synthetic convenience, but it may be readily replaced, if necessary, with 
other known two-photon caging molecules.
127-128
 It was established that complete 
uncaging of probes 2-P5 and 2-P6 occurred with 1000 μJ/cm2 UV exposure for 15 
min (Figure 2-7). Using UV-irradiated probes, four different PTPs, including PTP1B, 
TCPTP, LMWPTP, and PTPB, were tested in vitro (Figures 9-1); these PTP probes 
were found to work as expected with purified PTPs as well as PTP-expressing cell 
lysates. Furthermore, the photophysical properties of two-photon dye 2-22 and the 
corresponding 2-P probe, 2-P6, before/after uncaging plus enzymatic treatment of 
PTPB in Hepes buffer were determined and summarized in Table 2-1. Upon uncaging 
and enzymatic treatment of PTPB, the two-photon action cross-section values (Φδ) 
increased from 35 to 140 at 800 nm excitation, indicating a significant, definitive 
increase in the two-photon excited fluorescence (TPEF) intensity. In contrast, the Φδ 
value of 2-P5 was only 17, 8-fold lower than that of 2-P6 (Table 2-2). 
 














Figure 2-7. Uncaging experiment monitored by LCMS. (A): 2-P5, (B): 2-P6. The reactions 
were carried out in Hepes Buffer (1×) and the UV condition is 1000 μJ/cm2. The results 
indicated that the reactions were completed within 15 min. Peak 1: Caged compound; Peak 2: 
mono-caged product; Peak 3: uncaged product. 
 
 
Table 2-2. Photophysical properties of Fluorescein, dye 2-22, 2-P5 and 2-P6 before/after 









 Φ[c] δФ/ GM[d] 
Fluorescein 490 68000 511 0.49 30 
2-P5 (before uncaging) 496 67200 523 0.01 1 
2-P5 (after uncaging and 
treatment with PTPB) 
492 79600 520 0.26 17 
Dye 2-22 455 32000 560 0.35 188 
2-P6 (before uncaging) 480 35000 592 0.06 35 
2-P6 (after uncaging and 
treatment with PTPB) 
479 35000 569 0.26 140 
[a] Peak position of the longest absorption band. [b] Peak position of emission, exited at the 
absorption maximum. [c] Quantum yields determined by using fluorescein aqueous NaOH (pH = 13) 
as standard, respectively. [d] The maxima two-photon action cross section values upon excitation 

















Figure 2-8. One and two-photon imaging using 2-P5 and 2-P6. (A) Normal HeLa cells. Panel 
i: caged 2-P5 under one-photon excitation (488 nm). Panel ii: uncaged 2-P5 under one-photon 
excitation (488 nm). Panel iii: uncaged 2-P5 under two-photon excitation (800 nm). Panel iv: 
uncaged 2-P6 under two-photon excitation (800 nm). Scale bar = 20 μm. (B) PTP1B 
overexpressed HeLa cells (by transient transfection of pJ3H-PTP1B plasmid). Panel i: 
uncaged 2-P6 under two-photon excitation (800 nm). Panel ii: cells treated with ER tracker 
under one-photon excitation (543 nm). Panel iii: IF staining of PTP1B localization with 
mouse-anti-HA antibody (488 nm). Panel iv: merged images of i to iii. Scale bar = 20 μm. All 
images were acquired in the same way. (Inset) Corresponding DIC images. 
 
 
Next, TPM was carried out to image endogenous PTP activities in HeLa cells 
(Figure 2-8A). Under one-photon excitation at 488 nm, cells treated with 2-P5 
registered an increase in fluorescence upon UV irradiation (Panels i and ii). This 
clearly validates the temporal control of our probes in “turning-on” the detection only 
when needed. The fluorescence was observed throughout the cytosol of cells, 
indicating most endogenous PTP activities in HeLa cells were cytosolic. The same 
cells were imaged with TPM (excitation at 800 nm; Panel iii); no fluorescence was 
detected. In contrast, cells treated with 2-P6 exhibited strong fluorescence signals 
under the same conditions upon UV irradiation (Panel iv). Furthermore, it was 
observed that other fluorescence sources such as MitoTracker, LysoTracker and 
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Hoechst were silent and background autofluorescence from the cells was negligible 
(data not shown). Images obtained under TPM were in general of better clarity and 
potentially offer higher resolution. All these lines of evidence clearly indicate the 
numerous advantages of TPM and our 2-P probes for in vivo enzyme imaging 
experiments in future applications. Finally, the commercial availability of an 
endoplasmic reticulum (ER)-localizing PTP1B construct enabled us to quickly and 
unambiguously confirm that our probes could indeed image localized enzyme 
activities within the cell (Figure 2-8B); HeLa cells transiently transfected with the 
pJ3H-PTP1B plasmid (which overexpresses and accumulates HA-tagged PTP1B in 
ER
129
), followed by imaging with 2-P6, showed intense fluorescence only in ER 
(Panel i). Subsequent verifications were done with the ER tracker (Panel ii) and 
immunofluorescence staining of PTP1B (Panel iii). These results thus provide strong 
evidence that our probes were indeed successfully retained at the vicinity of targeted 
enzymes. 
 
2.3.6 Live Cell Imaging with CPP-Containing Probe (2-P7) 
The relatively large size of our probes (MW > 1000) thus far necessitated the 
permeabilization of cells prior to imaging experiments. The modularity of our probe 
design, however, has enabled us to address this problem by the introduction of 
cell-penetrating peptides (CPP).
116-120
 As shown in Figure 2-9A, the CPP-containing 
probe, 2-P7, is similar to 2-P5 but contains an additional well-known CPP moiety of 
nine consecutive arginine residues (R9).
119-120
 Similar to our other probes, this probe 
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was synthesized from the key intermediate 2-35 using solid-phase chemistry (Figure 
2-2 and Scheme 6-5). With 2-P7 in hand, we next carried out bioimaging of 
endogenous PTP activities in live HeLa cells. As shown in Figure 2-9B, when 2-P7 
was uncaged by UV irradiation prior to incubation with live HeLa cells, 
membrane-localized fluorescence was detected (Panel i), indicating that, upon 
reaching the cell membrane, the activated probe reacted with membrane-bound PTPs 
and was permanently “trapped”. On the contrary, when 2-P7 was first incubated with 
live HeLa cells, then uncaged by UV irradiation, followed by imaging of PTP 
activities, most of the fluorescence signals were detected intracellularly (Panel ii), 







Figure 2-9. Live cell imaging of PTP activities using CPP-containing probe 2-P7. (A) 
Structure of the cell-permeable 2-P7. (B) Imaging of endogenous PTP activities using 2-P7. 
Panel i: 2-P7 was uncaged prior to incubation with live HeLa cells. Fluorescence signals from 
2-P7 (pseudocolored in green) and membrane tracker (pseudocolored in red) were merged. 
Panel ii: 2-P7 was incubated with live HeLa cells for 1 h, then uncaged, followed by imaging. 
Fluorescence signals from 2-P7 (pseudocolored in green), membrane tracker (pseudocolored 
in red), and nucleus staining (pseudocolored in blue) were merged. All images were acquired 
under same settings. Scale bar = 25 μm.  
 
2.4 Conclusion 
In conclusion, we have successfully developed a new class of “turn-on” qABPs 
suitable for the imaging of enzymatic activities in live mammalian cells, with 
sufficient spatial resolution and temporal control. The modular design of our probes 
based on quinone methide chemistry allows convenient introduction of different 
combinations of warheads and dyes (as well as other tags including CPP), thus, 
enabling the strategy to be generally applicable to a variety of enzymes and imaging 
techniques. One valuable feature of these new qABPs is that they do not inactivate the 
enzyme target, allowing amplification of the target signal in situ. We have 
demonstrated, for the first time, two-photon activity-based probes for live cell enzyme 
imaging. This new class of probes is thus expected to extend the repertoire of in vivo 
activity-based probes, opening up many new avenues for dissecting the biology of 
cells. Unlike other well-known organelle specific trackers such as Mitotracker, which 
also make use of a reactive chemical handle to get “trapped” inside living cells,97 the 
key difference in the current qABP design is that the quinine methide in our system 
will only be “turned-on” in the presence of the active target enzyme, thus, greatly 
reducing background fluorescence and improving specificity, and is also 
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activity-based. While our manuscript was under review, Withers and co-workers 
reported what they call self-immobilizing fluorogenic imaging agents based on 
modified derivatives of coumarin glycosides for histological studies and 
fluorescence-activated cell sorting (FACS).
130-132
  Coincidently, quinine methide was 









In Situ “Click” Assembly of Small Molecule Matrix 






A panel of small molecule-based MMP inhibitors containing rhodanine warheads 
was assembled using “one-pot” click chemistry. Upon biological screening, moderate 




Matrix metalloproteases (MMPs) consist of a family of zinc-dependent 
endoproteinases which are involved in tissue remodeling and degradation of the 
extracellular matrix (ECM), angiogenesis, and cell motility. Currently, at least 26 
human MMPs have been discovered. Abnormal MMP activities are linked to many 
serious human diseases.
133
 Therefore, the development of potent MMP inhibitors has 
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received considerable interest in recent years.
3
 In most cases, MMP inhibitors contain 
a well-known zinc-binding group (ZBG) that chelates to the catalytic Zn2+ ion 
located in the enzyme active site and a peptide or nonpeptide group that interacts with 
the surrounding sites. One of the most widely exploited ZBGs of MMP inhibitors is 
the hydroxamic acid group, which has produced numerous nanomolar inhibitors but 
has not been successful in clinical trials.
3, 133
 The reason is that inhibitors containing 
this ZBG normally exhibit very potent but broad-spectrum inhibition toward most 
metalloproteases rather than MMPs alone. Furthermore, they exhibit poor 
pharmacokinetic and bioavailability properties. As a result, there has been intensive 
research efforts in the discovery of new ZBGs which may be further developed into 
highly potent and selective MMP inhibitors.
34, 134-137
 Of particular interest is the work 
of Cohen et al., where they exploited the pyrone- and thiopyrone-containing moieties 
as potential ZBGs and systematically evaluated their inhibitory properties against 
various classes of metalloproteases including MMPs and Anthrax Lethal Factor 
(ALF).
34, 135-137
 Our ongoing research interests in the use of high-throughput amenable 
chemistry (such as “click chemistry” and amide-forming reactions)138-139 have 
recently led us to the development of “click” assembled, hydroxamate-containing 
peptide analogues which showed micromolar inhibitory activities against various 
MMPs.
140
 Herein, we describe a “one-pot” click chemistry procedure for the rapid 





3.3 Results and Discussion 
3.3.1 Design and synthesis of our new small molecule MMPIs 
 
Figure 3-1. General structures of MMP inhibitors containing a rhodanine warhead and the 
“one-pot” click chemistry used in our approach. The rhodanine ZBG is highlighted (in red). 
Inset: known ALF inhibitors. 
 
The design principle of our inhibitors was based on a recent report that 
rhodanine-based molecules (inset in Figure 3-1), identified from high-throughput 
screening (HTS), are efficient micromolar inhibitors of ALF.
141
 Crystallographic 
analysis of the inhibitor-ALF complex further confirmed that the rhodanine ring is 
capable of interacting with Zn
2+
 ion via the thiazolidine sulfur atom. However, MMP 
inhibitors based on rhodanine ZBGs have yet to be reported in the literature. Our aims 
in this project are therefore to evaluate (1) whether rhodanine-containing small 
molecules constitute a novel class of potential MMP inhibitors and (2) whether our 
previously reported “click” approach could be used to rapidly assemble these 
inhibitors.
140
 The Cu(I)-catalyzed 1,3-dipolar cycloaddition between an alkyne and 
azide is the prime example of “click chemistry” popularized by Sharpless.142 In most 
cases, the 1,4-disubstituted-1,2,3- triazole ring is formed regioselectively by reacting a 
terminal alkyne with an azide in the presence of a Cu(I) catalyst. In recent years, 
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interests have been drawn toward the “one-pot” click chemistry approaches using in 
situ generated alkynes or azides.
143-147
 In our case, we found the two TMS-free 
rhodanine warheads 3-A and 3-B (Scheme 3-1) rapidly decomposed during column 
purification and could not be isolated in acceptable purity. We therefore developed a 
“one-pot” approach by using the TMS-protected rhodanine warheads instead (3-D and 
3-E; see also Figure 3-1) during click chemistry. Synthesis of the TMS-protected 
rhodanines involved three steps. Propargyl alcohol 3-1 was TMS-protected to give 3-2, 
which was subsequently oxidized to give aldehyde 3-3. The base-catalyzed 
Knoevenagel condensation between 3-3 and 3-4/3-5 then afforded the TMS-protected, 
alkyne-containing 3-D and 3-E. A total of 28 aromatic azides, 3-C1 to 3-C28, were 




Scheme 3-1. (Left) Synthetic Routes of Alkyne Building Blocks 3-A and 3-B. (Right) 





Scheme 3-2. “One-Pot” Click Chemistry of Rhodanine Inhibitors 
 
For the “one-pot” click chemistry between the TMS-protected 3-D and 3-E and 
the azides 3-C (Scheme 3-2), a variety of conditions were explored to ensure efficient 
TMS cleavage while maintaining minimum interference of the subsequent “click” 
assembly of the product followed by direct in situ biological screening. We eventually 
found that 3-D or 3-E (1 equiv) and 3-C1 to 3-C28 (1.1 equiv) with K2CO3 (1 equiv; 
used for in situ deprotection of TMS) in the presence of CuSO4 (0.1 equiv) and 
sodium ascorbate (0.4 equiv) in a solvent mixture of t-BuOH/H2O (1:1) afforded the 
56-membered, rhodanine-containing small molecule inhibitors in nearly quantitative 
yields with minimum side products, as judged by LCMS and NMR characterizations 
(see Chapter 9). We further confirmed that these compounds were indeed suitable for 
direct in situ screening without further purifications. 
 
3.3.2 Inhibitor Fingerprinting with MMPs  
We next obtained the inhibitor fingerprints of the 56-membered rhodanines 
against different MMPs (Figure 3-2). A standard microplate-based enzymatic assay 
was adopted as previously described.
140
 Representatives from different classes of 
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MMPs, including collagenases (MMP-8 and MMP-13), matrilysins (MMP-7), 
gelatinases (MMP-9), and membrane-type MMPs (MMP-14), were tested. 
 
 
Figure 3-2. Fingerprints of the 56-membered library against MMP-7, -8, -9, -13 and -14, at 
20 μM final inhibitor concentration. Strongest relative inhibition is visualized in bright red 
according to the scale shown. 
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At an inhibitor concentration of 20 μM, most compounds showed good inhibition 
toward MMP-13 while displaying very weak/no inhibition toward MMP-7/-8 and 
MMP-9/-14, respectively (see Figure 3-2). The most potent inhibitors appeared to be 
those containing alkoxyl substituents at the aromatic ring (Table 3-1). These 
compounds were resynthesized, purified, characterized (LCMS and NMR), and 
further studied in detail (to obtain their IC50/Ki); as shown in Table 3-1, 3-A25, the 
most potent inhibitor, displayed Ki values of 14.1 and 20.9 μM against MMP-7 and 
MMP-13, respectively, and appeared to show some degrees of selectivity over other 
MMPs tested. These values are moderate at best but well expected if one considers 
that the parental inhibitor (inset in Figure 3-1) showed micromolar inhibition against 
ALF
141
 and the previously reported “click-based” peptide hydroxamates were also 
micromolar MMP inhibitors.
140
 Nevertheless, our results unambiguously establish the 
feasibility of using rhodanines as novel ZBGs of MMP inhibitors. 
 





3.3.3 Docking Simulations  
Molecular modeling was carried out for 3-A25 with MMP-7 and MMP-13. 
Compared to MMP-7 (which has a shallow S1’ pocket), MMP-13 has a relatively deep 
S1’ pocket. As shown in Figure 3-3, 3-A25 fit nicely into the active site of both 
enzymes, with the two sulfur atoms from the rhodanine warhead chelating to the zinc 
ion. In addition, the aromatic moiety in 3-A25 appeared to extend snugly into the S1’ 
binding site of both enzymes. The docking results thus appeared to indicate that 
rhodanines are likely a novel class of ZBGs of MMP inhibitors. 
    
    
    
Figure 3-3. FlexX docking images of compounds 3-A23 and 3-A25 in the active site 
of MMP-7 and -13. (a) MMP-7 complexed with 3-A25. (b) MMP-13 complexed with 
3-A25. (c) MMP-13 complexed with 3-A23. The zinc ion in the active site is shown 







Several key findings arose from our current work. First, we have been able to 
show rhodanines as a novel class of ZBGs of MMP inhibitors for the first time. 
Second, we have demonstrated the compatibility of these ZBGs with “click chemistry” 
for rapid assembly and direct in situ screening of potential MMP inhibitors. Finally, 
we have developed a “one-pot” click chemistry protocol for above applications. Our 
best inhibitors possess moderate inhibitory activities against MMPs currently, but 
upon further optimizations, they may emerge as a new class of potent small 















A panel of 96 metalloprotease inhibitors was assembled using “click chemistry” 
by reacting eight zinc-binding hydroxamate warheads with 12 azide building blocks. 
Screens of the bidentate compounds against representative metalloproteases provided 
discerning inhibition fingerprints, revealing compounds with low micromolar potency 
against MMP-7. The relative ease and convenience of the strategy in constructing 








One of the most widely exploited scaffolds of MMP inhibitors is the 
peptide-based succinyl hydroxamate.
3
 Inhibitors containing this kind of zinc-binding 
groups normally exhibit broad-spectrum inhibition toward most metalloproteases, 
rather than MMPs alone. This is largely due to the structural similarity in the active 
sites of metalloproteases which possess highly conserved zinc-binding residues 
essential for enzyme catalysis. Therefore, it has been an ongoing challenge to develop 
highly efficient synthetic strategies that allow rapid generation and screening of small 




Fragment-based assembly, which allows medicinal chemists to explore N
2
 
possibilities with N+N combinations, is widely employed for high-throughput drug 
discovery.
148
 It typically involves a two-step process including fragment identification 
and fragment linkage. A number of methods have been developed to assist in this 
process,
138, 149-150
 including NMR/X-ray approaches,
150
 the MS-based tethering 
strategy,
149
 and “click chemistry” coupled with in situ screening.138  
Herein, we describe, for the first time, a “click chemistry” approach for the rapid 
synthesis/assembly of a small molecule library based on different succinyl 
hydroxamates, and subsequent in situ screening for identification of candidate hits 
which possess moderate inhibitory activity against MMPs over other metalloproteases. 
Our approach thus lays the foundation for future exploration of more potent and 




Figure 4-1. Structure of (top) general hydroxamate inhibitors and (bottom) “click chemistry” 
inhibitors reported herein against MMPs. 
 
4.3 Results and Discussion 
4.3.1 Design and synthesis of alkyne and azide building blocks 
Our library design was based on the general structure of hydroxamate-based 
MMP inhibitors (Figure 4-1). With this class of inhibitors, it was previously shown 
that (1) hydrophobic P1’ residues are in general preferred, (2) a variety of substitutions 
are tolerated at P2’ and P3’ positions, and (3) hydrophobic P4’ residues are preferred 
and sometimes could confer a good degree of specificity among different MMPs.
3
 As 
such, a total of eight succinyl hydroxamates bearing a variety of alkyl, cycloalkyl, and 
aromatic side chains were synthesized as shown in Scheme 4-1. A common alkyne 
handle was tethered to each warhead, facilitating the subsequent assembly with twelve 
different azides (Scheme 4-2) using “click chemistry”. The azides bear a hydrophobic 
moiety connected via a linker with a varying alkyl length (n = 2 - 4). By changing the 
linker length of the azides, our design facilitates the projection of the hydrophobic 
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moiety into the P4’ binding pocket of a targeted MMP, thereby improving both 
potency and specificity of the resulting inhibitors. 
 
 
Scheme 4-1. Synthesis of Eight Alkyne-containing warheads 
 
As shown in Scheme 4-1, a total of eight different hydrophobic warheads were 
synthesized (A-H). Briefly, a suitable carboxylic acid, 4-1, was converted to 4-2 with 
oxazolidinone, followed by enolate chemistry to introduce the succinyl template 4-3. 
In our case, a racemic mixture of 4-3 was synthesized in order to save cost. If desired, 
the same chemistry could be directly applied for the synthesis of chiral warheads 
using the corresponding chiral oxazolidinone. Next, selective removal of the tert-butyl 
group under acidic conditions (to give 4-4), followed by coupling of trityl-protected 
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hydroxylamine (to give 4-5) and base hydrolysis with H2O2/LiOH, gave 4-6A ~ 4-6H. 
Subsequently, 4-6A ~ 4-6H were coupled to propagylamine using the HATU/DIEA 
coupling method, giving 4-7A ~ 4-7H in excellent yields. Final deprotection of the 
trityl group with TFA furnished the final warheads, 4-8A ~ 4-8H, which were 







Scheme 4-2. Synthesis of 12 azides 
 
The 12-membered azide library was synthesized via a highly efficient two-step 
procedure (Scheme 4-2). Twelve different amines, each bearing a different 
hydrophobic moiety with varied functional groups, were first acylated with either 
2-bromoacetyl chloride, 3-bromopropionyl chloride, or 5-bromopentanoyl chloride, 
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followed by an SN2 substitution reaction with sodium azide in DMF to generate the 
corresponding azides in excellent yields. 
 
4.3.2 Rapid assembly and in situ screening of metalloprotease inhibitors 
Next, a 96-member inhibitor library was assembled using “click chemistry” in a 
96-deep well block. Each of the eight alkyne warheads was mixed with each of the 
twelve azides in a t-BuOH/H2O solution, followed by addition of catalytic amounts of 
sodium ascorbate and CuSO4. The “click chemistry” proceeded with high efficiency 
at room temperature for >12 h. LC-MS confirmed, in almost all cases, the complete 
consumption of the alkynes and quantitative formation of the desired triazole products, 
thus ensuring that they may be used directly for subsequent in situ enzymatic 
screening without any further purification. 
 
 
Scheme 4-3. Click assembly of 96 member MMPIs 
 
MMP-7 together with collagenase and thermolysin were chosen for this study. 
All three enzymes were screened in a high-throughput, automated fashion against the 
96-member library panel using standard fluorescence assays in microplates.
151-157
 The 
inhibitor potency was evaluated from the reduction in fluorescence output when 
introduced in standard enzymatic assays with quenched substrates. The resulting 
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inhibition fingerprints obtained are displayed in Figure 4-2a, demonstrating how such 
enzymes may be easily discerned through their unique inhibition “barcodes”, which 
differ from previous fingerprint profiles generated by other methods
59, 110, 158-159
 in that 
our current method is able to directly reflect an enzyme’s inhibition profiles (potency 
and selectivity). By taking advantage of such inhibition fingerprints, it would become 
possible to characterize and group proteins in an activity-dependent manner. 
Furthermore, such analysis may prove useful in distinguishing not only inhibitors that 
are potent against specific enzyme classes, but also those that provide good 




Figure 4-2. (a) Inhibitor fingerprints of (I) MMP-7, (II) thermolysin, and (III) collagenase, 
represented as “barcodes”. Black: minimum inhibition; Red: maximum inhibition. (b) 
Screening of “clicked” inhibitors against MMP-7. Heat map obtained using TreeView 
displays the inhibition fingerprint, with most potent inhibitors indicated in bright red. 
 
A broader evaluation of the inhibition profile obtained against MMP-7 (as shown 
in Figure 4-2b) revealed a unique and consistent trend. Hydroxamate warheads 
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containing alkyl and cycloalkyl side chains at the P1’ position (i.e., isobutyl, 
cyclohexyl and cyclopentyl in 4-8B, 4-8F, and 4-8G, respectively) contributed highly 
to potency of inhibitors against MMP-7. The strongest inhibition was observed for 
scaffolds containing the latter two unnatural cyclic analogues. This correlates well 
with generic inhibitors against metalloproteases such as GM6001 and batimastat that 
are designed with a small hydrophobic residue (Leu), i.e., isobutyl in the P1’ 
pocket.
160
 Furthermore, both thermolysin and collagenase (profiles provided in the 
Supporting Information) do not display such an exclusive and distinctive preference 
for these small cyclic residues. Our results thus highlight the potential of such 
pharmacophores in the design of novel inhibitors against MMP-7 and possibly other 
MMPs. Another observation is that, azides having a 4-carbon linker (n = 4; F8-11, 
G8-11 in Figure 4-2b) appeared to contribute negatively to the inhibitor potency, 
which indicates the linker might be too long to properly project the hydrophobic 
moiety of the azides into P4’ pocket of MMP-7. 
 





To unambiguously confirm the potency of these scaffolds from the preliminary 
screening, two compounds, 4-F5 and 4-G6, representing each of the cyclohexyl and 
cyclopentyl warheads were selected for detailed evaluations. These molecules were 
purified and fully characterized by NMR and LC-MS, before being evaluated against 
the panel of metalloproteases to elucidate the relevant inhibition constants. As shown 
in Table 4-1, 4-F5 and 4-G6 indeed inhibited MMP-7 strongly with a Ki of 1.4 and 
3.8 μM, respectively. More importantly, these inhibitors were 10-35 times more 
potent toward MMP-7 than the bacterial metalloproteases tested, demonstrating the 
potential of the strategy in elucidating inhibitors with both good potency and high 
selectivity against MMPs. 
 
4.3.3 Docking Simulations 
We docked 4-G6, the most potent inhibitor identified from our screening, against 
the MMP-7 active site using the Sybyl software, on the FlexX suite.
161
 As would be 
expected, the optimized docking configuration of the inhibitor/enzyme complex 
shows the inhibitor adopts an extended conformation, fitting comfortably in the 
enzyme active site (Figure 4-3). The hydroxamate group from the inhibitor was 
shown to chelate to the target zinc atom. The cyclopentyl P1’ side chain also fits 
nicely into the S1’ pocket. As we were hoping in the original design, the phenolic ring 





Figure 4-3. In silico docking displays the possible binding mode of 4-G6/MMP-7 complex. 
The hydroxamic group in the inhibitor chelates with the zinc atom (green sphere) in the 
enzyme active site, with the inhibitor projecting into the S’ pockets of the enzyme. Docking 
was performed using Sybyl v7.2 (Tripos, MO) with electrostatic surface images generated 
using WebLab ViewerLite (Accelrys, San Diego, CA). 
 
4.4 Conclusion 
In conclusion, we have developed a high-throughput strategy for assembling and 
screening MMP inhibitors. The panel of compounds we have synthesized show 
promise as a valuable resource for screening various MMPs and obtaining unique 
inhibition fingerprints. Moreover, we have identified specific scaffolds that show 
good potency and moderate selectivity for MMP-7 over other metalloproteases. We 
anticipate that the pharmacophore we have uncovered in this study may lead to future 
development of more potent and selective inhibitors against other MMPs. We are thus 
extending our experiments against a wider panel of MMPs to confirm the selectivity 








Chapter 5.  
 
“Click” Synthesis of Small Molecule Probes for 







By using ‘‘Click Chemistry’’, we achieved the facile synthesis of various 
affinity-based hydroxamate probes that enable generation of activity-based 
fingerprints of a variety of metalloproteases, including matrix metalloproteases 
(MMPs), in proteomics experiments. 
 
5.2 Introduction 
With the precise biological functions of other human MMPs remaining largely 
unknown, the development of novel chemical and biological methods capable of 
high-throughput identification and characterization of MMPs has become increasingly 
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urgent. Activity-based profiling (ABP), originally developed by Cravatt et al.,
52
 is one 
such technique that has recently been adapted for the study of metalloproteases 
including MMPs.
162
 ABP works by selectively targeting enzymes of choice from a 
crude proteome, in an activity-based manner, using the so-called activity- and 
affinity-based small molecule probes. In the case of MMPs, small molecule probes 
possessing a) a hydroxamic acid recognition moiety known to chelate to the 
active-site zinc of MMPs (as well as other zinc-containing proteins such as 
thermolysin and collagenase), b) a photolabile group (usually benzophenone or 
diazirine) capable of covalent crosslinking to the target enzyme, and c) a 
fluorescent/affinity tag for easy visualization/isolation of the cross-linked enzyme, 
have been successfully documented.
58-59
 Furthermore, in cases where a repertoire of 
probes having different recognition elements are available, one can obtain the 
“activity-based fingerprint” of the target enzyme, which reveals not only affinity, but 













As shown in Scheme 5-1, the previously reported first-generation MMP probes 
were peptides containing a C-terminal hydroxamic acid.
59
 Despite simplicity in their 
chemical synthesis, these so-called “left-handed” probes suffer a major drawback in 
that they bind to MMPs with relatively low affinity, making them less suitable for 
sensitive detection of MMPs from a complex proteome.
52, 133
 In this chapter, I report 1) 
the synthesis of second-generation “right-handed” probes aided by “click chemistry”, 
2) their application in gel-based activity-based fingerprinting of numerous 
metalloproteases (including MMPs), and 3) the related preliminary microarray-based 
experiments which, for the first time, demonstrate that affinity-based probes are 
indeed compatible with protein microarrays for potential enzyme profiling 
experiments. 
 
5.3 Results and Discussion 
5.3.1 Chemical design of the activity-based MMP probes 
Take the advantage of the “click chemistry” between an alkyne-derivatized 
succinyl hydroxamate warhead and an azide-containing trifunctional tag for the highly 
modular and facile synthesis, a total of 12 different activity-based probes against 





Scheme 5-2. General structures of the 12 MMP probes used in this work. Val (A); Leu (B); 
Ile (C); Phe (D); Long-Phe (E); Cyclohexyl (F); Cyclopentyl (G); O-Ph (H); Long-OH (I); 
Lys (J); Asp (K); Sulfone (L). 
 
Of the twelve succinyl hydroxamates, eight contain various alkyl and aromatic 
hydrophobic side chains (A to H). They were synthesized based on previously 
reported procedures.
164
 The remaining four hydroxamates (I to L) introduce side 
chains possessing acidic and basic groups, as well as hydrophilic groups with the 
property of hydrogen-bonding, at the P1’ position, thus are able to form favorable 
electrostatic interactions with different S1’ binding pockets of MMPs. 
 
5.3.2 Activity based fingerprinting of metalloproteases 
A diverse group of different classes of metalloproteases were chosen in our 
experiment, such that they highlight the potential of the strategy not only in 
distinguishing between both close and distant members, but also in potential 
identification and characterization of various disease-related enzymes, i.e. MMPs and 
anthrax lethal factor. In addition, carbonic anhydrase, a well-known zinc-binding 
protein (but not a metalloprotease) was also tested. Figure 5-1 displays the results 
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obtained using gel-based fingerprinting with the probe library. Notably, I was able to 
produce distinct and reproducible fingerprints for each of these proteins, thus 
providing a unique capability of identifying and classifying these proteins according 
to their labeling profiles. Generally the Lys and Ile probes showed the greatest degree 
of labeling and seemed to strongly label nearly all the enzymes tested. The other 
probes were however more discerning in their labeling patterns. It was observed that 
the strongest labeling for MMP-3 was that of Long-OH and Lys probes. This agrees 
well with the known long hydrophobic pocket of MMP-3 that has been previously 
reported to bind designed inhibitors with such long hydrophilic scaffolds.
133
 MT-1 
MMP also shares a similar long pocket toMMP-3 and is observed to possess greater 
affinity to the Long-Phe as well as the Lys probe relative to the other probe scaffolds. 
The short S1’ pocket of MMP-7 was shown to accommodate both the Val and Phe 
probes. The Asp and Sulfone probes showed the weakest labeling with most of the 
enzymes, indicating these moieties are generally unfavored for most of the 
metalloproteases tested. Overall the fingerprints enabled different enzymes to be 
classified according to their similarity. MMP-3 gave a distinct profile compared to the 
other enzymes screened. The labeling pattern of carbonic anhydrase was similar to 
that of MMP-7. Both anthrax lethal factor and MT-1 MMP show strong selective 
labeling with one of the probe library set, namely Ile and Lys respectively. 
Importantly the panel of probes we have designed enables sufficient coverage for one 





Figure 5-1. Fingerprints of 12 probes against 7 metalloenzymes. Strongest relative labeling is 
visualized in red according to the scale shown. The fingerprints were further hierarchically 
clustered according to their labeling profiles 
 
 
Figure 5-2. Protein microarray of various metalloenzymes screened by the Leu probe. Five 
different proteins were spotted in triplicate: 1. Carbonic anhydrase (300 μg/mL); 2. 
Collagenase (300 μg/mL); 3. Thermolysin (300 μg/mL); 4. Anthrax LF (6 μg/mL); 5. 
β-Chymotrypsin (300 μg/mL). 
 
We next tested the feasibility of these probes to be used in a protein microarray 
for potential high-throughput discovery of metalloproteases. Previously, only 
activity-based, but not affinity-based, probes have been shown to detect enzymes 
immobilized in a protein microarray.
110, 165-166
 Five different enzymes, comprising 
three metalloproteases (i.e. collagenase, thermolysin and anthrax LF), one serine 
protease (i.e. b-chymotrypsin) and carbonic anhydrase, were spotted in triplicate on a 
glass slide, and subsequently screened with the Leu probe (Figure 5-2). Results 
indicate that the probe was in general able to distinguish metalloenzyme activity over 
0%                   100% 
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other non-metalloenzyme activities, in most cases generating positive fluorescence 
signals only with metalloproteases (e.g. collagenase and thermolysin), as well as 
carbonic anhydrase (a zinc-binding enzyme), but not with b-chymotrypsin.  
 
5.4 Conclusion  
We have used “click chemistry” to successfully synthesize a second-generation 
library of metalloprotease probes containing succinyl warhead with a variety of P1’ 
functionalities. With these probes, I have been able to generate unique activity-based 
fingerprints against various metalloproteases including MMPs and other 
therapeutically important enzymes such as anthrax LF. Such fingerprinting strategies 
may lead to future identification and characterization of new MMPs, and the 
development of potential potent and selective inhibitors. I have also for the first time 
shown that affinity-based probes may be equally amenable for high-throughput 








6.1 General Information 
 
All chemicals were purchased from commercial vendors and used without further 
purification, unless indicated otherwise. Rink Amide resin, all Fmoc-protected amino 
acids, O-benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate 
(HBTU), N-hydroxybenzotriazole (HOBt), triisopropylsilane (TIS), and all other 
peptide synthesis reagents were purchased from GL Biochem (China). All 
nonaqueous reactions were carried out under a nitrogen atmosphere in oven-dried 
glassware. Reaction progress was monitored by TLC on precoated silica plates 
(Merck 60 F254, 250 μm thickness) and spots were visualized by Ceric Ammonium 
Molybdate (CAM), basic KMnO4, UV light or iodine. Flash column chromatography 





C NMR spectra were taken on a Bruker 300 MHz or DPX-300 MHz 
or Bruker Avance 500 MHz NMR spectrometer. Chemical shifts are reported in parts 
per million (ppm) referenced with respect to residual solvent (CDCl3 = 7.26 ppm, 
(CD3)2SO = 2.50 ppm) or Tetramethylsilane (Si(CH3)4 = 0.00 ppm). 
1
H NMR 
coupling constants (J) are reported in hertz (Hz) and the following abbreviations were 
used in reporting spectra: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, 
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dd = doublet of doublets, ddd = doublet of doublets of doublets, dt = doublet of 
triplets or overlap of nonequivalent resonances.  
Mass spectra were recorded on a Finnigan LCQ mass spectrometer, a Shimadzu 
LC-IT-TOF spectrometer or a Shimadzu LC-ESI spectrometer. Analytical HPLC was 
carried out on Shimadzu LC-IT-TOF or LC-ESI systems equipped with an 
autosampler, using reverse-phase Phenomenex Luna 5 μm C18 100 Å 50 × 3.0 mm 
columns. Preparative HPLC was carried out on Gilson preparative HPLC system 
using Trilution software and reverse-phase Phenomenex Luna 5 μm C18(2) 100 Å 50 × 
30.00 mm column. A 0.1% TFA/H2O and 0.1% TFA/acetonitrile were used as eluents 
for all HPLC experiments. The flow rate was 0.6 mL/min for analytical HPLC and 10 
mL/min for preparative HPLC. Details of synthetic procedures and characterizations 
of most compounds were reported in the Supporting Information. Characterizations of 
key intermediates and final probes are reported below. 
Recombinant Caspases were expressed, purified and fluorescently labeled as 
previously described.
130
 Other enzymes were obtained from commercial sources as 
specified below. We used in this study a repertoire of enzymes including a range of 
human matrix metalloproteases, namely MMP-7 (Calbiochem, USA. Cat# 444270), 
MMP-8 (Biomol, Cat# SE-255), MMP-9 (Calbiochem, USA. Cat# PF024), MMP-13 






6.2 Solution Phase Synthesis 
 
6.2.1 General Procedure for Synthesis of Dabcyl-containing linker 
 
Scheme 6-1. Synthesis of Dabcyl-containing linker 
 
Dabcyl-NHS (2-2) 
  N-hydroxysuccinimide (0.51 g, 4.5 mmol) and EDC (1.3 g, 6.8 mmol) were added 
to a solution of Dabcyl sodium salt (1.0 g, 3.4 mmol) in 60 mL DMF. The reaction 
mixture was stirred at room temperature overnight. The crude product was 
concentrated in vacuo and purified by flash chromatography (Ethyl Acetate : Hexane 
= 2:1) to obtain a purple solid compound 2-2 (0.78 g, 62.7%). 
1
H-NMR (300 MHz, 
CDCl3) δ 8.25 (d, J = 8.6 Hz, 2H), 7.92 (d, J = 8.9 Hz, 4H), 6.76 (d, J = 9.2 Hz, 2H), 
3.49-3.46 (m, 2H), 3.19-3.13 (m, 2H), 2.95 (s, 6H). IT-TOF: m/z [M+H]
+
 calcd: 





tert-Butyl 3-aminopropylcarbamate (2-3b) 
Under a nitrogen atmosphere, to a solution of propane-1,3-diamine 2-3a (41.7 
mL, 500 mmol) in anhydrous CHCl3 (100 mL) cooled to 0 °C was added dropwise 
di-tert-butyldicarbonate (10.9 g, 50 mmol) in 50 mL CHCl3. After being stirred for 24 
hrs at room temperature, the solvent was evaporated in vacuo. The thick oil obtained 
was taken up in CH2Cl2 (100 mL). The organic layer was successively washed with 
water, brine, dried over anhydrous Na2SO4 and concentrated in vacuo to afford 7.3 g 
(84%) of crude compound 2-3b. This material was used without further purification. 
1
H-NMR (300 MHz, CDCl3) δ 3.13 (q, J = 6.2 Hz, 2H), 2.69 (t, J = 6.6 Hz, 2H), 1.55 
(m, 2H), 1.37 (s, 9H). 
13
C-NMR (75 MHz, CDCl3) δ 156.08, 78.87, 39.40, 38.16, 
33.23, 28.28.  
 
Dabcyl derivative (2-4) 
Dabcyl-NHS (2-2) (0.78 g, 2.1 mmol) dissolved in 50 mL DMF was added 
tert-butyl 3-aminopropylcarbamate (2-3b) (0.44 g, 2.5 mmol) followed by DIEA (0.4 
mL, 2.5 mmol). The reaction mixture was stirred at room temperature overnight. The 
resulting solution was concentrated in vacuo and purified by flash chromatography 
(MeOH : DCM = 1:9) to afford Dabcyl derivative 2-4 (0.81 g, 91.2%). 
1
H-NMR (300 
MHz, CDCl3) δ 7.97-7.87 (m, 6H), 6.76 (d, J = 9.2 Hz, 2H), 4.01 (m, 2H), 3.27 (m, 
2H), 3.11 (s, 6H), 1.93 (m, 2H), 1.45 (s, 9H). IT-TOF: m/z [M+H]
+





Dabcyl derivative (2-5) 
Compound 2-4 (0.81 g, 1.9 mmol) was vigorously stirred in 20% TFA/DCM 
solution for around 3 hrs. The reaction solution was concentrated and dried in vacuo 
to afford Dabcyl derivative 2-5. The crude product was directly used without further 
purification. 
1
H-NMR (300 MHz, CDCl3) δ 7.83-7.77 (t, J = 9.0 Hz, 4H), 7.73-7.70 (d, 
J = 9.0 Hz, 2H), 6.75-6.71 (d, J = 12.0 Hz, 2H), 3.40-3.36 (t, J = 6.0 Hz, 2H), 3.05 (s, 
6H), 2.85-2.81 (t, J = 6.0 Hz, 2H), 1.86-1.82 (t, J = 6.0 Hz, 2H). 
13
C-NMR (75 MHz, 
CDCl3) δ 168.52, 153.67, 142.40, 133.14, 128.08, 126.75, 121.14, 112.47, 40.38, 
36.57, 35.92, 27.00. IT-TOF: m/z [M+H]
+
 calcd: 326.19, found 326.19. 
 
 
6.2.2 General Procedure for Synthesis of probe 2-P1 to 2-P4 
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Scheme 6-2. Synthesis of 2-P1 to 2-P4. The modularity of the probes were highlighted by 
showing the key components of each probe with a different color (Blue: enzymatic WH; Red: 
quinone methide; Orange: quencher; Green: fluorophore). Reagents and conditions: a) i. 
Fmoc-Gly-OH, HBTU, HOBt, DIEA, DMF; ii. 20% piperidine in DMF; b) i. 
Fmoc-Lys(Mtt)-OH, HBTU, HOBt, DIEA, DMF; ii. 20% piperidine in DMF; c) i. compound 
17, HATU, HOAt, DIEA, DMF; ii. 20% piperidine in DMF; d) i. Fmoc-Val-OH, HBTU, 
HOBt, DIEA, DMF; ii. 20% piperidine in DMF; e) i. Fmoc-Glu(OtBu)-OH, HBTU, HOBt, 
DIEA, DMF; ii. 20% piperidine in DMF; f) i. Fmoc-Asp(OtBu)-OH, HBTU, HOBt, DIEA, 
DMF; ii. 20% piperidine in DMF; iii. Acetic anhydride, DIEA; g) i. 1% TFA 5% TIS in 
DCM, 30 mins; ii. Fluorescein(OAc)2-NHS, DIEA, DMF; iii. 20% piperidine in DMF; h). 




tert-Butyl 2-(4-nitrophenyl)acetate (2-7) 
To a solution of 2-(4-nitrophenyl)acetic acid 2-6 (9.06 g, 50 mmol) in 100 mL 
CHCl3, pyridine (20 mL, 250 mmol) and t-BuOH (47 mL, 500 mmol) were added 
followed by POCl3 (6 mL, 65 mmol) dropwise over 2 mins. After 5 hrs, the reaction 
mixture was poured into a solution of ice containing 20 mL DCM and 10 mL 10% 
HCl. The organic layer was separated and washed with brine, dried over anhydrous 
Na2SO4. The pure product 2-7 was obtained by flash chromatography (Ethyl Acetate : 
Hexane = 1:9, 11.3 g, 95%). 
1
H-NMR (300 MHz, CDCl3) δ 8.19 (d, J = 8.8 Hz, 2H), 
7.44 (d, J = 8.8 Hz, 2H), 3.64 (s, 2H), 1.44 (s, 9H). 
13
C-NMR (75 MHz, CDCl3) δ 
173.11, 169.36, 142.08, 130.17, 123.63, 81.73, 42.35, 27.96. IT-TOF: m/z [M+H]
+
 
calcd: 238.10, found 238.09. 
 
tert-Butyl 2-bromo-2-(4-nitrophenyl)acetate (2-8) 
NBS (9.3 g, 52 mmol) was added to a solution of compound 2-7 (11.3 g, 47.5 
mmol) in 150 mL of CCl4 in a reaction flask equipped with a condenser. The flask 
was irradiated with a 100W tungsten lamp for 5 hrs resulting in the formation of a 
white precipitate. Following filtration, the filtrate was concentrated, subjected to silica 
gel column chromatography (Ethyl Acetate : Hexane = 1:9) to give the product 2-8 
(12.7 g, 85%) as a pale yellow solid. 
1
H-NMR (300 MHz, CDCl3) δ 8.22 (d, J = 8.7 
Hz, 2H), 7.72 (d, J = 8.8 Hz, 2H), 5.28 (s, 1H), 1.47 (s, 9H). 
13
C-NMR (75 MHz, 
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CDCl3) δ 166.23, 148.01, 143.11, 129.71, 123.77, 83.95, 45.99, 27.62. IT-TOF: m/z 
[M+H]
+
 calcd: 316.01, found 316.00. 
 
tert-Butyl 2-acetoxy-2-(4-nitrophenyl)acetate (2-9) 
Compound 2-8 (12.7 g, 40.4 mmol) was dissolved in a mixture of 100 mL DMF 
and 50 mL H2O under nitrogen with constant stirring. Following addition of 
CH3COONa (6.6 g, 48 mmol), the mixture was stirred at 100 °C. After 3 hrs, the 
solvent was removed by evaporation under reduced pressure, and the residue was 
partitioned between ethyl acetate (150 mL) and brine (150 mL). The organic layer 
was then separated, washed with 10% hydrochloric acid (100 mL) and brine (100 
mL), dried with anhydrous Na2SO4 and then concentrated under reduced pressure to 
give a brown oil which was subsequently purified by flash chromatography (Ethyl 
Acetate : Hexane = 1:8)to afford the pale yellow solid 2-9 (9.4 g, 79.1%). 
1
H-NMR 
(300 MHz, CDCl3) δ 8.24 (d, J = 8.8 Hz, 2H), 7.66 (d, J = 8.8 Hz, 2H), 5.90 (s, 1H), 
2.22 (s, 3H), 1.40 (s, 9H). 
13
C-NMR (75 MHz, CDCl3) δ 169.84, 166.57, 148.17, 
141.19, 128.16, 123.79, 83.47, 73.84, 27.75, 20.62. IT-TOF: m/z [M+H]
+
 calcd: 
296.11, found 296.10. 
 
2-Acetoxy-2-(4-nitrophenyl)acetic acid (2-9b) 
Compound 2-9 (9.4 g, 32.0 mmol) was vigorously stirred in 20% TFA/DCM 
solution for around 8 hrs. The reaction solution was concentrated and dried in vacuo 





H-NMR (300 MHz, CDCl3) δ 8.26 (d, J = 8.9 Hz, 2H), 7.70 (d, J = 8.6 
Hz, 2H), 6.05 (s, 1H), 2.24 (s, 3H). IT-TOF: m/z [M+H]
+
 calcd: 240.04, found 240.03. 
 
Allyl 2-(tert-butoxycarbonylamino)acetate (2-10b) 
To a solution of compound 2-10a (8.76 g, 50 mmol) in 100 mL DMF, K2CO3 was 
added at 0 °C. Then allyl bromide was added and the reaction mixture was stirred 
overnight. Most of DMF was removed in vacuo. The residue was redissolved in 
EtOAc and washed with water, brine, dried over anhydrous Na2SO4 to afford the 
crude product 2-10b (9.5 g, 88%). 
1
H-NMR (300 MHz, CDCl3) δ 5.98-5.85 (m, 1H), 
5.33 (d, J = 17.1 Hz, 1H), 5.25 (d, J = 10.4 Hz, 1H), 4.64 (d, J = 5.7 Hz, 2H), 3.93 (d, 
J = 5.6 Hz, 2H), 1.45 (s, 9H).  
 
Allyl 2-aminoacetate (2-10c) 
Compound 2-10b (9.5 g, 44 mmol) was vigorously stirred in 20% TFA/DCM 
solution for around 8 hrs. The reaction solution was concentrated and dried in vacuo 
to afford compound 2-10c. The crude product was directly used without further 
purification. 
 
Allyl 2-(2-acetoxy-2-(4-nitrophenyl)acetamido)acetate (2-11) 
To a solution of compound 2-9b (5.98 g, 25 mmol) in 100 mL DCM, EDC (5.7 g, 
30 mmol) and DIEA (5.1 mL, 30 mmol) were added under N2 protection. Then a 
solution of allyl 2-aminoacetate (2-10c) (3.5 g, 30 mmol) was added slowly and the 
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reaction mixture was stirred at room temperature for overnight. The mixture was 
diluted by DCM and washed with 1 M HCl, water and brine, dried over anhydrous 
Na2SO4. The pure compound 2-11 was obtained after flash chromatography (Ethyl 
Acetate : Hexane = 1:7, 6.8 g, 81.4%). 
1
H-NMR (300 MHz, CDCl3) δ 8.26 (d, J = 8.9 
Hz, 2H), 7.66 (d, J = 8.7 Hz, 2H), 6.90 (s, 1H), 6.21 (s, 1H), 5.96-5.83 (m, 1H), 5.33 
(d, J = 17.3 Hz, 1H), 5.27 (d, J = 11.5 Hz, 1H), 4.66 (d, J = 5.9 Hz, 2H), 4.10 (q, J = 
4.1 Hz, 2H), 2.24 (s, 3H). 
13
C-NMR (75 MHz, CDCl3) δ 169.04, 168.63, 167.32, 
142.11, 131.14, 128.25, 123.86, 119.31, 74.18, 66.35, 41.13, 20.85. IT-TOF: m/z 
[M+H]
+
 calcd: 337.10, found 337.10. 
 
Allyl 2-(2-hydroxy-2-(4-nitrophenyl)acetamido)acetate (2-12) 
A solution of compound 2-11 (2.6 g, 7.7 mmol) in 50 mL allyl alcohol, was 
added Cesium carbonate (1.2 g, 3.8 mmol) slowly. The reaction was monitored 
closely by TLC and quenched by 1 M HCl once the starting material disappeared. The 
reaction mixture was concentrated in vacuo and redissolved in Ethyl Acetate, washed 
with water, brine and dried over anhydrous Na2SO4. A yellow solid product 2-12 was 
obtained after flash chromatography (Ethyl Acetate : Hexane = 1:4, 1.9 g, 85.7%). 
1
H-NMR (300 MHz, CDCl3) δ 8.20 (d, J = 8.7 Hz, 2H), 7.67 (d, J = 8.8 Hz, 2H), 7.16 
(s, 1H), 5.94-5.81 (m, 1H), 5.34 (d, J = 1.2 Hz, 1H), 5.26 (d, J = 11.0 Hz, 2H), 4.63 
(d, J = 5.8 Hz, 2H), 4.21 (s, 1H), 4.05 (dq, 2H), 1.92 (s, 1H). 
13
C-NMR (75 MHz, 
CDCl3) δ 171.41, 169.31, 147.89, 145.81, 131.13, 127.41, 123.73, 119.27, 73.21, 
66.33, 41.05. IT-TOF: m/z [M+H]
+




Allyl 2-(2-(4-aminophenyl)-2-hydroxyacetamido)acetate (2-13) 
A mixture of 2-12 (1.9 g, 6.5 mmol), AcOH (1.9 mL, 32.5 mmol), and powdered 
Zn (4.3 g, 65 mmol) was stirred in THF (10 mL) at room temperature for 2 hrs. The 
mixture was diluted with EtOAc, filtered through Celite, washed with sat. NaHCO3 
and brine, dried over anhydrous Na2SO4, and concentrated in vacuo. The product was 
chromatographed on silica gel (Ethyl Acetate : Hexane = 3:1) to give compound 2-13 
(1.6 g, 95%). 
1
H-NMR (300 MHz, CDCl3) δ 7.20 (d, J = 8.5 Hz, 2H), 6.67 (d, J = 8.5 
Hz, 2H), 5.96-5.83 (m, 1H), 5.33 (d, J = 17.2 Hz, 1H), 5.27 (d, J = 10.5 Hz, 1H), 5.00 
(s, 1H), 4.64 (d, J = 5.8 Hz, 2H), 4.17-3.99 (m, 2H). IT-TOF: m/z [M+H]
+
 calcd: 




To a solution of compound 2-13 (1.6 g, 6.1 mmol), Fmoc-Asp(OtBu)-OH (2.76 g, 
6.7 mmol), EDC (1.4 g, 7.3 mmol), DMAP (0.074 g, 0.61 mmol) in 50 mL DCM, 
DIEA (1.24 mL, 7.3 mmol) was added under N2 protection. The reaction mixture was 
stirred at room temperature overnight. The mixture was diluted by DCM and washed 
with 10% citric acid, water and brine, dried over anhydrous Na2SO4. The pure 
compound 2-14 was obtained after flash chromatography (Ethyl Acetate : Hexane = 
1:2)3.0 g, 74.8%). 
1
H-NMR (500 MHz, CDCl3) δ 7.73 (d, J = 7.6 Hz, 2H), 7.56 (t, J = 
5.0 Hz, 2H), 7.40-7.35 (m, 4H), 7.31-7.24 (m, 4H), 7.17 (d, J = 2.6 Hz, 1H), 6.20 (s, 
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1H), 5.89-5.81 (m, 1H), 5.31-5.21 (m, 2H), 4.99 (d, J = 3.7 Hz, 1H), 4.65 (s, 1H), 
4.59 (d, J = 5.6 Hz, 2H), 4.41 (t, J = 6.9 Hz, 2H), 4.26 (d, J = 3.8 Hz, 1H), 4.19 (t, J = 
6.9 Hz, 1H), 4.04-3.97 (m, 2H), 1.43 (s, 9H). 
13
C-NMR (125 MHz, CDCl3) δ 172.78, 
172.76, 171.16, 170.89, 169.39, 168.89, 143.60, 143.56, 141.24, 137.53, 135.40, 
131.35, 127.74, 127.55, 127.07, 124.95, 120.33, 119.97, 118.96, 82.08, 73.67, 67.30, 
66.04, 60.36, 51.85, 47.03, 41.04, 38.54, 37.61, 27.97, 20.97, 14.13. IT-TOF: m/z 
[M+H]
+
 calcd: 658.27, found 658.26. 
 
(4S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-((4-(2-((2-(allyloxy)-2-oxoeth
yl)amino)-1-hydroxy-2-oxoethyl)phenyl)amino)-5-oxopentanoic acid (2-14b) 
Yield: 77.1%. 
1
H-NMR (500 MHz, CDCl3) δ 7.73-7.71 (d, J = 6.0 Hz, 1H), 
7.69-7.66 (t, J = 5.0 Hz, 1H), 7.57-7.53 (t, J = 5.7 Hz, 2H), 7.41-7.39 (t, J = 6.4 Hz, 
1H), 7.37-7.33 (m, 3H), 7.31-7.30 (d, J = 4.2 Hz, 2H), 7.26-7.24 (t, J = 2.6 Hz, 2H), 
7.22-7.20 (dd, J1 = 4.5 Hz, J2 = 9.5 Hz, 2H), 6.20-6.19 (d, J = 4.5 Hz, 1H), 5.88-5.80 
(m, 1H), 5.29-5.20 (m, 2H), 5.02-5.01 (d, J = 5.0 Hz, 1H), 4.59-4.57 (d, J = 3.2 Hz, 
2H), 4.38-4.31 (m, 3H), 4.17-3.97 (m, 4H), 1.42 (s, 9H). 
13
C-NMR (125 MHz, 
CDCl3) δ 173.20, 172.98, 170.21, 169.39, 169.34, 156.64, 143.58, 141.22, 137.59, 
131.34, 128.42, 127.71, 127.57, 127.08, 126.40, 125.05, 120.38, 119.93, 118.98, 
116.37, 111.58, 81.25, 73.73, 67.26, 66.09, 47.02, 41.09, 38.58, 31.69, 28.03. 
IT-TOF: m/z [M+H]
+








To a solution of compound 2-14 (3.0 g, 4.6 mmol), DMAP (0.056 g, 0.46 mmol) 
and pyridine (2.2 mL, 27.6 mmol) in 80 mL DCM, was added p-nitrophenyl 
chloroformate (1.9 g, 9.2 mmol) portion-wise at 0 °C. After 24 hrs, 10% citric acid 
was added to quench the reaction. The organic layer was washed with water, brine 
and dried over anhydrous Na2SO4. The pure compound 2-15 was obtained by flash 
chromatography (Ethyl Acetate : Hexane = 2:1, 2.3 g, 62%). 
1
H-NMR (300 MHz, 
CDCl3) δ 8.27 (d, J = 8.8 Hz, 1H), 7.77 (d, J = 7.6 Hz, 2H), 7.59-7.37 (m, 10H), 7.31 
(d, J = 7.4 Hz, 2H), 6.05 (s, 1H), 5.95-5.84 (m, 1H), 5.39-5.26 (m, 2H), 4.67 (d, J = 
5.7 Hz, 2H), 4.48 (d, J = 6.7 Hz, 2H), 4.23 (t, J = 6.7 Hz, 2H), 4.16-4.09 (m, 2H), 
2.95 (dd, 1H), 2.67 (dd, 1H), 1.46 (s, 9H). IT-TOF: m/z [M+H]
+





oic acid (2-15b) 
Yiled: 39.9%. The product is quite unstable, so we directly proceeded to the next 
step. IT-TOF: m/z [M+H]
+








To a solution of compound 2-15 (2.3 g, 2.9 mmol) and DIEA (0.64 mL, 3.8 
mmol) in 50 mL THF was added compound 5 (1.1 g, 3.5 mmol). The reaction was 
stirred overnight and concentrated in vacuo, redissolved in EtOAc. The solution was 
washed with 10% citric acid, water, brine and dried over anhydrous Na2SO4. An 
orange compound 2-16a was obtained after flash chromatography (Ethyl Acetate : 
Hexane = 1:1)2.4 g, 83%). 
1
H-NMR (300 MHz, CDCl3) δ 8.62 (s, 1H), 7.91-7.85 (m, 
6H), 7.75 (d, J = 7.6 Hz, 2H), 7.58 (d, J = 7.2 Hz, 2H), 7.50 (d, J = 8.8 Hz, 2H), 
7.44-7.37 (m, 4H), 7.30 (d, J = 7.4 Hz, 2H), 6.91 (s, 2H), 6.75 (d, J = 9.2 Hz, 2H), 
6.07 (s, 1H), 5.92-5.81 (m, 2H), 5.33-5.22 (m, 2H), 4.62 (d, J = 5.9 Hz, 3H), 4.46 (d, 
J = 7.1 Hz, 2H), 4.22 (t, J = 6.3 Hz, 2H), 4.09 (t, J = 5.9 Hz, 2H), 3.51 (q, J = 5.9 Hz, 
2H), 3.30 (s, 2H), 3.10 (s, 6H), 2.91 (dd, 1H), 2.69 (dd, 1H), 1.45 (s, 9H). 
13
C-NMR 
(75 MHz, CDCl3) δ 171.10, 169.65, 169.29, 168.82, 163.23, 156.34, 155.11, 152.86, 
143.59, 143.55, 141.28, 140.69, 131.28, 128.35, 127.78, 127.09, 126.06, 125.46, 
124.94, 122.25, 120.20, 120.01, 119.06, 115.68, 111.48, 82.26, 75.40, 66.15, 51.81, 
49.37, 47.08, 41.14, 40.67, 40.24, 33.76, 29.65, 28.00. IT-TOF: m/z [M+H]
+
 calcd: 






en-9-yl)phenyl)amino)-5-oxopentanoic acid (16b) 
Yiled: 69.9%. 
1
H-NMR (500 MHz, CDCl3) δ 7.89-7.85 (t, J = 6.2 Hz, 2H), 
7.82-7.81 (d, J = 3.8 Hz, 2H), 7.73-7.70 (t, J = 6.2 Hz, 2H), 7.61-7.60 (d, J = 3.8 Hz, 
1H), 7.55-7.53 (t, J = 4.2 Hz, 2H), 7.47-7.46 (d, J = 1.5 Hz, 2H), 7.43-7.33 (m, 6H), 
7.26 (s, 2H), 6.72-6.70 (d, J = 5.3 Hz, 1H), 6.03 (s, 1H), 5.89-5.78 (m, 1H), 5.77 (s, 
1H), 5.37-5.16 (m, 3H), 4.66-4.65 (d, J = 7.2 Hz, 1H), 4.58-4.54 (dd, J1 = 3.4 Hz, J2 = 
7.6 Hz, 1H), 4.35-4.30 (t, J = 15.2 Hz, 2H), 4.18-4.14 (q, J = 4.5 Hz, J = 9.1 Hz, 2H), 
4.09-3.97 (m, 2H), 3.42-3.41 (d, J = 3.4 Hz, 2H), 3.22-3.18 (m, 2H), 3.06 (s, 6H), 
2.11 (s, 2H), 1.94- 1.93 (d, J = 3.8 Hz, 2H), 1.73-1.68 (m, 2H), 1.41 (s, 9H). 
13
C-NMR (125 MHz, CDCl3) δ 172.79, 170.62, 165.69, 1.56.54, 155.38, 154.92, 
154.40, 152.72, 143.51, 143.50, 141.14, 141.11, 131.27, 130.80, 127.62, 127.60 , 
126.97, 125.28, 124.91, 122.05, 119.84, 119.82, 111.35, 80.91, 67.05, 66.71, 65.92, 
54,63, 46.96, 40.56, 40.08, 37.86, 31.37, 27.91. IT-TOF: m/z [M+H]
+





6,11- triazatridecan-13-oic Acid (2-17a) 
HPLC-grade THF was degassed with Argon for 1 h. Then compound 2-16a 
(prepared from Fmoc-Asp(t-Bu)-OH in multiple steps; see Scheme 6-2 in this section) 
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(2.4 g, 2.4 mmol) and PhSiH3 (0.6 mL, 4.8 mmol) were added, followed by Pd(PPh3)4 
(5 wt %, 120 mg) under an argon atmosphere. The reaction mixture was concentrated 
in vacuo and purified by flash chromatography (MeOH/DCM = 1:8) to afford 2-17a 
as an orange compound (1.6 g, 69.2%). 
1
H-NMR (300 MHz, CDCl3) δ 10.19 (s, 1H), 
8.67 (s, 1H), 8.01 (d, J = 8.6 Hz, 2H), 7.88-7.79 (m, 7H), 7.70 (t, J = 7.2 Hz, 3H), 
7.57 (t, J = 8.4 Hz, 3H), 7.38 (d, J = 7.2 Hz, 4H), 7.32-7.28 (m, 2H), 6.84 (d, J = 9.2 
Hz, 2H), 5.82 (s, 1H), 4.51 (q, J = 7.9 Hz, 1H), 4.34-4.19 (m, 3H), 3.07 (s, 6H), 2.72 
(m, 1H), 2.55 (m, 1H), 1.68 (t, J = 6.7 Hz, 2H), 1.36 (s, 9H). 
13
C-NMR (75 MHz, 
CDCl3) δ 169.7, 169.53, 165.77, 155.46, 154.39, 153.30, 144.27, 144.19, 143.13, 
141.17, 139.88, 139.29, 137.90, 135.26, 132.41, 129.40, 128.81, 128.31, 128.11, 
127.77, 127.52, 125.73, 125.54, 121.96, 121.84, 120.55, 120.49, 119.68, 112.05, 
110.20, 80.76, 74.90, 66.24, 52.68, 47.08, 38.69, 38.01, 37.42, 29.82, 28.23, 28.16. 
IT-TOF: m/z [M+H]
+




-triazatridecan- 13-oic Acid (2-17b). 
Obtained similarly from compound 2-16b (prepared from Fmoc-Glu(t-Bu)-OH as 
shown in Scheme 6-2). Yield: 61.8%. 
1
H-NMR (500 MHz, CDCl3) δ 7.77 (s, 2H), 
7.71 (s, 2H), 7.62 (s, 4H), 7.41 (s, 4H), 7.38-7.37 (d, J = 4.9 Hz, 2H), 7.26 (s, 4H), 
7.15 (s, 2H), 6.62 (s, 2H), 4.29 (s, 2H), 4.15-4.07 (m, 4H), 2.98 (s, 6H), 2.30 (s, 2H), 
2.15-2.09 (m, 2H), 1.58 (s, 2H), 1.34 (s, 9H). 
13
C-NMR (125 MHz, CDCl3) δ 172.56, 
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156.56, 156.52, 154.74, 152.62, 143.79, 143.54, 141.09, 128.02, 127.53, 126.97, 
125.29, 125.01, 122.03, 119.76, 111.38, 80.84, 67.16, 67.11, 66.31, 65.76, 60.46, 
54.87, 49.86, 49.68, 49.52, 49.34, 46.92, 40.11, 35.14, 31.85, 31.51, 29.62, 29.29. 
IT-TOF: m/z [M+H]
+
 calcd 983.42, found 983.41.  
 
6.2.3 General Procedure for Synthesis of 2-P5 (1-P PTP) and 2-P6 (2-P PTP) 




Methyl 4-bromobutanoate (2-19) 
A mixture of 4-bromobutanoic acid (4.15 g, 25 mmol) and 25 mL SOCl2 was 
stirred in 100 mL round-bottom flask in an ice bath for 30 mins. Then 25 mL MeOH 
was added slowly. After the completion of the reaction, the solvent was removed in 
vacuo to give the product as a colorless oil (4.30 g, 96%). 
1
H-NMR: (300 MHz, 
CDCl3), δ 3.69 (s, 3H), 3.47 (t, J = 6.6 Hz, 2H), 2.51 (t, J = 7.2 Hz, 2H), 2.17 (m, 2H). 
13
C-NMR (75 MHz, CDCl3)  172.72, 51.51, 32.55, 32.03, 27.62.  
 
Methyl 4-(4,6-bis(4-(diethylamino)styryl)pyrimidin-2-yloxy)butanoate (2-21) 
4,6-bis(4-(diethylamino)styryl)pyrimidin-2-ol (2-20)
167
 (2.16 g, 4.89 mmol) and 
K2CO3 (1.38 g, 100 mmol) were stirring in 70 mL DMF at 80 ºC for more than 1 hr. 
Then, methyl 4-bromobutanoate (1.76 g, 9.77 mmol) was added into the mixture 
slowly. After further stirring for more than 24 hrs, DMF was removed in vacuo. The 
residue was resuspended in 50 mL CH2Cl2 and washed with water twice. The organic 
layer was dried with anhydrous Na2SO4. After removing the CH2Cl2, the mixture was 
purified with silica-gel column (Ethyl Acetate : Hexane = 1:2) to give the product as 
yellow solid (1.88 g, 71%). 
1
H-NMR: (300 MHz, CDCl3), δ 7.80 (d, J = 15.9 Hz, 2H), 
7.45 (d, J = 9.0 Hz, 4H), 6.80 (s, 1H), 6.76 (d, J = 15.9 Hz, 2H), 6.65 (d, J = 9.0 Hz, 
4H), 4.52 (t, J = 6.3 Hz, 2H), 3.69 (s, 3H), 3.39 (q, J = 6.9 Hz, 8H), 2.60 (t, J = 7.2 
Hz, 2H), 2.20 (m, 2H), 1.18 (t, J = 7.2 Hz, 12H). 
13
C-NMR (75 MHz, CDCl3)  
173.89, 165.43, 165.19, 148.57, 136.92, 129.39, 123.39, 120.61, 111.44, 109.91, 
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65.84, 51.57, 44.43, 30.77, 24.54, 12.66. IT-TOF: m/z [M+H]
+
 calcd: 543.33, found: 
543.32. 
 
4-(4,6-Bis(4-(diethylamino)styryl)pyrimidin-2-yloxy)butanoic acid (2-22) 
Methyl 4-(4,6-bis(4-(diethylamino)styryl)pyrimidin-2-yloxy)butanoate (1.00 g, 
1.84 mmol) and 5 mL NaOH (8 M) were stirring in 20 mL THF/CH3OH (1:1) for 10 
hrs. After reaction completed, the mixture was adjusted to pH = 5. The precipitate was 
collected and dried in vacuo to give the product as orange-yellow solid (810 mg, 
83%). 
1
H-NMR (300 MHz, CDCl3), δ 7.80 (d, J = 15.6 Hz, 2H), 7.46 (d, J = 8.4 Hz, 
4H), 6.81 (s, 1H), 6.76 (d, J = 15.9 Hz, 2H), 6.65 (d, J = 8.7 Hz, 4H), 4.52 (t, J = 6.0 
Hz, 2H), 3.39 (q, J = 6.9 Hz, 8H), 2.64 (t, J = 7.2 Hz, 2H), 2.19 (m, 2H), 1.18 (t, J = 
7.2 Hz, 12H). 
13
C-NMR (75MHz, CDCl3)  169.31, 165.43, 165.10, 148.61, 137.12, 
129.44, 123.14, 120.52, 111.48, 109.72, 65.86, 44.45, 30.86, 24.46, 12.66. IT-TOF: 
m/z [M+H]
+
 calcd: 529.31, found 529.32. 
 
Two-Photon dye derivative (2-24) 
To a solution of 2-22 (60 mg, 0.11 mmol) in DMF, HATU (53 mg, 0.14 mmol) 
and tert-butyl 3-aminopropylcarbamate (28 mg, 0.16 mmol) were added and the 
reaction mixture was stirred at room temperature for 8 hrs. Upon removal of DMF, 
the residue was purified by flash chromatography (Ethyl Acetate : Hexane = 2:1) to 
obtain compound 2-23 as a green-yellow oil (71 mg, 95%). 
1
H-NMR (500 MHz, 
CDCl3) δ 7.76 (d, J = 7.9 Hz, 2H), 7.45 (d, J = 9.1 Hz, 4H), 6,76 (t, J = 15.7 Hz, 3H), 
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6.64 (d, J = 2.7 Hz，4H), 6.42 (broad, NH), 5.08 (broad, NH), 4.50 (t, J = 5.7 Hz, 2H), 
3.37 (dd, J = 6.9, 3.5 Hz, 8H), 3.30-3.26 (M, 2H), 3.11 (d, J = 2.8 Hz, 2H), 2.45 (t, J = 
7.5 Hz, 2H), 2.19 (t, J = 6.3 Hz, 2H), 2.01 (s, 1H), 1.59 (t, J = 6.3 Hz, 3H), 1.41 (s, 
9H), 1.17 (t, J = 6.9 Hz, 12H). 
13
C-NMR (125 MHz, CDCl3) δ 173.8, 166.0, 165.8, 
157.1, 149.2, 137.6, 130.0, 123.7, 121.2, 112.3, 110.3, 66.6, 45.0, 37.3, 36.8, 33.8, 
29.0, 25.9, 13.2. IT-TOF: m/z [M+H]
+
 calcd: 685.44, found 685.44. 
Compound 2-23 was further dissolved in DCM (0.4 mL) and TFA (80 μL, 1 
mmol), and the reaction was stirred at room temperature for 2 hrs. Then the solvent 
was removed in vacuo to give compound 2-24 as a dark green oil. IT-TOF: m/z 
[M+H]
+
 calcd: 585.28, found 585.27. 
 
Fluorescein derivative (2-27) 
Fluorescein 2-25 was synthesized according to reported procedures.
3
 After 
dissolving 2-25 (0.11 g, 0.3 mmol) in DMF, HATU (0.14 g, 0.36 mmol) and 
tert-butyl 3-aminopropylcarbamate (0.8 g, 0.4 mmol) were added and the reaction 
mixture was stirred at room temperature for 8 hrs. Upon removal of DMF, the residue 
was purified by flash chromatography (Ethyl Acetate : Hexane = 3:1)to give 
compound 2-26 as a yellow oil (0.13 g, 84%). 
1
H-NMR (500 MHz, MeOD) δ 8.21 (q, 
J = 4.1, 0.6 Hz, 1H), 7.94 (s, 1H), 7.27 (d, J = 3.8 Hz, 2H), 6.70 (s, 2H), 6.59-6.51 (m, 
4H), 3.47 (t, J = 6.9 Hz, 2H), 3.16 (t, J = 6.6 Hz, 2H), 1.80 (t, J = 6.9 Hz, 2H), 1.41 (s, 
9H). 
13
C-NMR (125MHz, MeOD) δ 172.8, 170.4, 168.1, 164.7, 161.2, 158.4, 156.4, 
153.9, 137.6, 135.4, 130.1, 130.0, 128.5, 125.6, 124.7, 113.6, 110.8, 103.6, 80.0, 61.4, 
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37.1, 38.8, 38.7, 38.5, 36.9, 31.7, 30.6, 28.8, 20.9, 14.4. IT-TOF: m/z [M+H]
+
 calcd: 
533.18, found 533.18. 
Next, 2-26 was dissolved in DCM (2 mL) and TFA (0.2 mL, 2.5 mmol), and the 
reaction was stirred at room temperature for 2 hrs. Subsequently, the solvent was 
removed in vacuo, giving product 2-27 as a red-yellow solid (0.13 g, >95%). IT-TOF: 
m/z [M+H]
+
 calcd: 451.18, found 451.17. 
 
2-Hydroxy-2-(4-hydroxyphenyl) acetic acid (2-28) 
2-hydroxy-2-(4-hydroxyphenyl)acetic acid was prepared following published 
procedures
4
 in 63% yield. 
1
H-NMR (300 MHz, MeOD) δ 7.28 (d, J = 4.3 Hz, 2H), 
6.78 (d, J = 4.3 Hz, 2H), 5.06 (s, 1H). 
13
C-NMR (75 MHz, MeOD) δ 176.54, 158.53, 




To a solution of 2-28 (3.36 g, 20 mmol) in DMF (50 mL) in an ice bath, EDC 
(4.6 g, 24 mmol) and HOBt (3.24 g, 24 mmol) were added slowly. The reaction 
mixture was stirred for 10 mins. Then 2-10c (5.5 g, 24 mmol) was added dropwise to 
the above solution, followed by DIEA (2.4 eq, 8.2 mL). The ice bath was removed 
after 1 hr and the reaction mixture was stirred at room temperature overnight.
6
 Upon 
removal of DMF in vacuo, the residue was dissolved in ethyl acetate and washed with 
H2O, brine and dried over anhydrous Na2SO4. Subsequent purification by flash 
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chromatography (Ethyl Acetate : Hexane = 4:1) afforded compound 2-29 as a light 
yellow oil (3.1 g, 59.3%). 
1
H-NMR (300 MHz, MeOD) δ 7.29 (d, J = 4.3 Hz, 2H), 
6.76 (d, J = 4.3 Hz, 2H), 5.98-5.85 (m, 1H), 5.36-5.20 (m, 2H), 4.98 (s, 1H ), 4.62 (dt, 
J = 2.9, 1.3 Hz, 2H), 4.02 (q, J = 11.8, 8.8 Hz, 2H). 
13
C-NMR (75 MHz, MeOD) δ 
176.43, 170.80, 158.49, 133.18, 129.68, 118.41, 116,10, 111.52, 75.15, 66.74, 41.71. 
IT-TOF: m/z [M+Na]
+
 calcd: 288.08, found 288.08. 
 
bis(2-nitrobenzyl) hydrogen phosphate (2-30) 





H-NMR (300 MHz, MeOD) δ 8.08 (d, 2H), 7.69-7.78 (m, 4H), 7.54 (t, J = 
9.0 Hz, 2H), 5.43 (d, J = 3.8 Hz, 4H). 
13
C-NMR (75 MHz, MeOD) δ 166.60, 148.50, 
135.11, 130.13, 129.76, 125.87. 
31
P-NMR (121 MHz, MeOD) δ -0.71. IT-TOF: m/z 
[2M+H]
+




2-30 (5.5g, 15mmol) was added to an oxalyl chloride solution (6.5mL, 75mmol; 85% 
in distilled DCM), followed by addition of a catalytic amount of DMF (2 drops) to 
initiate the reaction. After 2 hrs at room temperature, the reaction was concentrated in 
vacuo to give the desired product 2-31 as a light yellow oil.  
2-29 (1.4 g, 5 mmol) was dissolved in distilled dichloromethane (30 mL), followed 
by addition of DMAP (0.06 g, 0.5 mmol). The mixture was stirred at room 
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temperature for 10 mins before being cooled on an ice bath. Then a solution of 2-31 
(15 mmol) in 10 mL distilled dichloromethane was added dropwise, followed by 
triethyl amine (1.4 mL, 10 mmol). The reaction was left on ice for 2 hrs before being 
warmed to room temperature for another 4 hrs. The reaction mixture was concentrated 
in vacuo and purified by flash chromatography (Ethyl Acetate : Hexane = 1:1) to 
afford 2-32 as a light yellow oil (1.4 g, 47%). 
1
H-NMR (300 MHz, MeOD) δ 8.08 (d, 
J = 4.1 Hz, 2H), 7.71-7.61 (m, 4H), 7.58-7.49 (m, 4H), 7.19 (d, J = 3.9 Hz, 2H), 
5.96-5.83 (m, 1H), 5.59 (d, J = 4.0 Hz, 4H), 5.33-5.17 (m, 2H), 5.07 (s, 1H), 4.59 (dt, 
J = 2.8, 1.3 Hz, 2H), 4.02(q, J = 10.8, 1.8 Hz, 2H). 
13
C-NMR (75 MHz, MeOD) δ 
175.35, 170.69, 151.12, 151.01, 148.12, 139.17, 135.22, 133.07, 132.24, 130.52, 
129.95, 129.79, 125.98, 120.90, 118.70, 74.40, 68.12, 66.66, 41.66. 
31
P-NMR (121 
MHz, MeOD) δ -6.44. IT-TOF: m/z [2M+H]+ calcd: 1231.26, found 1231.26. 
 
(E)-allyl9-(4-(bis(2-nitrobenzyloxy)phosphoryloxy)phenyl)-1-(4-((4-(dimethylamino)
phenyl) diazenyl ) phenyl )-1,7,10-trioxo-8-oxa-2,6,11-triazatridecan-13-oate (2-34) 
Compound 2-32 (1.3 g, 2.1 mmol) in distilled dichloromethane (20 mL) was 
added DMAP (0.03 g, 0.24 mmol) over 10 mins in an ice bath. Then anhydrous 
pyridine (0.96 mL, 12 mmol) was added slowly followed by addition of 4-nitrophenyl 
carbonochloridate (0.85 g, 4.2 mmol dissolved in 2 mL DCM) dropwise. The reaction 
mixture was kept in ice bath for 2 hrs before being warmed to room temperature for 
another 5 hrs. Upon solvent removal, the resulting residue was purified by flash 
chromatography (Ethyl Acetate : Hexane = 4:1), giving the desired compound 2-33 as 
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a light yellow oil (0.79 g, 50.7%). 
1
H-NMR (300 MHz, CDCl3) δ 8.21 (d, J = 2.7 Hz, 
2H), 8.10 (d, J = 3.9 Hz, 2H), 7.69-7.62 (m, 4H), 7.54-7.46 (m, 4H), 7.39-7.34 (m, 
2H), 7.28-7.21 (m, 2H), 6.09 (s, 1H), 5.93-5.80 (m, 1H), 5.63 (d, J = 3.8 Hz, 4H), 
5.32-5.20 (m, 3H), 4.61 (d, J = 2.9 Hz, 2H). 
13
C-NMR (75MHz, CDCl3) δ 169.5, 
167.9, 155.7, 151.7, 151.6, 147.2, 146.1, 134.8, 132.1, 131.9, 130.3, 129.8, 129.1, 
125.9, 125.7, 122.3, 121.1, 121.0, 119.6, 79.1, 67.5, 66.7, 41.7. 
31
P-NMR (121 MHz, 
CDCl3) δ -6.54. 
After dissolving 2-33 (0.79 g, 1.01 mmol) in distilled THF (20 mL), 5 (0.53 g, 1.2 
mmol) was added, followed by addition of DIEA (0.22 mL, 1.2 mmol). The mixture 
was stirred at room temperature for 2 hrs before being concentrated in vacuo and 
purified by flash chromatography (Ethyl Acetate : Hexane = 2:1)to afford 2-34 as a 
red powder (0.83 g, 86%). 
1
H-NMR (300 MHz, CDCl3) δ 8.07-8.00 (m, 2H), 
7.87-7.76 (m, 6H), 7.61-7.57 (m, 4H), 7.46-7.41 (m, 4H), 7.34 (t, J = 5.9 Hz, NH), 
7.16 (d, J = 4.1 Hz, 2H), 6.82-6.67 (m, 2H), 6.26 (t, J = 6.1 Hz, NH), 5.87-5.74 (m, 
1H), 5.60 (d, J = 8.3 Hz, 4H), 5.26-5.15 (m, 2H), 4.54 (d, J = 2.9 Hz, 2H), 4.02 (q, J = 
5.6, 2.8 Hz, 2H), 3.44-3.41 (m, 2H), 3.22-3.14 (m, 2H), 3.04 (s, 1H), 1.69 (s, 2H). 
13
C-NMR (75MHz, CDCl3) δ 170.1, 169.8, 168.3, 155.7, 155.6, 153.4, 151.0, 150.9, 
147.2, 144.1, 134.8, 134.7, 134.1, 129.9, 129.8, 129.1, 128.5, 126.7, 126.0, 125.7, 
122.7, 120.8, 120.7, 119.5, 112.0, 75.4, 67.5, 67.4, 66.6, 41.6, 40.8, 38.6, 37.2, 30.17. 
31






nyl)diazenyl)phenyl)-1,7,10-trioxo-8-oxa-2,6,11-triazatridecan-13-oic Acid (2-35). 
Compound 2-34 (0.83 g, 0.86 mmol) and PhSiH3 (0.2 mL, 1.7 mmol) dissolved in 
THF were added Pd(PPh3)4 (5 wt %, 41 mg) under an argon atmosphere. The reaction 
mixture was stirred for 30 mins at room temperature before being concentrated in 
vacuo and purified by flash chromatography (MeOH/DCM= 1:8) to afford 2-35 as an 
orange product (0.63 g, 80%). 
1
H-NMR (300 MHz, CDCl3) δ 8.64 (broad, 1H), 8.11 
(d, J = 3.8 Hz, 2H), 8.00 (d, J = 4.3 Hz, 2H), 7.81-7.73 (m, 6H), 7.65-7.59 (m, 4H), 
7.52 (d, J = 4.3 Hz, 2H), 7.22 (d, J = 4.2 Hz, 2H), 6.82 (d, J = 4.6 Hz, 2H), 5.93 (s, 
1H), 5.58 (d, J = 3.7Hz, 4H), 3.68-3.53 (m, 4H), 3.30 (broad, 2H), 3.05 (s, 6H), 1.70 
(t, J = 6.4Hz, 2H). 
13
C-NMR (75MHz, CDCl3) δ 172.6, 167.9, 165.7, 154.9, 154.0, 
152.8, 149.8, 149.7, 146.8, 142.7, 134.8, 134.4, 134.3, 129.6, 129.6, 128.8, 128.3, 
125.1, 124.9, 121.5, 119.92, 119.86, 111.5, 73.8, 66.4, 66.3, 38.3, 37.0, 29.4. 
31
P-NMR (121 MHz, MeOD) δ -6.15. IT-TOF: m/z [M+H]+ calcd 927.26, found 
927.26. 
 




At -78 °C, BuLi (1.6 M in hexane, 27.5 mL, 44 mmol) was added dropwise to a 
solution of propargyl alcohol 1 (1.16 mL, 20 mmol) in THF (150 mL). After 30 min, 
TMS-Cl (5.75 mL, 45 mmol) was added dropwise into the mixture. The reaction 
mixture was then warmed to room temperature and stirred for another 2 h. After that, 
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HCl (2 M solution, 50 mL) was added and the reaction was stirred for another hour. 
The aqueous layer was washed by diethyl ether twice and the combined organic layers 
were washed with NaHCO3, brine and dried over Na2SO4. The pure product 3-2 was 
obtained after flash chromatography purification as a colorless oil (2.36 g, 92% 
yields). 
1
H-NMR (300 MHz, CDCl3) δ 4.25 (s, 2H), 0.17 (s, 9H). 
 
3-trimethylsilyl-2-propynal (3-3):168 
The Alcohol 3-2 (2.36 g, 18.4 mmol) was added dropwise at 0 °C in 10 mins to a 
suspension of PCC (5.95 g, 27.6 mmol) in CH2Cl2 (200 mL). After 2 h the dark 
suspension was filtered twice through a pad of silica gel and washed with CH2Cl2. 
The solvent was evaporated in vacuo to afford an oily residue. The compound 3-3 was 
obtained after column purification as a slightly yellow oil (1.48 g, 64% yields). 
1





3-3 (1.20 g, 9.5 mmol) and 3-4 (1.39 g, 10.5 mmol) were mixed in ethanol, 
followed by the addition of 1 eq. piperidine (1.0 mL, 10.5 mmol). The reaction 
mixture was then stirred at room temperature for 30 min. The solvent was evaporated 
in vacuo and the title products 3-D was obtained by column purification as a yellow 
solid (1.7 g, 86.7%). 
1
H-NMR (500 MHz, CDCl3) δ 6.62 (s, 1H), 0.26 (s, 9H). 
13
C-NMR (125 MHz, CDCl3) δ 192.27, 165.94, 139.35, 115.85, 112.97, 99.84. 
ESI-MS: m/z [M+1]
+








3-3 (1.20 g, 9.5 mmol) and 3-5 (1.91 g, 10 mmol) were mixed in ethanol, 
followed by the addition of 1 eq. piperidine (0.98 mL, 10 mmol). The reaction 
mixture was stirred at room temperature for 10 min. The solvent was evaporated in 
vacuo and the title products 3-E was obtained by column purification as a yellow 
solid (1.97 g, 69.3%). 
1
H-NMR (300 MHz, CDCl3) δ 6.72 (s, 1H), 4.84 (s, 2H), 0.26 
(s, 9H). 
13
C-NMR (75 MHz, CDCl3) δ 192.22, 171.45, 164.88, 136.85, 115.95, 
113.39, 99.86, 44.31. ESI-MS: m/z [M+1]
+
 = 299.97 
 
6.2.5 General Procedure for Synthesis of Azide building blocks (3-C)  
The aniline 3-6 (1 eq, 5 mmol) was dissolved in an HCl solution (50 mL) at room 
temperature. Upon cooling to 0 °C and addition of a solution of NaNO2 (1 eq, 5 
mmol), the reaction mixture was stirred for 10 mins at 0-5 °C. Sodium azide (1.2 eq, 6 
mmol) was added and the mixture was stirred at room temperature for 2 h. The 
reaction was worked up by dilution with EtOAc. The organic layer was washed with 
brine and dried over sodium sulphate. After evaporation of the solvent, the crude 
product 3-C was pure enough for further reactions. All the azides synthesized were 




1-azido-4-methoxybenzene (3-C1): Yield = 86.2%. 
1
H-NMR (500 MHz, CDCl3) δ 
6.96 (d, J = 8.8 Hz, 2H), 6.89 (d, J = 8.8 Hz, 2H), 3.80 (s, 3H). 
13
C-NMR (125 MHz, 
CDCl
3) δ 157.02, 132.38, 120.00, 115.15, 55.58.  
 
4-azido-1,2-dimethylbenzene (3-C2): Yield = 91.5%. 
1
H-NMR (500 MHz, CDCl3) δ 
7.11 (d, J = 8.2 Hz, 1H), 6.81 (s, 1H), 6.78 (d, J = 8.2 Hz, 1H), 2.26 (s, 3H), 2.24 (s, 
3H). 
13
C-NMR (125 MHz, CDCl3) δ 138.27, 137.31, 133.33, 130.76, 120.08, 116.29, 
19.83, 19.15.  
 
1-azido-4-chlorobenzene (3-C3): Yield = 85.2%. 
1
H-NMR (500 MHz, CDCl3) δ 7.32 
(d, J = 8.2 Hz, 2H), 6.96 (d, J = 8.2 Hz, 2H).  
 
1-azido-2,4-dichlorobenzene (3-C4): Yield = 89.1%. 
1
H-NMR (300 MHz, CDCl3) δ 
7.39 (s, 1H), 7.27 (d, J = 8.4 Hz, 1H), 7.10 (d, J = 8.3 Hz, 1H).  
 
1-azido-4-phenoxybenzene (3-C5): Yield = 92.3%. 
1
H-NMR (300 MHz, CDCl3) δ 
7.33 (t, J = 7.7 Hz, 2H), 7.10 (t, J = 7.3 Hz, 1H), 7.00 (s, 5H), 6.97 (s, 1H).  
 
1-azidonaphthalene (3-C6): Yield = 87.4%. 
1
H-NMR (300 MHz, CDCl3) δ 8.11-8.08 
(m, 1H), 7.82-7.79 (m, 1H), 7.62 (d, J = 8.4 Hz, 1H), 7.52-7.42 (m, 3H), 7.24 (d, J = 
7.3 Hz, 1H). 
13
C-NMR (75 MHz, CDCl3) δ 127.69, 126.85, 126.10, 125.62, 124.66, 




1-azido-3-methoxybenzene (3-C8): Yield = 80.2%. 
1
H-NMR (500 MHz, CDCl3) δ 
7.25 (t, J = 8.2 Hz, 1H), 6.70-6.63 (m, 2H), 6.54 (s, 1H), 3.80 (s, 3H)  
 
5-azido-1,2,3-trimethoxybenzene (3-C9): Yield = 96.7%. 
1
H-NMR (500 MHz, CDCl3) 
δ 6.24 (s, 2H), 3.84 (s, 6H), 3.81 (s, 3H).  
 
2-azido-4-chloro-1-methoxybenzene (3-C10): Yield = 94.5%. 
1
H-NMR (300 MHz, 
CDCl3) δ 7.04 (d, J = 8.7 Hz, 1H), 6.97 (s, 1H), 6.80 (d, J = 8.7 Hz, 1H), 3.86 (s, 3H).  
 
1-azido-4-fluorobenzene (3-C11): Yield = 91.4%. 
1
H-NMR (300 MHz, CDCl3) δ 
7.07-6.95 (m, 4H).  
 
1-azido-2-chloro-4-methylbenzene (3-C12): Yield = 93.3%. 
1
H-NMR (500 MHz, 
CDCl3) δ 7.19 (s, 1H), 7.09-7.04 (m, 2H), 2.31 (s, 3H).  
 
4-azido-2-fluoro-1-methylbenzene (3-C13): Yield = 90.8%. 
1
H-NMR (500 MHz, 
CDCl3) δ 7.15 (t, J = 8.2 Hz, 1H), 6.74-6.68 (m, 2H), 2.24 (s, 3H).  
 
1-azido-4-ethylbenzene (3-C14): Yield = 92.7%. 
1
H-NMR (300 MHz, CDCl3) δ 7.18 
(d, J = 8.3 Hz, 2H), 6.95 (d, J = 8.3 Hz, 2H), 2.63 (q, J1 = 7.7 Hz, J2 = 15.0 Hz, 2H), 




1-azido-2,3-dichlorobenzene (3-C15): Yield = 95.1%. 
1
H-NMR (300 MHz, CDCl3) δ 
7.26-7.22 (m, 2H), 7.10 (d, J = 7.3 Hz, 1H).  
 
(4-azidophenyl)(methyl)sulfane (3-C16): Yield = 86.7%. 
1
H-NMR (300 MHz, CDCl3) 
δ 7.26 (d, J = 8.7 Hz, 2H), 6.96 (d, J = 8.7 Hz, 2H), 2.47 (s, 3H).  
 
1-azido-3-isopropoxybenzene (3-C17): Yield = 94.2%. 
1
H-NMR (300 MHz, CDCl3) δ 
7.22 (t, J = 8.0 Hz, 1H), 6.67 (d, J = 8.0 Hz, 1H), 6.61 (d, J = 8.0 Hz, 1H), 6.54 (s, 
1H), 4.57-4.48 (m, 1H), 1.34 (s, 3H), 1.32 (s, 3H).
 13
C-NMR (75 MHz, CDCl3) δ 
130.40, 112.33, 111.08, 108.22, 107.54, 106.81, 70.12, 21.93.  
 
1-azido-2-methoxybenzene (3-C18): Yield = 88.8%. 
1
H-NMR (300 MHz, CDCl3) δ 
7.10 (t, J = 8.4 Hz, 1H), 7.01 (d, J = 7.7 Hz, 1H), 6.96-6.87 (m, 2H), 3.87 (s, 3H).  
 
2-azido-1,4-diethoxybenzene (3-C19): Yield = 87.5%. 
1
H-NMR (500 MHz, CDCl3) δ 
6.81 (d, J = 8.8 Hz, 1H), 6.60 (d, J = 8.85 Hz, 1H), 6.55 (s, 1H), 4.03 (q, J1 = 7.0 Hz, 
J2 = 14.0 Hz, 2H), 3.96 (q, J1 = 7.0 Hz, J2 = 14.0 Hz, 2H), 1.43 (t, J = 6.9 Hz, 3H), 




1-azido-2-chloro-4-fluorobenzene (3-C20): Yield = 89.1%. 
1
H-NMR (300 MHz, 
CDCl3) δ 7.16-7.10 (m, 2H), 7.02 (t, J = 7.7 Hz, 1H). 
13
C-NMR (75 MHz, CDCl3) δ 
120.48, 120.36, 118.22, 117.88, 115.17, 114.87.  
 
1-azido-4-fluoro-2-methylbenzene (3-C21): Yield = 92.3%. 
1
H-NMR (300 MHz, 
CDCl3) δ 7.05-7.00 (m, 1H), 6.94-6.85 (m, 2H), 2.19 (s, 3H). 
13
C-NMR (75 MHz, 
CDCl3) δ 119.01, 118.89, 117.95, 117.64, 113.78, 113.48, 17.29.  
 
1-azido-2,4-difluorobenzene (3-C22): Yield = 84.8%. 
1
H-NMR (300 MHz, CDCl3) δ 
7.07-6.99 (m, 1H), 6.91-6.83 (m, 2H). 
  
1-azido-4-ethoxybenzene (3-C23): Yield = 94.7%. 
1
H-NMR (500 MHz, CDCl3) δ 
6.94 (d, J = 8.9 Hz, 2H), 6.88 (d, J = 8.8 Hz, 2H), 4.00 (q, J1 = 7.0 Hz, J2 = 13.9 Hz, 
2H), 1.41 (t, J = 6.9 Hz, 3H). 
13
C-NMR (125 MHz, CDCl3) δ 157.07, 132.90, 120.67, 
116.44, 64.54, 15.48.  
 
1-azido-4-(trifluoromethoxy)benzene (3-C24): Yield = 89.5%. 
1
H-NMR (300 MHz, 
CDCl3) δ 7.21 (d, J = 8.4 Hz, 2H), 7.03 (d, J = 9.1 Hz, 2H).  
 
1-azido-2-ethoxybenzene (3-C25): Yield = 91.6%. 
1
H-NMR (500 MHz, CDCl3) δ 
7.07 (t, J = 8.2 Hz, 1H), 6.97 (d, J = 7.6 Hz, 2H), 6.92-6.87 (m, 2H), 4.09 (q, J1 = 6.9 
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Hz, J2 = 14.5 Hz, 2H), 1.46 (t, J = 7.0 Hz, 3H). 
13
C-NMR (125 MHz, CDCl3) δ 
151.56, 128.32, 125.59, 121.19, 120.61, 113.05, 64.61, 14.56.  
 
2-azido-9H-fluorene (3-C26): Yield = 88.9%. 
1
H-NMR (300 MHz, CDCl3) δ 7.73 (d, 
J = 8.0 Hz, 2H), 7.53 (d, J = 7.3 Hz, 1H), 7.40-7.21 (m, 4H), 7.03 (d, J = 6.3 Hz, 1H), 
3.89 (s, 2H). 
13
C-NMR (75 MHz, CDCl3) δ 126.91, 126.65, 125.02, 120.85, 119.64, 
117.84, 115.73, 36.85.  
 
ethyl 3-azidobenzoate (3-C27): Yield = 90.3%. 
1
H-NMR (300 MHz, CDCl3) δ 7.82 (d, 
J = 7.7 Hz, 1H), 7.71 (s, 1H), 7.42 (t, J = 8.0 Hz, 1H), 7.20 (d, J = 8.0 Hz, 1H), 4.39 
(q, J1 = 7.3 Hz, J2 = 14.3 Hz, 2H), 1.41 (t, J = 7.3 Hz, 3H). 
13
C-NMR (75 MHz, 
CDCl3) δ 165.66, 140.48, 132.23, 129.72, 125.92, 123.24, 119.89, 61.30, 14.23.  
 
1-azido-4-pentylbenzene (3-C28): Yield = 90.3%. 
1
H-NMR (300 MHz, CDCl3) δ 7.15 
(d, J = 8.4 Hz, 2H), 6.93 (d, J = 8.4 Hz, 2H), 2.57 (t, J = 7.7 Hz, 2H), 1.64-1.54 (m, 
2H), 1.32-1.23 (m, 4H), 0.89 (t, J = 6.6 Hz, 3H). 
13
C-NMR (75 MHz, CDCl3) δ 




H-NMR (300 MHz, (CD3)2SO) δ 9.20 (s, 1H), 7.58-7.49 (m, 4H), 7.13-7.11 (d, 
J = 8.07 Hz, 1H), 3.87 (s, 3H). ESI-MS: m/z [M+1]
+






H-NMR (300 MHz, (CD3)2SO) δ 9.10 (s, 1H), 7.83-7.80 (d, J = 9.06 Hz, 2H), 
7.60 (s, 1H), 7.17-7.14 (d, J = 9.03 Hz, 2H), 4.15-4.08 (q, J = 7.05 Hz, 2H), 1.39-1.34 
(t, J = 7.0 Hz, 3H). ESI-MS: m/z [M+1]
+




H-NMR (300 MHz, (CD3)2SO) δ 8.97 (s, 1H), 7.77-7.71 (m, 2H), 7.58-7.52 
(m, 1H), 7.35-7.33 (m, 1H), 7.19-7.14 (m, 1H), 4.21-4.14 (q, J = 7.0 Hz, 2H), 
1.34-1.29 (t, J = 7.05 Hz, 3H). ESI-MS: m/z [M+1]
+
 = 332.99 
 
6.2.6 Synthesis of succinyl hydroxamate-based alkyne-containing warheads (4-8) 
General procedure for the coupling reaction of acids 1 with 2-oxazolidinone 
To a suspension of 2-oxazolidinone (5.30 g, 60 mmol), DMAP (0.96 g, 7.8 mmol) 
and 1 (78 mmol) in CH2Cl2
 
(100 mL) at 0 °C, under a nitrogen atmosphere, was added 
DCC in one portion (16.1 g, 78 mmol). After 10 min the temperature was raised to RT 
and stirring was continued overnight. The dicyclohexylurea formed was filtered and 
the precipitate washed with CH2Cl2
 
(20 mL). The filtrate was washed with sat. 
NaHCO3 (100 mL), dried with Na2SO4
 
and concentrated at reduced pressure to 
furnish the crude product, which was purified by silica gel chromatography (20%-30% 
EtOAc in hexanes) to afford 4-2 as a colorless oil. 
 
General procedure for alkylation of oxazolidinone 4-2 with tert-butyl 2-bromoacetate 
To a flame-dried 500 mL three-necked RBF was added 9.26 g (50 mmol) of 
oxazoline 4-2 in 100 mL of dry THF. This mixture was cooled to -78 
o
C, and 1.0 M 
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sodium bis(trimethylsilyl)amide in THF (65 mL, 65 mmol) was added dropwise. The 
internal reaction temperature was kept below -71 
o
C. The solution was then stirred at 
-78
 o
C for 1 hour, then neat tert-butyl bromoacetate (11.1 mL, 75 mmol) was added 
via a syringe over a 10-minute period. The mixture was stirred at -78
 o
C for 2 hours 
then warmed to 0
o
C and quenched with Et2O and aqueous 2 M NH4Cl. The aqueous 
layer was separated and extracted with diethyl ether. The combined organic layers 
were washed with brine, dried, filtered, and concentrated to give a brown oil. The oil 
was purified by silica gel chromatography (15%-20% EA in hexane) to isolate desired 
product 4-3 as a colorless oil. 
 
General procedure for the cleavage of the tert-butyl group in 4-3: 
Compound 4-3 (40 mmol) was dissolved in 320 mL of DCM, then TFA (30.6 mL, 
400 mmol) was added, the mixture was vigorously stirred at room temperature for 4 
hours. After removal of the solvent, the product was diluted with ethyl acetate (100 
mL), then washed with water and brine, followed by drying in Na2SO4. The solution 
was concentrated to give the corresponding carboxylic acid 4-4 as a brownish oil, 
which was dried in vacuo for 4 hours to completely remove TFA. 
 
General procedure for the coupling of carboxylic acids 4-4 with trityloxyamine 
Carboxylic acid 4-4 (50 mmol) in DCM (150 mL) was cooled down to 0
o
C, 
before addition of DCC (12.4 g, 60 mmol). Ten minutes later, the trityl-protected 
hydroxyamine (14.6 g, 60 mmol) was subsequently added to the reaction mixture, and 
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the mixture was allowed to warm up to room temperature and stirred for 3 hours. The 
dicyclohexylurea formed was filtered and the filtrate was washed with saturated 
NaHCO3, brine, dried over Na2SO4, then concentrated to give a brown oil, which was 
purified by silica gel chromatography (20%-30% EA in hexane) to isolate the desired 
product 4-5 as a white solid. 
 
General procedure for the hydrolytic cleavage of the 2-oxazolidinone moiety in 4-5 
To imide 4-5 (35 mmol) in 4/1 of THF/H2O (600 mL) was added 30% aqueous 
H2O2
 
(14.3 mL, 136 mmol) at 0 
o
C over 5 minutes. The internal temperature was kept 
at or below 5 
o
C. Lithium hydroxide (2.8 g, 116.7 mmol) in 20 mL of water was then 
added over 5 minutes to ensure the internal temperature was kept below 4 
o
C. After 
addition, the mixture was allowed to warm to room temperature. After two hours, the 
reaction mixture was cooled to 0 
o
C and sodium nitrite (7.2 g, 103.7 mmol.) was 
added. The mixture was allowed to warm to room temperature and concentrated under 
reduced pressure. The resulting liquid was extracted with CHCl3. The combined 
organic layers were washed with aqueous 0.1 M NaOH. The combined aqueous layers 
were acidified with aqueous 1 M HCl to pH = 7, then extracted with ethyl acetate. 







General procedure for the coupling of 4-6 with propargyl amine 
To a solution of 4-6 (5 mmol), HATU (6 mmol) and DIEA (6 mmol) in DMF (10 
mL) was added propargyl amine (6 mmol) at room temperature under a nitrogen 
atmosphere. The mixture was stirred for 2-4 hrs. The solvent was removed in vacuo 
and the resulting oil residue was diluted with DCM and extracted with water. The 
combined DCM layers were dried over Na2SO4, filtered and concentrated. The crude 
product was purified by column chromatography (80% DCM/hexane – 10% 
MeOH/DCM) to afford 4-7 in 80 – 91% yield, typically as a white or off-white solid.  
 
General procedure for the cleavage of trityl moiety 
To a solution of 4-7 (4 mmol) in DCM (8 mL) was added TFA (40 mmol) and 
TIS (8 μL). The mixture was stirred for 1 hr, following which the solvent was 
removed in vacuo. The crude product was purified by column chromatography (5% 
MeOH/DCM–10% MeOH/DCM). Alkyne 4-8 (A-H) was isolated in 40-55% yield.  
 
3-(3-methylbutanoyl)oxazolidin-2-one (4-2A): Yield = 88%. 
1
H-NMR (300 MHz, 
CDCl3) δ 4.41 (t, J = 8.34 Hz, 2H), 4.05 (t, J = 8.37 Hz, 2H), 2.81 (d, J = 6.96 Hz, 
2H), 2.30 – 2.08 (m, 1H), 0.98 (d, J = 6.60 Hz, 6H); ESI-MS: m/z [M+Na]+ = 194.0.  
 
3-(4-methylpentanoyl)oxazolidin-2-one (4-2B): Yield = 93%. 
1
H-NMR (300 MHz, 
CDCl3) δ 4.26 (t, J = 16.1 Hz, 2H), 3.85 (t, J = 16.1 Hz, 2H), 2.73 (t, J = 15.2 Hz, 2H), 
109 
 
1.50-1.33 (m, 3H), 0.77 (d, J = 7.2 Hz, 6H); ESI-MS cald for C9H15NO3Na [M+Na]
+
 
=208.2, found 208.0. 
 
 
3-(3-methylpentanoyl)oxazolidin-2-one (4-2C): Yield = 76 %. 
1
H -NMR (300 MHz, 
CDCl3) δ 4.37 (t, J = 8.01 Hz, 2H), 3.98 (t, J = 8.03 Hz, 2H), 2.91 – 2.84 (dd, J1 = 
16.02 Hz, J2 = 5.58 Hz, 1H), 2.74 – 2.66 (dd, J1 = 16.00 Hz, J2 = 7.98 Hz, 1H), 2.00 – 
1.87 (m, 1H), 1.46 – 1.32 (m, 1H), 1.28 – 1.12 (m, 1H), 0.96 – 0.82 (m, 6H); ESI-MS: 
m/z [M+Na]
+
 = 208.2.  
 
3-(3-phenylpropanoyl)oxazolidin-2-one (4-2D): Yield = 91%. 
1
H-NMR (300 MHz, 
CDCl3) δ 7.34 – 7.19 (m, 5H), 4.38 (t, J = 8.01 Hz, 2H), 4.00 (t, J = 8.01 Hz, 2H), 
3.26 (t, J = 7.49 Hz, 2H), 2.99 (t, J = 7.50 Hz, 2H); ESI-MS: m/z [M+Na]
+
= 242.2.  
 
3-(5-phenylpentanoyl)oxazolidin-2-one (4-2E): Yield = 82%. 
1
H-NMR (300 MHz, 
CDCl3) δ 7.42 – 7.04 (m, 5H), 4.38 (t, J = 8.01 Hz, 2H), 3.99 (t, J = 8.01 Hz, 2H), 
2.95 (m, 2H), 2.65 (t, J = 6.96 Hz, 2H), 1.73 – 1.68 (m, 4H); ESI-MS: m/z [M+Na]+ = 
270.3.  
 
3-(2-cyclohexylacetyl)oxazolidin-2-one (4-2F): Yield = 95%. 
1
H-NMR (300 MHz, 
CDCl3) δ 4.39 (t, J = 8.19 Hz, 2H), 4.01 (t, J = 8.19 Hz, 2H), 2.80 (d, J = 6.96 Hz, 
2H), 2.01 – 1.79 (m, 1H), 1.79 – 1.54 (m, 5H), 1.38 – 0.86 (m, 5H); ESI-MS: m/z 
[M+Na]
+




3-(3-cyclopentylpropanoyl)oxazolidin-2-one (4-2G): Yield = 70%. 
1
H-NMR (300 
MHz, CDCl3) δ 4.38 (t, J = 8.01 Hz, 2H), 3.99 (t, J = 8.19 Hz, 2H), 2.89 (t, J = 7.67 
Hz, 2H) 1.77 – 1.64 (m, 3H), 1.62 – 1.47 (m, 6H), 1.11 – 1.09 (m, 2H); ESI-MS: m/z 
[M+Na]
+
 = 234.2.  
 
3-(4-(benzyloxy)butanoyl)oxazolidin-2-one (4-2H): Yield = 82%. 
1
H-NMR (300 
MHz, CDCl3) δ 7.38-7.26 (m, 5H), 4.47 (s, 2H), 4.29 (t, J = 8.37 Hz, 2H), 3.99 (t, J = 
8.37 Hz, 2H), 3.55 (t, J = 6.27 Hz, 2H), 3.03 (t, J = 7.32 Hz, 2H), 1.98 (t, J = 6.63 Hz, 
2H). ESI-MS: m/z [M+Na]
+
 = 286.2.  
 
tert-butyl 4-methyl-3-(2-oxooxazolidine-3-carbonyl)pentanoate (4-3A): Yield = 66%. 
1
H-NMR (300 MHz, CDCl3) δ 4.39 (t, J = 7.32 Hz, 2H), 4.09 – 3.98 (m, 3H), 2.82 – 
2.78 (m, 1H), 2.41 – 2.35 (dd, J1 = 16.87 Hz, J2 = 3.15 Hz, 1H), 2.03 – 1.94 (m, 1H), 
1.40, (s, 9H), 0.99 – 0.97 (m, 3H), 0.87 (d, J = 6.96 Hz); ESI-MS: m/z [M+Na]+ = 
308.2.  
 
tert-butyl 5-methyl-3-(2-oxooxazolidine-3-carbonyl)hexanoate (4-3B): Yield = 83%. 
1
H-NMR (300 MHz, CDCl3) δ 4.37 (t, J = 17.2 Hz, 2H), 4.20-4.10 (m, 1H), 3.97 (t, J 
= 17.2 Hz, 2H), 2.63 (q, 1H), 2.35 (q, 1H), 1.52-1.48 (m, 2H); 1.35 (s, 9H), 1.17-1.24 
(m, 1H), 0.84 (q, 4H). ESI-MS cald for C15H25NO5Na [M+Na]
+ 




tert-butyl 4-methyl-3-(2-oxooxazolidine-3-carbonyl)hexanoate (4-3C): Yield = 88%. 
1
H-NMR (300 MHz, CDCl3) δ 4.40 – 4.34 (m, 2H), 4.12 – 3.94 (m, 3H), 2.86 – 2.72 
(m, 1H), 2.38 – 2.25 (m, 1H), 1.47 – 1.32 (m, 1H), 1.37 (s, 9H), 1.28 – 1.14 (m, 2H), 
0.92 – 0.77 (m, 6H); ESI-MS: m/z [M+Na]+ = 322.1.  
 
tert-butyl 3-benzyl-4-oxo-4-(2-oxooxazolidin-3-yl)butanoate (4-3D): Yield = 83%. 
1
H-NMR (300 MHz, CDCl3) δ 7.34 – 7.17 (m, 5H), 4.44 – 4.28 (m, 3H), 4.08 – 3.88 
(m, 2H), 3.08 – 3.02 (dd, J1 = 12.87 Hz , J2 = 5.58 Hz, 1H), 2.83 – 2.74 (dd, J1 = 
17.05, J2 = 11.16 Hz, 1H), 2.60 – 2.52 (dd, J1 = 13.06 Hz, J2 = 9.75 Hz, 1H), 2.33 – 





tert-butyl 3-(2-oxooxazolidine-3-carbonyl)-6-phenylhexanoate (4-3E): Yield = 85%. 
1
H-NMR (300 MHz, CDCl3) δ 7.31 – 7.11 (m, 5H), 4.41 – 4.32 (m, 2H), 4.17 – 3.93 
(m, 3H), 2.80 – 2.71 (dd, J1 = 16.71 Hz, J2 = 10.80 Hz, 1H), 2.66 – 2.51 (m, 2H), 2.42 
– 2.35 (dd, J1 = 16.71 Hz, J2 = 4.17 Hz, 1H), 1.78 – 1.58 (m, 4H), 1.35 (s, 9H); 
ESI-MS: m/z [M+Na]
+
 = 384.4.  
 
tert-butyl 3-cyclohexyl-4-oxo-4-(2-oxooxazolidin-3-yl)butanoate (4-3F): Yield = 67%. 
1
H-NMR (300 MHz, CDCl3) δ 4.52 – 4.36 (m, 2H), 4.15 – 4.01 (m, 3H), 2.86 – 2.77 
(m, 1H), 2.50 – 2.43 (m, 1H), 1.74 – 1.63 (m, 6H), 1.43 (s, 9H) 1.39 – 0.94 (m, 5H); 
ESI-MS: m/z [M+H]
+
 = 326.4.  
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tert-butyl 3-(cyclopentylmethyl)-4-oxo-4-(2-oxooxazolidin-3-yl)butanoate (4-3G):  
Yield = 74%. 
1
H-NMR (300 MHz, CDCl3) δ 4.43 – 4.38 (m, 2H), 4.24 – 4.15 (m, 1H), 
4.07 – 3.98 (m, 2H), 2.78 – 2.69 (dd, J1 = 16.53 Hz, J2 = 10.80 Hz, 1H), 2.49 – 2.42 
(dd, J1 = 16.53 Hz, J2 = 4.17 Hz, 1H), 1.80 – 1.66 (m, 3H), 1.66 – 1.47 (m, 6H), 1.40 
(s, 9H), 1.18 – 1.00 (m, 2H); ESI-MS: m/z [M+Na]+ = 348.4.  
 
tert-butyl 5-(benzyloxy)-3-(2-oxooxazolidine-3-carbonyl)pentanoate (4-3H):  
Yield = 78%. 
1
H-NMR (300 MHz, CDCl3) δ 7.35 – 7.20 (m, 5H), 4.50 – 4.30 (m, 2H), 
4.30 – 4.20 (m, 2H), 4.17 – 3.81 (m, 2H), 3.69 – 3.52 (m, 3H), 2.87 – 2.76 (dd, J1 = 
16.5 Hz, J2 = 10.44 Hz, 1H), 2.85 – 2.76 (dd, J1 = 16.71 Hz, J2 = 4.53Hz, 1H), 2.09 – 
1.98 (m, 1H), 1.35 (s, 9H); ESI-MS: m/z [M+Na]
+
= 400.3.  
 
4-methyl-3-(2-oxooxazolidine-3-carbonyl)pentanoic acid (4-4A): Yield = 98%. 
1
H-NMR (300 MHz, CDCl3) δ 4.50 – 4.39 (m, 2H), 4.12 – 3.98 (m, 3H), 2.98 – 2.80 
(m, 1H), 2.56 – 2.50 (dd, J1 = 17.60 Hz, J2 = 3.32 Hz, 1H), 2.16 – 2.03 (m, 1H), 1.02 
– 0.87 (m, 6H); ESI-MS: m/z [M-H]- = 228.3.  
 
5-methyl-3-(2-oxooxazolidine-3-carbonyl)hexanoic acid (4-4B): Yield = 99%. 
1
H-NMR (300 MHz, CDCl3) δ 4.44-4.37 (m, 2H), 4.28-4.12 (m, 1H), 4.05-3.95 (m, 
2H), 2.81 (q, 1H), 2.52 (q, 1H); 1.57-1.51 (m, 2H), 1.35-1.23 ( m, 1H), 0.91(q, 4H); 
ESI-MS cald for C11H17NO5Na [M+H]
+
 




4-methyl-3-(2-oxooxazolidine-3-carbonyl)hexanoic acid (4-4C): Yield = 99%. 
1
H-NMR (300 MHz, CDCl3) δ 8.87 (br s,1H), 4.43 – 4.37 (m, 2H), 4.14 – 3.92 (m, 
3H), 2.95 – 2.69 (m, 1H), 2.54 – 2.37 (m, 1H), 2.20 – 1.68 (m, 1H), 1.45 – 1.20 (m, 
2H), 1.00 – 0.78 (m, 6H); ESI-MS: m/z [M-H]- = 242.4.  
 
3-benzyl-4-oxo-4-(2-oxooxazolidin-3-yl)butanoic acid (4-4D): Yield = 98%. 
1
H-NMR (300 MHz, CDCl3) δ 7.35 – 7.17 (m, 5H), 4.45 – 4.27 (m, 3H), 4.08 – 3.87 
(m, 2H), 3.12 – 3.06 (dd, J1 = 13.23 Hz, J2 = 5.22 Hz, 1H), 2.94 – 2.84 (dd, J1 = 17.58 
Hz, J2 = 10.80 Hz, 1H), 2.60 – 2.53 (dd, J1 = 13.23 Hz, J2 = 9.75 Hz, 1H), 2.43 – 2.36 
(dd, J1 = 17.42 Hz, J2 = 3.84 Hz, 1H); ESI-MS: m/z [M-H]
-
 = 276.3.  
 
3-(2-oxooxazolidine-3-carbonyl)-6-phenylhexanoic acid (4-4E): Yield = 99%. 
1
H-NMR (300 MHz, CDCl3) δ 8.26 (br s, 1H), 7.42 – 7.15 (m, 5H), 4.45 – 4.37 (m, 
2H), 4.35 – 4.15 (m, 1H), 4.04 – 3.93 (m, 2H), 2.94 – 2.85 (dd, J1 = 17.42 Hz, J2 = 
10.44 Hz, 1H), 2.64 – 2.48 (m, 3H), 1.76 – 1.58 (m, 5H); ESI-MS: m/z [M-H]- = 
304.3.  
 
3-cyclohexyl-4-oxo-4-(2-oxooxazolidin-3-yl)butanoic acid (4-4F): Yield = 99%. 
1
H-NMR (300 MHz, CDCl3) δ 8.60 (br s, 1H), 4.45 – 4.38 (m, 2H), 4.14 – 3.94 (m, 
3H), 2.99 – 2.76 (m, 1H), 2.57 – 2.50 (m, 1H), 1.74 – 1.62 (m, 6H), 1.31 – 0.82 (m, 
5H); ESI-MS: m/z [M-H]
-




3-(cyclopentylmethyl)-4-oxo-4-(2-oxooxazolidin-3-yl)butanoic acid (4-4G):  
Yield = 97%. 
1
H-NMR (300 MHz, CDCl3) δ 8.15 (br s, 1H), 4.46 – 4.38 (m, 2H), 
4.27 – 4.12 (m, 1H), 4.00 (m, 2H), 2.91 – 2.82 (dd, J1 = 17.25 Hz, J2 = 10.80 Hz, 1H), 
2.61 – 2.55 (dd, J1 = 17.24 Hz, J2 = 4.17 Hz, 1H), 1.79 – 1.54 (m, 9H), 1.25 – 1.08 (m, 
2H); ESI-MS: m/z [M-H]
-
 = 268.4.  
 
5-(benzyloxy)-3-(2-oxooxazolidine-3-carbonyl)pentanoic acid (4-4H):  
Yield = 99%. 
1
H-NMR (300 MHz, CDCl3) δ 7.72 (br s, 1H), 7.46-7.28 (m, 5H), 
4.58-4.42 (m, 2H), 4.38 – 4.20 (m, 2H), 4.05-3.85 (m, 2H), 3.72-3.52 (m, 3H), 2.98 – 
2.85 (dd, J1 = 17.25 Hz, J2 = 10.80 Hz, 1H), 2.61 – 2.55 (dd, J1 = 17.24 Hz, J2 = 4.17 
Hz, 1H), 2.08-1.79 (m, 2H); δ ESI-MS: m/z [M-H]- = 320.3.  
 
4-methyl-3-(2-oxooxazolidine-3-carbonyl)-N-(trityloxy)pentanamide (4-5A):  
Yield = 74%. 
1
H-NMR (300 MHz, CDCl3) δ 7.30 – 7.15 (m, 16H), 4.34 (t, J = 8.0 Hz, 
2H), 4.09 – 3.90 (m, 3H), 2.41 – 2.32 (m, 1H), 1.88 – 1.70, (1H, m), 1.46 – 1.27 (m, 
1H), 0.71 – 0.60 (m, 6H); ESI-MS: m/z [M+Na]+ = 509.2.  
 
5-methyl-3-(2-oxooxazolidine-3-carbonyl)-N-(trityloxy)hexanamide (4-5B):  
Yield = 70%. 
1
H-NMR (300 MHz, CDCl3) δ 7.66 (br s, 1H), 7.35 (s, 15H), 4.35 (t, J 
= 16.4Hz, 2H), 4.13-3.89 (m, 3H), 2.33 (q, 1H); 1.66 (br s, 1H), 1.36-1.07 ( m, 3H), 
0.82(m, 6H); ESI-MS cald for C30H32N2O5Na [M+Na]
+
 




4-methyl-3-(2-oxooxazolidine-3-carbonyl)-N-(trityloxy)hexanamide (4-5C):  
Yield = 78%. 
1
H-NMR (300 MHz, CDCl3) δ 7.66 (br s, 1H), 7.42 – 7.28 (m, 15H), 
4.33 (t, J = 7.83 Hz, 2H), 4.01 – 3.70 (m, 3H), 2.46 – 2.33 (m, 1H), 2.04 – 1.86 (m, 
1H), 1.74 – 1.58 (m, 1H), 1.41 – 0.62 (m, 8H); ESI-MS: m/z [M+Na]+ = 523.6.  
 
3-benzyl-4-oxo-4-(2-oxooxazolidin-3-yl)-N-(trityloxy)butanamide (4-5D):  
Yield = 82%. 
1
H-NMR (300 MHz, CDCl3) δ 7.60 (br s, 1H), 7.38 – 7.19 (m, 20H), 
4.38 – 4.20 (m, 3H), 3.98 – 3.78 (m, 2H), 3.10 – 2.76 (m, 2H), 2.41 – 2.21 (m, 2H); 
ESI-MS: m/z [M+Na]
+
 = 557.5.  
 
3-(2-oxooxazolidine-3-carbonyl)-6-phenyl-N-(trityloxy)hexanamide (4-5E):  
Yield = 81%. 
1
H-NMR (300 MHz, CDCl3) δ 7.71 (br s, 1H), 7.44 – 7.11 (m, 20H), 
4.34 – 4.29 (t, J = 8.37 Hz, 2H), 4.00 – 3.65, (m, 3H), 2.61 – 2.28 (m, 4H), 1.55 – 
1.25 (m, 4H); ESI-MS: m/z [M+Na]
+
 = 585.3.  
 
3-cyclohexyl-4-oxo-4-(2-oxooxazolidin-3-yl)-N-(trityloxy)butanamide (4-5F):  
Yield = 74%. 
1
H-NMR (300 MHz, CDCl3) δ 7.60 (br s, 1H), 7.49 – 7.28 (m, 15H), 
4.45 – 4.23 (m, 2H), 4.04 – 3.59 (m, 3H), 2.41 – 2.32 (m, 1H), 1.75 – 1.30 (m, 7H), 
1.19 – 0.78 (m, 5H); ESI-MS: m/z [M+Na]+ = 549.6.  
 
3-(cyclopentylmethyl)-4-oxo-4-(2-oxooxazolidin-3-yl)-N-(trityloxy)butanamide(4-5G): 
Yield = 54%. 
1
H-NMR (300 MHz, CDCl3) δ 7.45 – 7.30 (m, 15H), 4.33 (t, J = 8.01 
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Hz, 2H), 4.05 – 3.88 (m, 3H), 2.46 – 2.34 (m, 1H), 1.73 – 1.46 (m, 10H), 1.15 – 0.87 
(m, 2H); ESI-MS: m/z [M+Na]
+
 = 549.5.  
 
5-(benzyloxy)-3-(2-oxooxazolidine-3-carbonyl)-N-(trityloxy)pentanamide (4-5H):  
Yield = 72%. 
1
H-NMR (300 MHz, CDCl3) δ 7.48-7.30 (m, 20H), 4.48-4.30 (m, 2H), 
4.25 – 4.13 (m, 2H), 3.98-3.82 (m, 2H), 3.52-3.38 (m, 3H), 2.47-2.25 (m, 1H), 
2.12-1.98 (m, 1H), 1.79-1.65 (m, 2H); ESI-MS: m/z [M+Na]
+
 = 601.5.  
 
2-isopropyl-4-oxo-4-(trityloxyamino)butanoic acid (4-6A): Yield = 76%. 
1
H-NMR 
(300 MHz, CDCl3) δ 7.80 (br s, 1H), 7.49 – 7.26, (m, 15H), 2.74 – 2.59 (m, 1H), 2.45 
– 2.15 (m, 2H), 1.82 – 1.68 (m, 1H), 1.06 – 0.66 (m, 6H); 13C-NMR (75 MHz, CDCl3) 
δ 174.4, 171.9, 146.8, 129.3 – 126.5 (m), 13C-NMR (75 MHz, CDCl3) δ 82.2, 42.9, 
28.7, 27.7, 19.5, 17.4; ESI-MS: m/z [M+Na]
+
 = 440.3.  
 
4-methyl-2-(2-oxo-2-(trityloxyamino)ethyl)pentanoic acid (4-6B): Yield = 80%. 
1
H-NMR (300 MHz, CDCl3) δ 7.46 (br s, 1H), δ 7.32 (br s, 15H), 4.10 (q, 1H), 
2.59-2.53 (m, 1H), 2.32-2.20 (m, 1H), 1.45-1.32 (m, 3H); 0.84(m, 6H); ESI-MS cald 
for C27H29NO4Na [M+Na]
+
 = 454.2, found 454.0.  
 
3-methyl-2-(2-oxo-2-(trityloxyamino)ethyl)pentanoic acid (4-6C): Yield = 70%. 
1
H-NMR (300 MHz, CDCl3) δ 7.43 – 7.28 (m, 16H), 2.95 – 2.86 (m, 1H), 2.75 – 2.56 





C-NMR (75 MHz, CDCl3) δ 175.1, 172.2, 146.8, 130.1-126.5 (m), 82.1, 
41.1, 34.6, 26.9, 26.8, 14.0, 11.7; ESI-MS: m/z [M+Na]
+
 = 454.2.  
 
2-benzyl-4-oxo-4-(trityloxyamino)butanoic acid (4-6D): Yield = 79%. 
1
H-NMR (300 
MHz, CDCl3) δ 7.49 – 6.96 (m, 20H), 3.03 – 2.86 (m, 1H), 2.59 – 2.42, (m, 2H), 2.09 
– 1.92 (m, 1H), 1.69 – 1.52 (m, 1H); 13C-NMR (75 MHz, CDCl3) δ 174.5, 171.8, 
146.8, 136.5, 129.3 – 127.2 (m), 82.1, 38.4, 36.1, 30.6; ESI-MS: m/z [M+Na]+ = 
488.3.  
 
2-(2-oxo-2-(trityloxyamino)ethyl)-5-phenylpentanoic acid (4-6E): Yield = 65%. 
1
H-NMR (300 MHz, CDCl3) δ 7.38 – 7.22 (m, 21H), 2.59 – 2.43 (m, 4H), 2.31 – 2.15 
(m, 1H), 1.54 – 1.26 (m, 4H); 13C-NMR (75 MHz, CDCl3) δ 178.2, 174.9, 146.8, 
141.7, 130.0 – 125.5 (m), 82.2, 36.9, 35.4, 31.6, 30.6, 28.2; ESI-MS: m/z [M+Na]+ = 
516.6.  
 
2-cyclohexyl-4-oxo-4-(trityloxyamino)butanoic acid (4-6F): Yield = 64%. 
1
H-NMR 
(300MHz, CDCl3) δ 7.33 – 7.18 (m, 15H), 3.16 – 2.91 (m, 1H), 2.79 – 2.71 (m, 1H), 
2.46 – 2.42 (m, 1H), 2.50 – 1.52 (m, 6H), 1.24 – 1.09 (m, 5H); 13C-NMR (75 MHz, 
CDCl3) δ 174.4, 171.9, 146.8, 130.0 – 126.5 (m), 82.0, 42.5, 38.6, 30.2, 28.3, 27.7, 
25.8; ESI-MS: m/z [M+Na]
+




2-(cyclopentylmethyl)-4-oxo-4-(trityloxyamino)butanoic acid (4-6G): Yield = 83%. 
1
H-NMR (300 MHz, CDCl3) δ 7.42 – 7.19 (m, 15H), 2.20 – 2.05 (m, 3H), 1.41 – 1.26 
(m, 9H), 1.14 – 0.68 (m, 2H); 13C-NMR (75 MHz, CDCl3) δ 176.2, 173.0, 146.8, 
128.5 – 127.0 (m), 92.8, 45.7, 37.9 – 36.6 (m), 32.4 – 31.9 (m), 25.0; ESI-MS: m/z 
[M+Na]
+
 = 480.6.  
 
2-(2-(benzyloxy)ethyl)-4-oxo-4-(trityloxyamino)butanoic acid (4-6H): Yield = 73%. 
1
H-NMR (300 MHz, CDCl3) δ 7.48 – 7.20 (m, 20H), 4.55 - 4.34 (m, 2H), 3.62-3.36 
(m, 2H), 2.61-2.57 (m, 1H), 2.41-2.30 (m, 1H), 2.22-2.15 (m, 1H), 1.82-1.62 (m, 2H); 
13
C-NMR (75 MHz, CDCl3) δ 176.2, 173.0, 146.8, 128.5 – 127.0 (m), 92.8, 45.7, 37.9 






-(trityloxy)succinamide (4-7A): Yield = 88%. 
1
H-NMR (300 MHz, DMSO-d6) δ 7.39 – 7.18 (m, 15H), 3.89 – 3.63 (m, 2H), 2.50 (s, 
1H), 2.38 – 1.72 (m, 3H), 1.53 – 1.43 (m, 1H), 0.63 – 0.49 (m, 6H); ESI-MS: m/z 
[M+Na]
+






-(trityloxy)succinamide (4-7B): Yield = 80%. 
1
H-NMR (300 MHz, CDCl3) δ 7.43 – 7.38 (m, 15H), 3.85 – 3.69 (m, 2H), 2.80 (s, 
1H), 2.45 – 2.31 (m, 1H), 2.23 – 2.08 (m, 2H), 1.42 – 1.28 (m, 3H), 0.84 – 0.68 (m, 
6H); ESI-MS: m/z [M+Na]
+








-(trityloxy)succinamide (4-7C): Yield = 91%. 
1
H-NMR (300 MHz, CDCl3) δ 7.44 – 7.26 (m, 15H), 3.94 – 3.78 (m, 2H), 2.50 – 2.34 
(m, 1H), 2.28 – 2.13 (m, 2H), 1.70 (s, 1H), 1.35 – 1.19 (m, 3H), 0.85 – 0.69 (m, 6H); 
ESI-MS: m/z [M+Na]
+






-(trityloxy)succinamide (4-7D): Yield = 82%. 
1
H-NMR 
(300 MHz, CDCl3) δ 7.65 – 6.93 (m, 20H), 4.02 – 3.57 (m, 2H), 2.80 (s, 1H), 2.68 – 






-(trityloxy)succinamide (4-7E): Yield = 82%. 
1
H-NMR (300 MHz, CDCl3) δ 7.45 – 6.99 (m, 20H), 3.90 – 3.73 (m, 2H), 2.79 (s, 






-(trityloxy)succinamide (4-7F): Yield = 83%. 
1
H-NMR (300 MHz, MeOD) δ 7.48 – 7.22 (m, 15H), 4.06 – 3.81 (m, 2H), 2.81 (s, 
1H), 2.57 – 2.54 (m, 1H), 2.30 – 2.15 (m, 2H), 1.69 – 0.89 (m, 11H); ESI-MS: m/z 
[M+Na]
+






-(trityloxy)succinamide (4-7G):  
Yield = 85%. 
1
H-NMR (300 MHz, CDCl3) δ 7.48 – 7.26 (m, 15H), 4.03 – 3.81 (m, 
2H), 2.41 – 2.38 (m, 2H), 2.19 – 2.16 (m, 2H), 1.63 – 1.26 (m, 8H), 1.09 – 0.88 (m, 










-(trityloxy)succinamide (4-7H):  
Yield = 80%. 
1
H-NMR (300 MHz, CDCl3) δ 7.44 – 7.20 (m, 20H), 4.48 – 4.39 (m, 
1H), 4.35 – 4.21 (m, 1H), 4.02 – 3.62 (m, 2H), 3.48 – 3.22 (m, 2H), 2.75-2.52 (m, 1H), 
2.48-2.22 (m, 1H), 2.20 (s, 1H), 1.95-1.80 (m, 1H), 1.73-1.51 (m, 3H); ESI-MS: m/z 
[M+23]
+






-(prop-2-ynyl)succinamide (4-8A): Yield = 52%. 
1
H-NMR (300 MHz, MeOD) δ 4.08 – 4.00 (m, 1H), 3.90 – 3.83 (m, 1H), 2.65 – 2.56 
(m, 1H), 2.56 – 2.46 (m, 1H), 2.45 – 2.36 (m, 1H), 2.34 – 2.26 (m, 1H), 1.87 – 1.83 
(m, 1H), 1.04 – 0.94 (m, 6H); 13C-NMR (75 MHz, CDCl3) δ 177.2, 172.2, 81.3, 72.9, 










-(prop-2-ynyl)succinamide (4-8B): Yield = 43%. 
1
H-NMR 
(300 MHz, MeOD) δ 4.06 – 3.96 (m, 1H), 3.93 – 3.87 (m, 1H), 2.86 – 2.76 (m, 1H), 
2.64 – 2.53 (m, 1H), 2.39 – 2.29 (m, 1H), 2.23 – 2.13 (m, 1H), 1.61 – 1.56 (m, 2H), 
1.26 – 1.16 (m, 1H), 0.98 – 0.89 (m, 6H); 13C-NMR (75 MHz, CDCl3) δ 177.9, 171.5, 
81.3, 73.0, 43.4, 40.3, 30.3, 27.8, 24.4, 23.2; HRMS cald for C11H18O3N2Na 
[M+Na]
+








-(prop-2-ynyl)succinamide (4-8C): Yield = 45%. 
1
H-NMR 
(300 MHz, MeOD) δ 4.07 – 3.98 (m, 1H), 3.97 – 3.82 (m, 1H), 2.72 – 2.62 (m, 1H), 
2.61 – 2.53 (m, 1H), 2.45 – 2.35 (m, 1H), 2.31 – 2.21 (m, 1H), 1.71 – 1.61 (m, 1H), 
1.52 – 1.43 (m, 1H), 1.24 – 1.14 (m, 1H), 0.99 – 0.89 (m, 6H); 13C-NMR (75 MHz, 










-(prop-2-ynyl)succinamide (4-8D): Yield = 48%. 
1
H-NMR 
(300 MHz, MeOD) δ 7.39 – 7.11 (m, 5H), 3.97 – 3.82 (m, 2H), 3.01 – 2.99 (m, 1H), 
2.99 – 2.86 (m, 1H), 2.74 – 2.72 (m, 1H), 2.59 – 2.53 (m, 1H), 2.43 – 2.35 (m, 1H), 
2.23 – 2.20 (m, 1H); 13C-NMR (75 MHz, CDCl3) δ 176.8, 171.5, 140.9, 131.0, 130.3, 
128.4, 81.0, 73.0, 46.8, 40.3, 36.6, 30.2; HRMS cald for C14H16O3N2Na [M+Na]
+
 






-(prop-2-ynyl)succinamide (4-8E): Yield = 41%. 
1
H-NMR (300 MHz, MeOD) δ 7.37 – 7.18 (m, 5H), 4.06 – 4.04 (m, 1H), 3.98 – 3.82 
(m, 1H), 2.76 – 2.63 (m, 1H), 2.61 – 2.60 (m, 1H), 2.59 (s, 1H), 2.49 – 2.47, 2.19 – 
2.16 (m, 1H), 2.40 – 2.31 (m, 1H), 1.66 – 1.51 (m, 3H), 1.50 – 1.47 (m, 1H); 
13
C-NMR (75 MHz, CDCl3) δ 177.6, 171.6, 144.2, 130.2, 127.6, 81.4, 73.0, 42.0, 40.0, 














-(prop-2-ynyl)succinamide (4-8F): Yield = 48%. 
1
H-NMR (300 MHz, MeOD) δ 4.08 – 3.97 (m, 1H), 3.86 – 3.80 (m, 1H), 2.56 (br s, 
1H), 2.56 – 2.38 (m, 2H), 2.35 – 2.27 (m, 1H), 1.77 – 1.73 (m, 3H), 1.69 – 1.49 (m, 
2H), 1.54 – 1.44 (m, 1H), 1.30 – 1.21 (m, 2H), 1.20 – 1.11 (m, 1H), 1.09 – 0.91 (m, 
2H); 
13
C-NMR (75 MHz, CDCl3) δ 177.2, 172.2, 81.4, 72.9, 42.6, 37.2, 34.4, 32.6, 
30.5, 28.3; HRMS cald for C13H20O3N2Na [M+Na]
+
 






-(prop-2-ynyl)succinamide (4-8G):  
Yield = 55%. 
1
H-NMR (300 MHz, MeOD) δ 4.03 – 4.01 (dd, J = 17.6 Hz, J = 2.4 Hz, 
1H), 3.97 – 3.84 (m, 1H), 2.77 – 2.70, 2.59 – 2.56 (m, 1H), 2.56 (s, 1H), 2.44 – 2.42, 
2.18 – 2.15 (m, 1H), 2.32 – 2.28 (m, 1H), 1.86 – 1.84 (m, 1H), 1.77 – 1.74 (m, 2H), 
1.71 – 1.63 (m, 1H), 1.62 – 1.61 (m, 2H), 1.54 – 1.51 (m, 2H), 1.35 – 1.32 (m, 1H), 
1.12 – 1.07 (m, 2H); 13C-NMR (75 MHz, CDCl3) δ 177.9, 174.1, 81.4, 72.9, 41.5, 










-(prop-2-ynyl)succinamide (4-8H):  
Yield = 52%. 
1
H-NMR (300 MHz, MeOD) δ 7.40 – 7.23 (m, 5H), 4.46 (s, 2H), 3.92 – 
3.74 (m, 2H), 3.48 (br s, 1H), 3.02 – 2.84 (m, 1H), 2.57 (s, 1H), 2.40 – 2.25 (m, 2H), 
1.38 – 1.30 (m, 2H); 13C-NMR (75 MHz, CDCl3) δ 177.3, 171.5, 140.5, 130.2, 129.8, 








6.2.7 Synthesis of succinyl hydroxamate-based warheads with P1’ substitution 
mimicking nature amino acid sides 
 
 
Scheme 6-4. Synthesis route of warhead 5-I and 5-K 
 
General procedure for the conversion of 5-1 to 5-2 
To a solution of the diol 5-1 (a or b; 120 mmol) in DCM (300 mL) was added 
Ag2O (41.7 g, 180 mmol) and benzyl bromide (15.7 mL, 132 mmol) at room 
temperature under a nitrogen atmosphere. The reaction was stirred further for 4 hrs 
before the solid was removed by filtration. The resulting filtrate was concentrated in 






5-(benzyloxy)pentan-1-ol (5-2a):  
Yield = 84%. 
1
H-NMR (300 MHz, CDCl3) δ 7.40-7.25 (m, 5H), 4.50 (s, 2H), 3.58 (t, 
J = 12.2 Hz, 2H), 3.48 (t, J = 12.9 Hz, 1H), 2.28 (s, 1H), 1.67-1.54 (m, 4H), 1.51-1.40 
(m, 2H); ESI-MS: m/z [M+Na]
+
 
= 217.3.  
 
4-(benzyloxy)butan-1-ol (5-2b):  
Yield = 80%. 
1
H-NMR (300 MHz, CDCl3) δ7.48 – 7.21, (m, 5H), 4.49, (s, 2H), 3.57 





General procedure for oxidation of 5-2 to 5-3 
To a solution of 5-2 (a or b; 96 mmol) in DMF (250 mL) at 0 ºC under a nitrogen 
atmosphere was added pyridinium dichromate (170.6 g, 453 mmol). The mixture was 
gradually raised to room temperature and stirred overnight. Water was subsequently 
added and the resulting mixture was extracted with ether. The combined ether layers 
were washed with brine, dried over Na2SO4, filtered and concentrated. The oil 
obtained was purified by flash chromatography (10 – 20% EA/hexane) to give 5-3.  
 
5-(benzyloxy)pentanoic acid (5-3a):  
Yield = 50%. 
1
H-NMR (300 MHz, CDCl3) δ 9.96 (br s, 1H), 7.42-7.25 (m, 5H), 4.51 
(s, 2H), 3.50 (t, J = 10.8 Hz, 2H), 2.38 (t, J = 12.6 Hz, 1H), 2.71 (m, 4H); ESI-MS: 
m/z [M-H]
-




4-(benzyloxy)butanoic acid (5-3b):  
Yield = 64%. 
1
H-NMR (300 MHz, CDCl3) δ 10.10 (br s, 1H), 7.42-7.30 (m, 5H), 4.54 
(s, 2H), 3.56 (t, J = 5.94 Hz, 2H), 2.51 (t, J = 6.96 Hz, 2H), 1.98 (t, J = 6.63 Hz, 2H). 
ESI-MS: m/z [M-H]
-
= 193.1.  
 
Procedures for conversion of 5-3 to 5-4, then to 5-5 or 5-6:  
The synthesis of 5-5 and 5-6 from 5-3 was accomplished using procedures as 
described in section 6.2.6. 
 
3-(5-(benzyloxy)pentanoyl)oxazolidin-2-one (5-4a):  
Yield = 80%. 
1
H-NMR (300 MHz, CDCl3) δ 7.33-7.22 (m, 5H), 4.60 (s, 2H), 4.35 (t, 
J = 16.2 Hz, 2H), 3.90 (t, J = 15.9 Hz, 2H), 3.50 (t, J = 12.9 Hz, 2H), 2.96 (t, J = 12.9 
Hz, 2H), 1.82-1.67 (m, 4H); ESI-MS: m/z [M+Na]
+
 
= 300.2.  
 
3-(4-(benzyloxy)butanoyl)oxazolidin-2-one (5-4b):  
Yield = 82%. 
1
H-NMR (300 MHz, CDCl3) δ 7.38-7.26 (m, 5H), 4.47 (s, 2H), 3.56 (t, 




= 286.2.  
 
6-(benzyloxy)-3-(2-oxooxazolidine-3-carbonyl)hexanoic acid (5-5):  





and characterized by NMR and MS. 
1
H-NMR (300 MHz, CDCl3) δ 7.38-7.26 
(m, 5H), 4.47 (s, 2H), 4.38-4.30 (m, 2H), 4.25-4.16 (m, 1H), 4.08-3.92 (m, 2H), 3.46 
(m, 2H), 2.83-2.74 (dd, J1 = 17.97 Hz, J2 = 10.68 Hz, 1H), 2.45-2.38 ( dd, J1 = 16.70 
Hz, J2 = 4.11 Hz, 1H), 1.78-1.56 ( m, 4H); ESI-MS: m/z [M+Na]
+
= 414.2.  
The above intermediate (13.3 g, 34 mmol) was treated with TFA (26.2 mL, 340 mmol) 
in DCM (170 mL), based on a previously published procedure, to give 5-5 (11.3 g, 
33.7 mmol) in 99% yield. 
1
H-NMR (300 MHz, CDCl3) δ 7.38-7.26 (m, 5H), 4.38 (s, 
2H), 4.42-4.28 (m, 2H), 4.24-4.12 (m, 1H), 4.08-3.92 (m, 2H), 3.50 (m, 2H), 
2.83-2.74 ( dd, J1 = 17.26 Hz, J2 = 10.18 Hz, 1H), 2.56-2.42 (dd, J1 = 16.70 Hz, J2 = 
4.11 Hz, 1H), 1.78-1.56 ( m, 4H); ESI-MS: m/z [M-H]
-
 
= 334.3.  
 
tert-butyl 5-hydroxy-3-(2-oxooxazolidine-3-carbonyl)pentanoate (5-6):  
The oxazolidine precursor of 5-6 was synthesized from 5-4b accordingly (Yield = 
78%),
  
and characterized by NMR and MS. 
1
H-NMR (300 MHz, CDCl3) δ 7.35 – 
7.20 (m, 5H), 4.50 – 4.30 (m, 2H), 4.30 – 4.20 (m, 2H), 4.17 – 3.81 (m, 2H), 3.69 – 
3.52 (m, 3H), 2.87 – 2.76 (dd, J1 = 16.5 Hz, J2 = 10.44 Hz, 1H), 2.85 – 2.76 (dd, J1 = 
16.71 Hz, J2 = 4.53Hz, 1H), 2.09 – 1.98 (m, 1H), 1.35 (s, 9H); ESI-MS: m/z [M+Na]
+
 
= 414.3.  
Hydrogenolysis of above intermediate (13.2 g, 35 mmol) was accomplished in 
THF (175 mL) with Pd/C (1.32 g) by stirring the mixture at room temperature under a 
hydrogen atmosphere for 1.5 hrs. The mixture was filtered, and the filtrate 
concentrated and purified by flash chromatography (80-100% EA/hexane) to yield 5-6 
127 
 
(7.96 g, 27.7 mmol, 79%). 
1
H-NMR (300 MHz, CDCl3) δ 4.43 – 4.35 (m, 2H), 4.24 – 
4.14 (m, 2H), 4.05 – 3.96 (m, 2H), 3.65 – 3.60 (t, J = 5.94 Hz, 2H), 2.83 – 2.74 (dd, J1 
= 16.89 Hz, J2 = 10.47 Hz, 1H), 2.46 – 2.39 (dd, J1 = 16.89 Hz, J2 = 4.20 Hz, 1H), 
1.92 – 1.65 (m, 2H), 1.35 (s, 9H); ESI-MS: m/z [M+Na]+
 
= 310.2.  
 
6-hydroxy-3-(2-oxooxazolidine-3-carbonyl)-N-(trityloxy)hexanamide (5-7):  
Coupling of acid 5-5 (11.4 g, 34.0 mmol) with trityl-protected hydroxylamine 
(11.2 g, 40.8 mmol) and DCC (8.42 g, 40.8 mmol) in DCM (120 mL), following 
previously published procedures,
 
yielded the corresponding intermediate (80%) after 
purification by flash chromatography (40-60% EA/hexane). 
1
H-NMR (300 MHz, 
CDCl3) δ 7.68 (br s, 1H), 7.38-7.26 (m, 20H), 4.45 (s, 2H), 4.38-4.22 (m, 2H), 
4.04-3.82 (m, 3H), 3.37 (m, 2H), 2.40-2.37 (m, 1H), 2.12-2.01 ( m, 1H), 1.58-1.32 (m, 
4H); ESI-MS: m/z [M+Na]
+
 
= 615.1.  
The above intermediate (16.1 g, 27.2 mmol) in THF (130 mL) and Pd/C (1.61 g) 
was stirred at room temperature under a hydrogen atmosphere for 1.5 hrs. The 
mixture was filtered, and the filtrate concentrated and purified by column 
chromatography (80-100% EA/hexane) to afford 5-7 (10.8g, 21.5 mmol, 
75%).
1
H-NMR (300 MHz, CDCl3) δ 7.68 (br s, 1H), 7.38-7.26 (m, 15H), 4.47-4.34 
( m, 2H), 4.06-3.85 (m, 3H), 3.56-3.42 (m, 2H), 2.43-2.34 (m, 1H), 2.02-1.88 (m, 1H), 
1.48-1.20 (m, 4H); ESI-MS: m/z [M+Na]
+
 





2-(2-oxo-2-(trityloxyamino)ethyl)-5-(trityloxy)pentanoic acid (5-I):  
To a solution of 5-7 (10.8 g, 21.5 mmol), DMAP (0.26 g, 2.15 mmol) and TEA 
(5.36 mL, 38.7 mmol) in DCM (240 mL) was added CPh3Cl (6.00 g, 21.5 mmol) and 
the reaction was stirred at room temperature overnight. DCM was removed in vacuo 
to yield a yellow semi-solid. Subsequently, 20% EA/hexane was added to the residue. 
The white solid obtained was filtered off and washed again with 20% EA/hexane to 
afford the pure intermediate (15.6 g, 21.0 mmol, 98%). 
1
H-NMR (300 MHz, CDCl3) δ 
7.18-7.56 (m, 31H), 4.22 (t, J = 7.83 Hz, 2H), 3.61 (t, J = 8.73 Hz, 2H), 3.14-3.06 (q, 
2H), 2.99-2.97 (m, 1H), 2.38-2.22 (m, 1H), 1.96-1.78 (m, 1H), 1.48-1.20 (m, 4H); 
ESI-MS: m/z [M+Na]
+
= 767.8.  
The above intermediate (15.6 g, 21.0 mmol) was treated with LiOH (1.51 g, 63.0 
mmol) and 30% H2O2
 
(11.8 mL, 113 mmol) using previously published procedures,
 
followed by purification with flash chromatography (5-10% MeOH) to give 5-I (9.66 
g, 14.3 mmol, 68%). 
1
H-NMR (300 MHz, CDCl3) δ 7.25-7.16 (m, 31H), 3.18-2.82 (m, 
2H), 2.71-2.55 (m, 1H), 2.48-2.25 (m, 1H), 2.18-2.02 (m, 1H), 1.72-1.25 (m, 4H); 
13
C-NMR (75 MHz, CDCl3) δ 176.0, 174.5, 146.8, 129.2-126.4 (m), 88.9, 82.0, 68.6, 
36.2, 35.4, 24.7, 22.1; ESI-MS: m/z [M-H]
-
= 674.3.  
 
tert-butyl 5-oxo-3-(2-oxooxazolidine-3-carbonyl)-5-(trityloxyamino)pentanoate (5-8):  
Alcohol 5-6 (7.96 g, 27.7 mmol) was treated with PDC (31.3 g, 83.1 mmol) in 
DMF (70 mL) to furnish the corresponding intermediate (6.51 g, 21.6 mmol, 78%). 
1
H-NMR (300 MHz, CDCl3) δ 4.48 – 4.34 (m, 3H), 4.08 – 3.93 (m, 2H), 2.84 – 2.69 
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(m, 2H), 2.54 – 2.38 (m, 2H), 1.40 (br s, 9H); ESI-MS: m/z [M-H]-
 
= 300.3.  
Above intermediate (65.1 g, 21.6 mmol) was coupled with trityl-protected 
hydoxylamine (7.13 g, 25.9 mmol) using DCC (5.34 g, 25.9 mmol) in DCM (65 mL), 
following previously published procedures. Upon purification by flash 
chromatography (50-70% EA/hexane), the desired product 5-8 was isolated (7.37 g, 
13.2 mmol, 61%).
1
H-NMR (300 MHz, CDCl3) δ 7.47 – 7.32 (m, 16H), 4.37 (t, J = 
8.01 Hz, 2H), 4.12 (q, J = 7.32 Hz, 1H), 3.96 (t, J = 7.32 Hz, 2H), 2.39 – 1.85 (m, 4H), 
1.40 (s, 9H); ESI-MS: m/z [M+Na]
+
 
= 581.5.  
 
2-(2-tert-butoxy-2-oxoethyl)-4-oxo-4-(trityloxyamino)butanoic acid (5-K):  
Hydrolytic cleavage of the oxazolidinone moiety in 5-8 (7.37 g, 13.2 mmol) was 
accomplished by LiOH (0.95 g, 39.6 mmol) and 30 % H2O2
 
(6.36 mL, 60.7 mmol) 
using previously published procedures, 
 
which upon purification by flash 
chromatography (70-80% EA/hexane) yielded 5-K (4.72 g, 9.64 mmol, 73%). 
1
H-NMR (300 MHz, CDCl3) δ 7.43-7.29 (m, 16H), 3.02-2.87 (m, 1H), 2.79-2.63 (m, 
1H), 2.48-2.25 (m, 2H), 2.18-2.02 (m, 1H), 1.43 (s, 9H); 
13
C-NMR (75 MHz, CDCl3) 






6.2.8 General Procedure of in situ Click Chemistry  
The first 56-membered library of small molecule-bases MMP inhibitors was 
assembled in situ in a 96-deep well microplate. All the alkynes and azides were made 
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100 mM stock in DMSO before loading into each well in proportions. The catalysts 
(50 mM sodium ascorbate and 12.5 mM CuSO4 in H2O) were also prepared before 
starting the reactions. Potassium carbonate solution (100 mM) was prepared and used 
to deprotect the TMS-protecting group. And the azides were used in slight excess (1.1 
eq) so as to ensure that all alkynes were consumed completely. 
 
100 mM Azide stock (1.1 eq):    11 μL  (final conc: 5.5 mM) 
  100 mM Alkyne stock (1 eq):    10 μL    (final conc: 5 mM) 
  12.5 mM CuSO4
.
H2O (0.1 eq):    8 μL  (final conc: 0.5 mM) 
  50 mM Sodium ascorbate (0.4 eq):  8 μL  (final conc: 2 mM) 
100 mM K2CO3 (1 eq)            10 μL    (final conc: 5 mM) 
  H2O              64 μL 
  t-BuOH                 79 μL   
total Vol.                   200 μL 
 
The alkyne and azide were transferred into a 96-deep well microplate and then 
t-BuOH/H2O (around 1:1 volume ratio) was applied to each well. The microplate was 
shaken for a few minutes, followed by sequential addition of catalytic amounts of 
sodium ascorbate (0.4 eq) and CuSO4 (0.1 eq) into each well. Potassium carbonate 
solution was added subsequently to deprotect the TMS on the alkyne and to initiate 
the “Click Chemistry” assembly. The whole plate was continuously shaken at room 
temperature for another 2 days. The assembled products were concentrated by 
Genevac Evaporator and redissolve in 100 μL of DMSO to make the concentration 
around 10 mM in each well. These samples were used directly for subsequent LC-MS 
analysis and enzymatic assays without any further purification. LC-MS analysis of in 
situ-assembled products indicated the complete consumption of the alkynes and 
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quantitative formation of the correct triazole products in almost every case. The 
LC-MS profiles of representative examples were shown below. HPLC conditions: 30% 
B to 90% B in 20 min gradients (A: H2O + 0.1% TFA, B: Acetonitrile + 0.1% TFA). 
 
6.3 Solid Phase Synthesis 
 
6.3.1 Loading of Fmoc-Lys(Biotin)-OH onto Rink Amide AM Resin 
Fmoc-Lys(Biotin)-OH (4 eq.) was synthesized followed our previous 
procedures
164
 and dissolved in dry DMF (1.5 mL) together with HBTU (4 eq.), HOBt 
(4 eq.) and DIEA (8 eq.). The Rink Amide AM Resin (50 mg, loading ~ 0.5 mmol/g, 
previously swollen in dry DMF) was added and shaken for 3 hrs at room temperature. 
The resin was filtered and washed thoroughly with DMF (3×), DCM (3×) and DMF 
(3×) until the filtrate became colorless. After this first coupling, any unreacted resin 
residue was capped with a solution of Ac2O (10 eq.), DIEA (20 eq.) in DCM, and the 
reaction mixture was allowed to react for 2 hr at room temperature, followed by 
extensive wash with DCM (3×) and DMF (3×). 
 
6.3.2 General procedure for Fmoc deprotection 
The Fmoc-protected amino-functionalized resin was treated with 20% piperidine 
in DMF for 1 hr at room temperature. The resin was extensive washed with DMF (3×), 





6.3.3 General procedure for coupling of Fmoc-amino acids 
Fmoc-amino acid (4 eq.), HBTU (4 eq.) and HOBt (4 eq.) were dissolved in dry 
DMF (1.5 mL) and DIEA (8 eq.) was added and agitated for 5 min. This pre-activated 
Fmoc-amino acid solution was added to the amino-functionalized resin and shaken for 
3 hrs at room temperature. The resin was filtered and washed with DMF (3×), DCM 
(3×) and DMF (3×).  
 
6.3.4 Procedure for coupling of compound 2-17 
Compound 2-17 (4 eq), HATU (4 eq.) and HOAt (4 eq.) were dissolved in dry 
DMF (1.5 mL) and DIEA (8 eq.) was added and agitated for 5 min. This pre-activated 
unnatural amino acid solution was added to the resin and shaken for overnight at room 
temperature. The resin was filtered and washed with DMF (3×), DCM (3×) and DMF 
(3×). 
 
6.3.5 Procedure for coupling of Fluorescein(OAc)-NHS 
The resin was swollen in dry DCM for 30 mins and then treated with 1% TFA, 5% 
TIS in DCM (1.5 mL) for another 30 mins. The Mtt deprotection was indicated by 
ninhydrin test. The resin was washed with DMF (3×), DCM (3×) and DMF (3×) and 
added into Fluorescein(OAc)-NHS (4 eq.) and DIEA (8 eq.) solution in DMF (1.5 mL) 
and shaken overnight at room temperature. The resin was filtered and washed with 
DMF (3×), DCM (3×) and DMF (3×). After the final coupling, all unreacted amines 
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were capped by treated with Ac2O (10 eq.), DIEA (20 eq.) in DCM for 2 hrs at room 
temperature, followed by extensive wash with DCM (3×) and DMF (3×). 20% 
piperidine in DMF was used to deprotect the acetyl group to form the free 
Fluorescein. 
 
6.3.6 Cleavage of peptide from resin 
The resin was washed with MeOH (3×) and dried thoroughly in vacuo. A solution 
of TFA/TIS/H2O (95/2.5/2.5, 2 mL) was added to the resin at room temperature and 
shaken for 2.5 hrs. The resin was filtered off and washed with DCM (2×). The 
combined DCM and cleavage solutions were concentrated to ~0.5 mL, and then cold 
diethyl ether (5 mL) was added to precipitate the peptide. The peptide was then 
collected by centrifugation, washed with cold diethyl ether twice and dried in vacuo. 
 
6.3.7 Purification of the peptides 
The dried peptide was dissolved in DMSO and purified by Prep-HPLC using 
Eluent A (0.1 % TFA/water) and B (0.1 % TFA/acetonitrile) from 10% B to 70% B in 
35 mins. The eluent containing the products were collected and combined together. 
These combined solutions were concentrated and lyophilized. The solid products were 




Scheme 6-5. Synthesis of CPP-containing probe 2-P7. Reagents and conditions: a) i. 
Fmoc-Arg-OH, HBTU, HOBt, DIEA, DMF; ii. 20% piperidine in DMF; b) i. 
Fmoc-Lys(Mtt)-OH, HBTU, HOBt, DIEA, DMF; ii. 20% piperidine in DMF; c) i. compound 
2-35, HATU, HOAt, DIEA, DMF; ii. 20% piperidine in DMF; g) i. 1% TFA 5% TIS in 
DCM, 30 mins; ii. Fluorescein(OAc)2-NHS, DIEA, DMF; iii. 20% piperidine in DMF; h). 
95% TFA 2.5% TIS 2.5% H2O, 2 hrs. 
 
6.4 Microplate-Based Enzyme Profiling Procedures 
 
6.4.1 Caspase activity assay on microplate 
Ten millimolar DMSO stock solutions of 2-P1, and 2-P2 ~ 2-P4 were diluted 
with Caspase-3/7 Assay Buffer (50 mM PIPES, 100 mM NaCl, 1 mM EDTA, 10 mM 
DTT, 0.1% w/v CHAPS, 25% w/v sucrose, pH = 7.2) and PBS buffer, respectively, to 
make 10 μM working solutions. 2-C1 and 2-C2 (negative control probes) were 
similarly diluted with PBS buffer. Ten millimolar DMSO stocks of 2-P5 and 2-P6 
were diluted with Hepes buffer (25 mM HEPES, 0.05 M NaCl, 2.5 mM EDTA, 2 mM 
DTT, 0.02% Triton X-100, pH = 7.5) to give 40 μM working solutions, then exposed 
under UV to uncage the phosphate group. The recombinant Caspase-3 and -7 were 
freshly diluted to ∼0.02 μg/μL using Caspase-3/7 Assay Buffer containing 5 mM 
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TCEP. Other commercial caspases and cathepsins were used following protocols 
provided by the vendor. Recombinant PTPs were freshly prepared in the Hepes buffer 
to ∼0.1 μg/μL concentration. Legumain was freshly diluted to 100 μg/mL in 
activation buffer (50 mM sodium acetate, 100 mM NaCl, pH = 4.0) and incubated for 
2 h at 37 °C followed by further dilution to 0.01 μg/μL in assay buffer (50 mM MES, 
250 mM NaCl, pH = 5.0). In a typical enzymatic reaction, 10 μL of each probe (for 
positive controls, a commercially available fluorogenic substrate was used) was 
mixed with 10 μL of the enzyme solution and the reaction was continuously 
monitored at room temperature. 
 
6.4.2 High-Throughput Inhibitor Screening against MMPs  
After Click chemistry, a master plate was prepared from the “click library 
reaction plate” (10 mM in 100% DMSO) to make the final concentration in each well 
as 1 mM (10% DMSO in H2O). Serial dilution plates can be further prepared by 
making 2X, 5X and 10X diluted master plates to give 3 more concentrations of 500 
μM, 200 μM and 100 μM, respectively (10% DMSO in H2O). All these dilutions were 
labeled as different concentration of “working plate”, which can be used for 
microplate assays directly. 
The MMP activity was determined by measuring the rate of hydrolysis of the 
corresponding fluorogenic substrates, which were all commercial available. The 
inhibition of MMPs was screened using black polypropylene flat-bottom 384-well 
microtiter plates (Nunc, USA) in a total reaction volume of 50 μL/assay, and 
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monitored with a SpectraMAX
TM
 Gemini XS fluorescence plate reader (Molecular 
Devices, USA). Different concentrations of inhibitors were used in the assay (500 
μM, 200 μM, 100 μM, etc), where necessary. Controls were done with 1,3-dipolar 
ligation reactions carried out without addition of Cu(I) catalyst (e.g. CuSO4 and 
sodium ascorbate), and showed no inhibition against any of the enzymes. The detailed 
assay conditions were given below: 
 
Table 6-1. the general information for inhibition activity assays 
Enzymes Substrates Buffers Scan @ 
MMP-7 (Matrilysin) MMP-2/MMP-7 Substrate Knight Buffer 325/393 
MMP-8 (Collagenase 2) MMP-13 Substrate Knight Buffer 325/393 
MMP-9 (Gelatinase B) MMP Substrate III, Tno211 Beekman Buffer 340/485 
MMP-13 (Collagenase 3) MMP-13 Substrate Knight Buffer 325/393 




Enzyme (in 2X Buffer)   = 10 μL 
Substrate (in 2X Buffer)   = 15 μL  
Inhibitor (10% DMSO)   = 5 μL  
Double Distilled Water   = 20 μL  
Total Vol.      = 50 μL 
 
Reaction components were dispensed using an automated fluidics workstation 
(Precision XS, Biotek USA) to ensure consistent and homogenous treatment of all 
samples. Changing the positions of samples in the plate did not affect their fluorescent 
outputs. The reactions were initiated by adding the enzymes lastly and monitored at 
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the corresponding λex and λem by the fluorescence plate reader. The activity was 
compared in the absence and presence of inhibitors. 
 
Data processing and analysis  
The fluorescence outputs were background subtracted. Inhibition potency was 
calculated using normalization against reactions performed without the inhibitor:  
 
Intensity with Inhibitor X




The results were visualized using TreeView, producing heat maps that displayed 
the most potent inhibitors in bright red and least potent inhibitors in dark blue. 
 
6.4.3 IC50 Measurements against MMPs 
The IC50 values were obtained using dose-dependent reactions by varying the 
concentrations of the inhibitor, under the same enzyme concentration. Briefly, 8 serial 
dilutions of each inhibitor, from approximately 500 μM to 0.5 μM (final 
concentrations) were prepared. The assay condition for each enzyme was the same as 
above. The enzymatic reactions were allowed to incubate at 37 °C for 30 min before 
being interrogated for end-point fluorescence at corresponding λex and λem. The IC50 
was calculated by fitting the fluorescence outputs obtained using the Graphpad Prism 







Measurements against MMPs 
The Ki values were determined using the three purified compounds (A8, A23 and 
A25) against MMP-7 and MMP-13. Dose-dependent reactions were performed by 
varying both the concentrations of the substrate and inhibitor, whilst maintaining a 
consistent enzyme concentration. Briefly, three concentrations of 40 μM, 20 μM and 
10 μM (final concentration) were prepared for each inhibitor to be tested in black 
flat-bottom polypropylene 384-well plates (Nunc, USA). A final concentration (1.34 
μΜ, 0.67 μM and 0.34 μM for MMP-7 and 3.0 μΜ, 1.5 μM and 075 μM for MMP-13) 
of the corresponding substrate was added to each of these dilutions and the reaction 
was initiated by introducing 5.7 ng of MMP-7 or 2.5 ng of respectively into a 50 μL 
reaction volume of knight buffer. The plate was scanned immediately under the 
kinetic mode at λex = 325 nm and λem = 393 nm at a minimized interval for a period of 
10 min using a Tecan
TM
 Infinite F200 microplate reader. Kinetic data obtained were 
analyzed using the Dixon plot (1/initial velocity plotted against inhibitor 
concentration); affording three different linear graphs (corresponding to each of the 
substrate concentrations used) that converged at a point. The x-axis value at that point 
gives direct readouts of the Ki values. 
 
6.5 Gel-Based Labeling Experiments with 2-P1 and 2-P5 
 
Both stock solutions of 2-P1 and 2-P5 were prepared as described above and used 
for labeling with recombinant caspases/PTPs and lysates, respectively. For labeling 
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with recombinant proteins, around 1 μg of each protein was incubated with the 
corresponding probe (2-P1, 25 μM final probe concentration giving 1:20 caspase/2-P1 
molar ratio; 2-P5, 40 μM final probe concentration giving 1:40 PTP/2-P5 molar ratio) 
at room temperature for 3 h. For lysates labeling, bacterial and mammalian lysates 
were prepared as described below. Bacteria transformed with a caspase-3/7 
expressing plasmid was used. For bacterial lysates, upon induction of caspase 
expression and further growth, cells were collected and lysed to obtain the 
corresponding lysates. For mammalian lysate labeling, HeLa cells were cultured in 
DMEM growth media supplemented with 10% FBS and 1% penstrep. Cells were 
grown to a confluency of around 90% at 37 
o
C and 5% CO2 in a humidified 
incubation chamber, followed by treatment with 1 μM staurosporine (STS) for 6 h to 
induce apoptosis. The cell pellets were harvested and lysed in PBS buffer with 6% 
glycerol. The supernatant was obtained by centrifugation at 13 000 rpm for 40 min at 
4 
o
C. The amount of total proteins in the lysate was determined using the Bradford 
assay according to manufacturer’s protocol. Caspase activities in both bacterial and 
mammalian lysates were confirmed using a Caspase-3/7 substrate (Ac-DEVD-AFC) 
as well as Western blotting according to the protocol provided by the vendor. In a 
labeling reaction, 30 μg (in protein content) of each lysate was incubated with 5 μM of 
2-P1 or uncaged 2-P5, respectively, at room temperature for 3 h. All labeling 
reactions were stopped by addition of 6× SDS loading dye, followed by heating at 95 
o
C for 10 min. The mixture was resolved on a 12% or 20% SDS-PAGE gel and 
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fluorescently labeled bands were visualized by in-gel fluorescence scanning. 
Coomassie blue staining and/or Western blotting were carried out, where applicable. 
 
6.6 Western Blot 
 
To induce apoptosis, Hela cells were incubated with 200 nM of staurosporine 
(STS), for overnight. Cells were detached by cell scraper, washed by cold PBS for 
three times, centrifuged, and keep in -80°C for further usage. Caspase-3, Calpain-1 
and Cathepsin L antibodies were purchased from Abcam®. Briefly, equal amount of 
proteins were loaded and separated by SDS-PAGE and transferred onto PVDF 
membrane, blocked at room temperature for 1 hr using primary antibody blocking 
buffer (containing 0.1% Tween® 20) and incubated with HRP-conjugated secondary 
antibody for 1 hr at room temperature. At the end of this period, blots were washed 
thrice for 10 min each time in TBST (TBS containing 0.1% Tween® 20) and detected 
by chemiluminescence using ECL Plus Western Kit (Amersham, GE Healthcare, 
USA). 
 
6.7 Mass Spectrometry 
 
Twenty micrograms of Caspase-7 was labeled as above-described (1:20 
caspase/2-P1 molar ratio) overnight at room temperature. The sample, together with 
another control sample of unlabeled Caspase-7, was purified using a C4 Ziptip 
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(Millipore) according to manufacturer’s instructions. Purified samples were eluted 
using 60% acetonitrile (in water) containing 0.1% formic acid. The samples were 
analyzed with a quadrupole time-of-flight QTOF Premier mass spectrometer (Waters, 
U.K.) equipped with a nanoelectrospray ion source. The protein molecular weight was 
acquired using lysozyme as an internal standard.  
 
6.8 Cell Culture  
 
The human carcinoma epithelial carcinoma cell line HeLa was cultured in growth 
media (DMEM supplemented with 10% fetal bovine serum, 100.0 mg/L streptomycin, 
and 100 IU/mL penicillin). Cells were maintained in a humidified atmosphere of 5% 
CO2 at 37 °C.  
 
6.9 Transfection Experiment 
 
The pJ3H-PTP1B plasmid, which expresses PTP1B with an HA tag, was 
purchased from Addgene, and transiently transfected into HeLa cells (at 90% 
confluence) with Lipofectamine 2000 reagent (Invitrogen), as previously described.
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After proteins were expressed, cells were permeabilized and incubated with P6 for 1 h. 
Nontransfected cells were used as negative controls. Subsequently, cells were fixed 
and blocked with 2% BSA in PBS for 30 min at room temperature, washed twice with 
PBS, then further incubated with mouse anti-HA primary antibody (Roche, 1:200) for 
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1 h at room temperature, and with FITC-conjugated anti-mouse IgG (Santa Cruz, 
1:500) for 1 h, then imaged. For co-localization experiments, cells were further 
incubated with ER-Tracker Red (Invitrogen) for 1 h at room temperature, washed, and 
then imaged. All images were taken under similar conditions. 
 
6.10 Live Cell Imaging 
 
HeLa cells were cultured as above-described. Subsequently, cells were 
permeabilized by treatment with 1% digitonin (in 10% DMSO) for 1 min and washed 
with PBS buffer (3×). 2-P1 (33.3 μM final conc.; with or without an inhibitor), 2-P5, 
or 2-P6 (20 μM final conc.), prediluted with phenol-red free DMEM, was 
subsequently added. After 30 min, 500 nM of STS was added to induce apoptosis (for 
2-P1 imaging only). Cells were further incubated for another 1.5 h and washed with 
PBS buffer (3×). For 2-P5/2-P6 imaging, cells were subsequently UV-iradiated (1000 
μJ/cm2) for 10 min. Nucleus was stained with Hoechest stain. To fix the cells, 4% 
formaldehyde was applied for 30 min, and cells were washed with PBS, then treated 
with 1% BSA in PBS buffer (to quench free aldehyde and block nonspecific binding), 
before application of primary and secondary antibodies (anti-rabbit IgG-TR), prepared 
in PBS buffer containing 1% BSA according to protocols from the vendor. Upon 
further incubation and washing with PBS buffer, cells were imaged using Leica TCS 
SP5X optical Microscope System equipped with a Ti:Sappire femtosecond laser and 
HCX PL APO 100×/1.40-0.70 OIL CS objective. One- and two-photon imaging was 
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carried out using HeLa cells, similar to what was described above. For live-cell 
imaging using 2-P7, cells were directly treated with the probe without any 
permeabilization steps. 
 
6.11 Docking Simulations 
 
The mol2 format of two ligands (3-A23 and 3-A25) was prepared by Sybyl v7.2 
(Tripos, Missouri, USA). The structures of ligands were drawn and using the “Sketch 
Molecule” option, hydrogens were added and formal charges were assigned, 
minimized using 100 iterations at 0.05 kcal/mol Å to relieve any torsional strain. 
Coordinates for both MMP-7 and MMP-13 were obtained from the Protein Data Bank. 
Water molecules were removed from the protein structure, and the docking sphere 
was set at 10 Å and centered on the zinc residue in the enzyme active site. Docking 
was carried out by Autodock4 - Lamberking Genetic algorithm (The Scripps Research 
Institute). Applying these criteria, the docking was performed for 100 iterations. The 
macromolecule molecular surface and secondary structure were displayed by PyMol 











Herein, I have described several chemical biology platforms to study a few 
different families of enzymes such as Matrix Metalloproteases and Caspases. 
 High-throughput click chemistry and solid-phase synthesis have been utilized in 
the assembly of several types of small molecule-based MMP inhibitors using either 
succinyl hydroxamic acid or rhodanine as the ZBGs. Several promising ‘hits’ have 
been identified and exhibit good selectivity amongst the subfamily of MMPs but 
inhibitory activity remains moderate. With further optimizations, this new class of 
small molecule-based MMP inhibitors could possibly achieve more promising results. 
Also, a new class of “turn-on” qABPs has been successfully developed and found 
to be suitable for the imaging of enzymatic activities in live mammalian cells with 
sufficient spatial resolution and temporal control. The modular design of these probes 
based on quinone methide chemistry allows convenient introduction of different 
colored dyes and different warheads, thus, enabling this method to be used to target 
different classes of enzymes. These novel probes have the potential to be applied to 








1. Freilich, S.; Spriggs, R. V.; George, R. A.; Al-Lazikani, B.; Swindells, M.; 
Thornton, J. M., J. Mol. Biol. 2005, 349 (4), 745-763. 
2. Barrett, A. J.; Rawlings, N. D.; Woessner, J. F., Handbook of Proteolytic 
Enzymes, Second Edition, Elsevier Academic Press: California 2004. 
3. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. H., Chem. Rev. 1999, 99 
(9), 2735-2776. 
4. Babine, R. E.; Bender, S. L., Chem. Rev. 1997, 97 (5), 1359-1472. 
5. Leung, D.; Abbenante, G.; Fairlie, D. P., J. Med. Chem. 2000, 43 (3), 305-341. 
6. Sternlicht, M. D.; Werb, Z., Annu. Rev. Cell Dev. Biol. 2001, 17 (1), 463-516. 
7. Kontogiorgis, C. A.; Papaioannou, P.; Hadjipavlou-Litina, D. J., Curr. Med. 
Chem. 2005, 12 (3), 339-355. 
8. Cheng, M.; De, B.; Pikul, S.; Almstead, N. G.; Natchus, M. G.; Anastasio, M. V.; 
McPhail, S. J.; Snider, C. E.; Taiwo, Y. O.; Chen, L.; Dunaway, C. M.; Gu, F.; 
Dowty, M. E.; Mieling, G. E.; Janusz, M. J.; Wang-Weigand, S., J. Med. Chem. 
2000, 43 (3), 369-380. 
9. Skiles, J. W.; Monovich, L. G.; Jeng, A. Y., Chapter 15. Matrix 
metalloproteinase inhibitors for treatment of cancer. In Annu. Rep. Med. Chem., 
Academic Press: 2000; Vol. 35, pp 167-176. 
146 
 
10. Harrison, R. K.; Chang, B.; Niedzwiecki, L.; Stein, R. L., Biochemistry 1992, 31 
(44), 10757-10762. 
11. Lovejoy, B.; Hassell, A. M.; Luther, M. A.; Weigl, D.; Jordan, S. R., 
Biochemistry 1994, 33 (27), 8207-8217. 
12. Summers, J. B.; Davidsen, S. K., Chapter 13. Matrix Metalloproteinase Inhibitors 
and Cancer. In Annu. Rep. Med. Chem., James, A. B., Ed. Academic Press: 1998; 
Vol. Volume 33, pp 131-140. 
13. Overall, C. M.; Kleifeld, O., Br J Cancer 2006, 94 (7), 941-946. 
14. Mannello, F., Recent Patents on Anti-Cancer Drug Discovery 2006, 1 (1), 
91-103. 
15. Skiles, J. W.; Gonnella, N. C.; Jeng, A. Y., Curr. Med. Chem. 2001, 8 (4), 
425-474. 
16. Moore, W. M.; Spilburg, C. A., Biochem. Biophys. Res. Commun. 1986, 136, 
390. 
17. Moore, W. M.; Spilburg, C. A., Biochemistry 1986, 25, 5189. 
18. Johnson, W. H.; Roberts, N. A.; Borkakoti, N., J. Enz. Inhib. 1987, 2, 1-22. 
19. Porter, J. R.; Beeley, N. R. A.; Boyce, B. A.; Mason, B.; Millican, A.; Millar, K.; 
Leonard, J.; Morphy, J. R.; O'Connell, J. P., Bioorg. Med. Chem. Lett. 1994, 4, 
2741. 




21. Miller, A.; Askew, M.; Beckett, R. P.; Bellamy, C. L.; Bone, E. A.; Coates, R. E.; 
Davidson, A. H.; Drummond, A. H.; Huxley, P.; Martin, F. M.; Saroglou, L.; 
Thompson, A. J.; van Dijk, S. E.; Whittaker, M., Bioorg. Med. Chem. Lett. 1997, 
7, 193. 
22. Tomczuk, B. E.; Gowravaram, M. R.; Johnson, J. S.; Delecki, D.; Cook, E. R.; 
Ghose, A. K.; Mathiowetz, A. M.; Spurlino, J. C.; Rubin, B.; Smith, D. L.; 
Pulvino, T.; Wahl, R. C., Bioorg. Med. Chem. Lett. 1995, 5, 343. 
23. Wahl, R. C.; Pulvino, T. A.; Mathiowetz, A. M.; Ghose, A. K.; Johnson, J. S.; 
Delecki, D.; Cook, E. R.; Gainor, J. A.; Gowravaram, M. R.; Tomczuk, B. E., 
Bioorg. Med. Chem. Lett. 1995, 5, 349. 
24. Gowravaram, M. R.; Tomczuk, B. E.; Johnson, J. S.; Delecki, D.; Cook, E. R.; 
Ghose, A. K.; Mathiowetz, A. M.; Spurlino, J. C.; Rubin, B.; Smith, D. L.; 
Pulvino, T. A.; Wahl, R. C., J. Med. Chem. 1995, 38, 2570. 
25. Levy, D. E.; Lapierre, F.; Liang, W.; Ye, W.; Lange, C. W.; Li, X.; Grobelny, D.; 
Casabonne, M.; Tyrrell, D.; Holme, K.; Nadzan, A.; Galardy, R. E., J. Med. 
Chem. 1998, 41, 199. 
26. Beckett, R. P.; Miller, A.; Spavold, Z. M.; Whittaker, M., Chem. Abstr. 1997, 
126, 7832. 
27. Beckett, R. P.; Miller, A.; Spavold, Z. M.; Whittaker, M., Chem. Abstr. 1997, 
126, 18654. 




29. Hidalgo, M.; Eckhardt, S. G., J. Natl. Cancer I. 2001, 93 (3), 178-193. 
30. Peterson, J. T., Cardiovascular Research 2006, 69 (3), 677-687. 
31. Puerta, D. T.; Cohen, S. M., Curr. Top. Med. Chem. 2004, 4 (15), 1551-1573. 
32. Mookhtiar, K. A.; Marlowe, C. K.; Bartlett, P. A.; Van Wart, H. E., Biochemistry 
1987, 26, 1962. 
33. Goulet, J. L.; Kinneary, J. F.; Durette, P. L.; Stein, R. L.; Harrison, R. K.; 
Izquierdo-Martin, M.; Kuo, D. W.; Lin, T. Y.; Hagmann, W. K., Bioorg. Med. 
Chem. Lett. 1994, 4, 1221. 
34. Puerta, D. T.; Lewis, J. A.; Cohen, S. M., J. Am. Chem. Soc. 2004, 126 (27), 
8388-8389. 
35. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, 
K. D., J. Med. Chem. 2002, 45 (12), 2615-2623. 
36. Puerta, D. T.; Mongan, J.; Tran, B. L.; McCammon, J. A.; Cohen, S. M., J. Am. 
Chem. Soc. 2005, 127 (41), 14148-14149. 
37. Puerta, D.; Griffin, M.; Lewis, J.; Romero-Perez, D.; Garcia, R.; Villarreal, F.; 
Cohen, S., J. Biol. Inorg. Chem. 2006, 11 (2), 131-138. 
38. Johnson, S. L.; Jung, D.; Forino, M.; Chen, Y.; Satterthwait, A.; Rozanov, D. V.; 
Strongin, A. Y.; Pellecchia, M., J. Med. Chem. 2005, 49 (1), 27-30. 
39. Powers, J. C.; Asgian, J. L.; Ekici, Ö. D.; James, K. E., Chem. Rev. 2002, 102 
(12), 4639-4750. 
40. Mladenovic, M.; Fink, R. F.; Thiel, W.; Schirmeister, T.; Engels, B., J. Am. 
Chem. Soc. 2008, 130 (27), 8696-8705. 
149 
 
41. Lecaille, F.; Kaleta, J.; Brömme, D., Chem. Rev. 2002, 102 (12), 4459-4488. 
42. Huet, G.; Flipo, R.; Richet, C.; Thiebaut, C.; Demeyer, D.; Balduyck, M.; 
Duquesnoy, B.; Degand, P., Clin Chem 1992, 38 (9), 1694-1697. 
43. Fuentes-Prior, P.; Salvesen, G. S., Biochem. J. 2004, 384 (2), 201-232. 
44. Denault, J.-B.; Salvesen, G. S., Chem. Rev. 2002, 102 (12), 4489-4500. 
45. Talanian, R. V.; Brady, K. D.; Cryns, V. L., J. Med. Chem. 2000, 43 (18), 
3351-3371. 
46. Goode, D. R.; Sharma, A. K.; Hergenrother, P. J., Org. Lett. 2005, 7 (16), 
3529-3532. 
47. Talanian, R. V.; Quinlan, C.; Trautz, S.; Hackett, M. C.; Mankovich, J. A.; 
Banach, D.; Ghayur, T.; Brady, K. D.; Wong, W. W., J. Biol. Chem. 1997, 272 
(15), 9677-9682. 
48. Thornberry, N. A.; Rano, T. A.; Peterson, E. P.; Rasper, D. M.; Timkey, T.; 
Garcia-Calvo, M.; Houtzager, V. M.; Nordstrom, P. A.; Roy, S.; Vaillancourt, J. 
P.; Chapman, K. T.; Nicholson, D. W., J. Biol. Chem. 1997, 272 (29), 
17907-17911. 
49. Grütter, M. G., Curr. Opin. Struct. Biol. 2000, 10 (6), 649-655. 
50. Evans, M. J.; Cravatt, B. F., Chem. Rev. 2006, 106 (8), 3279-3301. 
51. Sadaghiani, A. M.; Verhelst, S. H.; Bogyo, M., Curr. Opin. Chem. Biol. 2007, 11 
(1), 20-28. 




53. Kidd, D.; Liu, Y.; Cravatt, B. F., Biochemistry 2001, 40 (13), 4005-4015. 
54. Patricelli, M. P.; Giang, D. K.; Stamp, L. M.; Burbaum, J. J., PROTEOMICS 
2001, 1 (9), 1067-1071. 
55. Greenbaum, D.; Medzihradszky, K. F.; Burlingame, A.; Bogyo, M., Chem. Biol. 
2000, 7 (8), 569-581. 
56. Kato, D.; Boatright, K. M.; Berger, A. B.; Nazif, T.; Blum, G.; Ryan, C.; 
Chehade, K. A. H.; Salvesen, G. S.; Bogyo, M., Nat Chem Biol 2005, 1 (1), 
33-38. 
57. Li, Y.-M.; Xu, M.; Lai, M.-T.; Huang, Q.; Castro, J. L.; DiMuzio-Mower, J.; 
Harrison, T.; Lellis, C.; Nadin, A.; Neduvelil, J. G.; Register, R. B.; Sardana, M. 
K.; Shearman, M. S.; Smith, A. L.; Shi, X.-P.; Yin, K.-C.; Shafer, J. A.; Gardell, 
S. J., Nature 2000, 405 (6787), 689-694. 
58. Saghatelian, A.; Jessani, N.; Joseph, A.; Humphrey, M.; Cravatt, B. F., Proc. 
Natl. Acad. Sci. USA 2004, 101 (27), 10000-10005. 
59. Chan, E. W. S.; Chattopadhaya, S.; Panicker, R. C.; Huang, X.; Yao, S. Q., J. Am. 
Chem. Soc. 2004, 126 (44), 14435-14446. 
60. Sieber, S. A.; Niessen, S.; Hoover, H. S.; Cravatt, B. F., Nat Chem Biol 2006, 2 
(5), 274-281. 
61. Patricelli, M. P.; Szardenings, A. K.; Liyanage, M.; Nomanbhoy, T. K.; Wu, M.; 
Weissig, H.; Aban, A.; Chun, D.; Tanner, S.; Kozarich, J. W., Biochemistry 2006, 
46 (2), 350-358. 
151 
 
62. Hekmat, O.; Kim, Y.-W.; Williams, S. J.; He, S.; Withers, S. G., J. Biol. Chem. 
2005, 280 (42), 35126-35135. 
63. Vocadlo, D. J.; Hang, H. C.; Kim, E.-J.; Hanover, J. A.; Bertozzi, C. R., Proc. 
Natl. Acad. Sci. USA 2003, 100 (16), 9116-9121. 
64. Salisbury, C. M.; Cravatt, B. F., Proc. Natl. Acad. Sci. USA 2007, 104 (4), 
1171-1176. 
65. Adam, G. C.; Sorensen, E. J.; Cravatt, B. F., Nat Biotech 2002, 20 (8), 805-809. 
66. Barglow, K. T.; Cravatt, B. F., Chem. Biol. 2004, 11 (11), 1523-1531. 
67. Adam, G. C.; Burbaum, J.; Kozarich, J. W.; Patricelli, M. P.; Cravatt, B. F., J. 
Am. Chem. Soc. 2004, 126 (5), 1363-1368. 
68. Speers, A. E.; Cravatt, B. F., J. Am. Chem. Soc. 2005, 127 (28), 10018-10019. 
69. Okerberg, E. S.; Wu, J.; Zhang, B.; Samii, B.; Blackford, K.; Winn, D. T.; 
Shreder, K. R.; Burbaum, J. J.; Patricelli, M. P., Proc. Natl. Acad. Sci. USA 2005, 
102 (14), 4996-5001. 
70. Greenbaum, D.; Baruch, A.; Hayrapetian, L.; Darula, Z.; Burlingame, A.; 
Medzihradszky, K. F.; Bogyo, M., Mol. Cell. Proteomics 2002, 1 (1), 60-68. 
71. Leung, D.; Hardouin, C.; Boger, D. L.; Cravatt, B. F., Nat Biotech 2003, 21 (6), 
687-691. 
72. Terai, T.; Nagano, T., Curr. Opin. Chem. Biol. 2008, 12 (5), 515-521. 
73. Zhang, J.; Campbell, R. E.; Ting, A. Y.; Tsien, R. Y., Nat. Rev. Mol. Cell Biol. 
2002, 3 (12), 906-918. 
74. Wang, H.; Nakata, E.; Hamachi, I., ChemBioChem 2009, 10 (16), 2560-2577. 
152 
 
75. Mank, M.; Griesbeck, O., Chem. Rev. 2008, 108 (5), 1550-1564. 
76. van Dongen, E. M. W. M.; Evers, T. H.; Dekkers, L. M.; Meijer, E. W.; Klomp, 
L. W. J.; Merkx, M., J. Am. Chem. Soc. 2007, 129 (12), 3494-3495. 
77. Kihara, T.; Nakamura, C.; Suzuki, M.; Han, S.-W.; Fukazawa, K.; Ishihara, K.; 
Miyake, J., Biosens. Bioelectron. 2009, 25 (1), 22-27. 
78. Chen, N.; Huang, Y.; Yang, L.; Liu, R.; Yang, J. J., Chem. Eur. J. 2009, 15 (37), 
9311-9314. 
79. Chen, N.; Zou, J.; Wang, S.; Ye, Y.; Huang, Y.; Gadda, G.; Yang, J. J., 
Biochemistry 2009, 48 (15), 3519-3526. 
80. Jost, C. A.; Reither, G.; Hoffmann, C.; Schultz, C., ChemBioChem 2008, 9 (9), 
1379-1384. 
81. Lin, C.-W.; Ting, A. Y., Angew. Chem., Int. Ed. 2004, 43 (22), 2940-2943. 
82. Zhang, J.; Ma, Y.; Taylor, S. S.; Tsien, R. Y., Proc. Natl. Acad. Sci. USA 2001, 
98 (26), 14997-15002. 
83. Wang, Y.; Botvinick, E. L.; Zhao, Y.; Berns, M. W.; Usami, S.; Tsien, R. Y.; 
Chien, S., Nature 2005, 434 (7036), 1040-1045. 
84. Xiong, C.; Lu, W.; Zhang, R.; Tian, M.; Tong, W.; Gelovani, J.; Li, C., Chem. 
Eur. J. 2009, 15 (36), 8979-8984. 
85. Maxwell, D.; Chang, Q.; Zhang, X.; Barnett, E. M.; Piwnica-Worms, D., 
Bioconjugate Chem. 2009, 20 (4), 702-709. 
86. Mizukami, S.; Kikuchi, K.; Higuchi, T.; Urano, Y.; Mashima, T.; Tsuruo, T.; 
Nagano, T., FEBS letters 1999, 453 (3), 356-360. 
153 
 
87. Sexton, K. B.; Witte, M. D.; Blum, G.; Bogyo, M., Bioorg. Med. Chem. Lett. 
2007, 17 (3), 649-653. 
88. Pratt, M. R.; Sekedat, M. D.; Chiang, K. P.; Muir, T. W., Chem. Biol. 2009, 16 
(9), 1001-1012. 
89. Blum, G.; Mullins, S. R.; Keren, K.; Fonovic, M.; Jedeszko, C.; Rice, M. J.; 
Sloane, B. F.; Bogyo, M., Nat Chem Biol 2005, 1 (4), 203-209. 
90. Blum, G.; von Degenfeld, G.; Merchant, M. J.; Blau, H. M.; Bogyo, M., Nat 
Chem Biol 2007, 3 (10), 668-677. 
91. Tsien, R. Y., Angew. Chem., Int. Ed. 2009, 48, 5612-5626. 
92. Fernandez-Suarez, M.; Ting, A. Y., Nat. Rev. Mol. Cell Biol. 2008, 9, 929-943. 
93. Biju, V.; Itoh, T.; Ishikawa, M., Chem. Soc. Rev. 2010, 39, 3031-3056. 
94. Domaille, D. W.; Que, E. L.; Chang, C. J., Nat. Chem. Biol. 2008, 4, 168-175. 
95. Wang, X.; Nguyen, D. M.; Yanez, C. O.; Ahn, H. Y.; Bondar, M. V.; Belfield, K. 
D., J. Am. Chem. Soc. 2010, 132 (35), 12237-12239. 
96. Kim, H. J.; Han, J. H.; Kim, M. K.; Lim, C. S.; Kim, H. M.; Cho, B. R., Angew. 
Chem., Int. Ed. 2010, 49, 6786-6789. 
97. www.invitrogen.com. 
98. Edgington, L. E.; Berger, A. B.; Blum, G.; Albrow, V. E.; Paulick, M. G.; 
Lineberry, N.; Bogyo, M., Nat. Med. 2009, 15, 967-973. 
99. Li, J.; Yao, S. Q., Org. Lett. 2009, 11, 405-408. 
100.Watzke, A.; Kosec, G.; Kindermann, M.; Jeske, V.; Nestler, H. P.; Turk, V.; Turk, 
B.; Wendt, K. U., Angew. Chem., Int. Ed. 2008, 47, 406-409. 
154 
 
101. Baruch, A.; Jeffery, D. A.; Bogyo, M., Trends Cell Biol. 2004, 14, 29-35. 
102. Aye-Han, N. N.; Li, Q.; Zhang, J., Curr. Opin. Chem. Biol. 2009, 13, 392-397. 
103. Zhang, X. B.; Waibel, M.; Hasserodt, J., Chem. Eur. J. 2010, 16, 792-795. 
104. Uttamchandani, M.; Li, J.; Sun, H.; Yao, S. Q., ChemBioChem 2008, 9, 667-675. 
105. Blum, G.; Weimer, R. M.; Edgington, L. E.; Adams, W.; Bogyo, M., PLoS One 
2009, 4, e6374. 
106. Weinert, E. E.; Dondi, R.; Colloredo-Melz, S.; Frankenfield, K. N.; Mitchell, C. 
H.; Freccero, M.; Rokita, S. E., J. Am. Chem. Soc. 2006, 128 (36), 11940-11947. 
107. Sellars, J. D.; Landrum, M.; Congreve, A.; Dixon, D. P.; Mosely, J. A.; Beeby, 
A.; Edwards, R.; Steel, P. G., Org. Biomol. Chem. 2010, 8, 1610-1618. 
108. Lo, L. C.; Pang, T. L.; Kuo, C. H.; Chiang, Y. L.; Wang, H. Y.; Lin, J. J., J. 
Proteome Res. 2002, 1, 35-40. 
109. Zhu, Q.; Girish, A.; Chattopadhaya, S.; Yao, S. Q., Chem. Commun. 2004, 
1512-1513. 
110. Srinivasan, R.; Huang, X.; Ng, S. L.; Yao, S. Q., ChemBioChem 2006, 7, 32-36. 
111. Komatsu, T.; Kikuchi, K.; Takakusa, H.; Hanaoka, K.; Ueno, T.; Kamiya, M.; 
Urano, Y.; Nagano, T., J. Am. Chem. Soc. 2006, 128, 15946-15947. 
112. Blais, D. R.; Br lotte, M.; Qian, Y.; B langer, S.; Yao, S. Q.; Pezacki, J. P., J. 
Proteome Res. 2010, 9, 912-923. 




114.Lo, L. C.; Chiang, Y. L.; Kuo, C. H.; Liao, H. K.; Chen, Y. J.; Lin, J. J., Biochem. 
Biophys. Res. Commun. 2005, 326, 30-35. 
115. Cravatt, B. F.; Wright, A. T.; Kozarich, J. W., Annu. Rev. Biochem. 2008, 77, 
383-414. 
116. Lee, M. R.; Baek, K. H.; Jin, H. J.; Jung, Y. G.; Shin, I., Angew. Chem., Int. Ed. 
2004, 43, 1675-1678. 
117. Loh, Y.; Shi, H.; Hu, M.; Yao, S. Q., Chem. Commun. 2010, 46, 8407-8409. 
118. Rajendran, L.; Knolker, H. J.; Simons, K., Nat. Rev. Drug Disc. 2010, 9, 29-42. 
119. Stewart, K. M.; Horton, K. L.; Kelley, S. O., Org. Biomol. Chem. 2008, 6, 
2242-2255. 
120. Futaki, S., Biopolymers 2006, 84, 241-249. 
121. Mayer, G.; Heckel, A., Angew. Chem., Int. Ed. 2006, 45, 4900-4921. 
122. Rothman, D. M.; Vazquez, E. M.; Vogel, E. M.; Imperiali, B., Org. Lett. 2002, 4 
(17), 2865-2868. 
123. Manoury, B.; Hewitt, E. W.; Morrice, N.; Dando, P. M.; Barrett, A. J.; Watts, C., 
Nature 1998, 396, 695-699. 
124. Kim, H. M.; Cho, B. R., Chem. Commun. 2009, 153164. 
125. Pawlicki, M.; Collins, H. A.; Denning, R. G.; Anderson, H. L., Angew. Chem., 
Int. Ed. 2009, 48, 3244-3266. 




127. Neveu, P.; Aujard, I.; Benbrahim, C.; Le Saux, T.; Allemand, J. F.; Vriz, S.; 
Bensimon, D.; Jullien, L., Angew. Chem., Int. Ed. 2008, 47, 3744-3746. 
128.Zhu, Y.; Pavlos, C. M.; Toscano, J. P.; Dore, T. M., J. Am. Chem. Soc. 2006, 128, 
4267-4276. 
129. Kwan, D. H.; Chen, H. M.; Ratananikom, K.; Hancock, S. M.; Watanabe, Y.; 
Kongsaeree, P. T.; Samuels, A. L.; Withers, S. G., Angew. Chem., Int. Ed. 2011, 
50, 300-303. 
130. Ng, S. L.; Yang, P. Y.; Chen, K. Y. T.; Srinivasan, R.; Yao, S. Q., Org. Biomol. 
Chem. 2008, 6, 844-847. 
131. Yang, P. Y.; Wu, H.; Lee, M. Y.; Xu, A.; Srinivasan, R.; Yao, S. Q., Org. Lett. 
2008, 10, 1881-1884. 
132. Tan, L. P.; Wu, H.; Yang, P. Y.; Kalesh, K. A.; Zhang, X.; Hu, M.; Srinivasan, 
R.; Yao, S. Q., Org. Lett. 2009, 11, 5102-5105. 
133. Overall, C. M.; Kleifeld, O., Nat. Rev. Cancer 2006, 6, 227-239. 
134. Jacobsrn, F. E.; Lewis, J. A.; Cohen, S. M., ChemMedChem 2007, 2, 152-171. 
135.Lewis, J. A.; Mongan, J.; McCammon, J. A.; Cohen, S. M., ChemMedChem 2006, 
1, 694-697. 
136. Yan, Y. L.; Cohen, S. M., Org. Lett. 2007, 9, 2517-2520. 
137. Agrawal, A.; Romero-Perez, D.; Jacobsen, J. A.; Villarreal, F. J.; Cohen, S. M., 
ChemMedChem 2008, 3, 812-820. 
138. Brik, A.; Wu, C. Y.; Wong, C. H., Org. Biomol. Chem. 2006, 4, 1446-1457. 
157 
 
139. Kalesh, K. A.; Yang, P. Y.; Srinivasan, R.; Yao, S. Q., QSAR Comb. Sci. 2007, 
26, 1135-1144. 
140. Wang, J.; Uttamchandani, M.; Li, J.; Hu, M.; Yao, S. Q., Org. Lett. 2006, 8, 
3821-3824. 
141. Forino, M.; Sherida, J.; Wong, T. Y.; Rozanov, D. V.; Savinov, A. Y.; Li, W.; 
Fattorusso, R.; Becattini, B.; Orry, A. J.; Jung, D.; Abagyan, R. A.; Smith, J. W.; 
Alibek, K.; Liddington, R. C.; Strongin, A. Y.; Pellecchia, M., Proc. Natl. Acad. 
Sci. U.S.A. 2005, 102, 9499-9504. 
142. Kolb, H. C.; Sharpless, K. B., Drug Discovery Today 2003, 8, 1128-1137. 
143. Aucagne, V.; Leigh, D. A., Org. Lett. 2006, 8, 4505-4507. 
144. Appukkuttan, P.; Dehaen, W.; Fokin, V. V.; Van der Eycken, E., Org. Lett. 2004, 
6, 4223-4225. 
145. Hansen, T. V.; Wu, P.; Fokin, V. V., J. Org. Chem. 2005, 70, 7761-7764. 
146. Beckmann, H. S. G.; Wittmann, V., Org. Lett. 2007, 9, 1-4. 
147. Barral, K.; Moorhouse, A. D.; Moses, J. E., Org. Lett. 2007, 9, 1809-1811. 
148. Arkin, M. R.; Wells, J. A., Nat. Rev. Drug Disc. 2004, 3, 301-317. 
149. Erlanson, D. A.; Braisted, A. C.; Raphael, D. R.; Randal, M.; Stroud, R. M.; 
Gordon, E. M.; Wells, J.; Proc, n., Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 
9367-9372. 
150. Szczepankiewicz, B. G., J. Am. Chem. Soc. 2003, 125, 4087-4096. 
151. Birk, A.; Lin, Y. C.; Elder, J.; Wong, C. H., Chem. Biol. 2002, 9, 891-896. 
158 
 
152.Whiting, M.; Muldoon, J.; Lin, Y. C.; Silverman, S. M.; Lindstrom, W.; Olson, A. 
J.; Kolb, H. C.; Finn, M. G.; Sharpless, K. B.; Elder, J. H.; Fokin, V. V., Angew. 
Chem., Intl. Ed. 2006, 45, 1435-1439. 
153. Best, M. D.; Birk, A.; Chapman, E.; Lee, L. V.; Cheng, W. C.; Wong, C. H., 
ChemBioChem 2004, 5, 811-819. 
154. Lee, L. V.; Mitchell, M. L.; Huang, S. J.; Fokin, V. V.; Sharpless, K. B.; Wong, 
C. H., J. Am. Chem. Soc. 2003, 125, 9588-9589. 
155. Srinivasan, R.; Uttamchandani, M.; Yao, S. Q., Org. Lett. 2006, 8, 713-716. 
156. Manetsch, R.; Krasinski, A.; Radic, Z.; Raushel, J.; Taylor, P.; Sharpless, K. B.; 
Kolb, H. C., J. Am. Chem. Soc. 2004, 126, 12809-12818. 
157. Pagliai, F.; Pirali, T.; Del Grosso, E.; Di Brisco, R.; Tron, G. C.; Sorba, G.; 
Genazzani, A. A., J. Med. Chem. 2006, 49, 467-470. 
158. Reddy, M. M.; Kodadek, T., Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 
12672-12677. 
159. Takahashi, M.; Nokihara, K.; Mihara, H., Chem. Biol. 2003, 10, 53-60. 
160. Rao, B. G., Curr. Pharm. Des. 2005, 11, 295-322. 
161. Kramer, B.; Rarey, M.; Lengauer, T.; Klebe, G., J. Mol. Biol. 1996, 261, 
470-489. 
162. Saghatelian, A.; Cravatt, B. F., Nat Chem Biol 2005, 1 (3), 130-142. 
163.Greenbaum, D. C.; Arnold, W. D.; Lu, F.; Hayrapetian, L.; Baruch, A.; Krumrine, 
J.; Toba, S.; Chehade, K.; Brömme, D.; Kuntz, I. D.; Bogyo, M., Chem. Biol. 
2002, 9 (10), 1085-1094. 
159 
 
164. Wang, J.; Uttamchandani, M.; Sun, L. P.; Yao, S. Q., Chem. Commun. 2006,  
(7), 717-719. 
165. Chen, G. Y. J.; Uttamchandani, M.; Zhu, Q.; Wang, G.; Yao, S. Q., 
ChemBioChem 2003, 4 (4), 336-339. 
166. Funeriu, D. P.; Eppinger, J.; Denizot, L.; Miyake, M.; Miyake, J., Nat Biotech 
2005, 23 (5), 622-627. 
167. Liu, Z.; Shao, P.; Huang, Z.; Liu, B.; Chen, T.; Qin, J., Chem. Commun. 2008,  
(19), 2260-2262. 
168. Sorg, A.; Siegel, K.; Brückner, R., Chem. Eur. J. 2005, 11 (5), 1610-1624. 
169. Li, S.-L.; Jiang, K.-J.; Shao, K.-F.; Yang, L.-M., Chem. Commun. 2006,  (26), 
2792-2794. 
170. Yang, P. Y.; Liu, K.; Ngai, M. H.; Lear, M. J.; Wenk, M.; Yao, S. Q., J. Am. 










9.1 Supplemental Tables 
 
Table 9-1. ID of “Click” products 





 1 3-A1 D 3-C1 
2 3-A2 D 3-C2 
3 3-A3 D 3-C3 
4 3-A4 D 3-C4 
5 3-A5 D 3-C5 
6 3-A6 D 3-C6 
7 3-A7 D 3-C7 
8 3-A8 D 3-C8 
9 3-A9 D 3-C9 
10 3-A10 D 3-C10 
11 3-A11 D 3-C11 
12 3-A12 D 3-C12 
13 3-A13 D 3-C13 
14 3-A14 D 3-C14 
15 3-A15 D 3-C15 
16 3-A16 D 3-C16 
17 3-A17 D 3-C17 
18 3-A18 D 3-C18 
19 3-A19 D 3-C19 
20 3-A20 D 3-C20 
21 3-A21 D 3-C21 
22 3-A22 D 3-C22 
23 3-A23 D 3-C23 
24 3-A24 D 3-C24 
25 3-A25 D 3-C25 
26 3-A26 D 3-C26 
27 3-A27 D 3-C27 
28 3-A28 D 3-C28 
29 3-B1 E 3-C1 
30 3-B2 E 3-C2 
31 3-B3 E 3-C3 
161 
 
32 3-B4 E 3-C4 
33 3-B5 E 3-C5 
34 3-B6 E 3-C6 
35 3-B7 E 3-C7 
36 3-B8 E 3-C8 
37 3-B9 E 3-C9 
38 3-B10 E 3-C10 
39 3-B11 E 3-C11 
40 3-B12 E 3-C12 
41 3-B13 E 3-C13 
42 3-B14 E 3-C14 
43 3-B15 E 3-C15 
44 3-B16 E 3-C16 
45 3-B17 E 3-C17 
46 3-B18 E 3-C18 
47 3-B19 E 3-C19 
48 3-B20 E 3-C20 
49 3-B21 E 3-C21 
50 3-B22 E 3-C22 
51 3-B23 E 3-C23 
52 3-B24 E 3-C24 
53 3-B25 E 3-C25 
54 3-B26 E 3-C26 
55 3-B27 E 3-C27 
56 3-B28 E 3-C28 
 
 
Table 9-2. The average IC50 values of three Hits 
 MMP-7 MMP-8 MMP-13 
A8(a) - - - 
A23 37.3±1.8 μM 73.7±3.7 μM 42.5±2.1 μM 
A25 24.0±1.2 μM 97.9±4.9 μM 36.5±1.8 μM 















Table 9-3. The average Ki values of three Hits 
  MMP-7 MMP-8 MMP-13 
A8(a) - - - 
A23 17.6±0.8 μM ND 24.8±1.2 μM 
A25 14.1±0.7 μM ND 20.9±1.0 μM 
          (a) has solubility problems the screening conditions and therefore Ki  
was not determined. ND: not determined  
 
 
9.2 Supplemental Figures 
 




















































































































































































Figure 9-1. Enzymatic screening of uncaged 2-P5 against recombinant PTPs (PTP1B, 
TCPTP, PTPB, LMWPTP) monitored by microplate reader.  
 
    




























    





































Figure 9-2. (A) Time-dependent emission spectra of uncaged 2-P6 after adding PTP1B 
(protein:probe = 1:40). (B) The time-dependent steady state fluorescence emission spectra of 
uncaged 2-P6 react with PTP1B from 0 min to 150 min. 
 




















Figure 9-3. Two-photon action spectra of Fluorescein, uncaged 2-P5 + PTPB (protein:probe 









































Figure 9-4. (A) Two-photon action spectra of dye 2-22, uncaged 2-P6 + PTPB (protein:probe 
= 1:40) and uncaged 2-P6 only in Hepes buffer (1×). (B) The time dependent two-photon 





Inhibitor (33.3 µM) 
STS (500 nM)   


























Figure 9-5. (A) Live cell imaging. (Left) normal HeLa cells treated with 2-P1; (Middle) 
apoptotic HeLa cells treated with 2-P1 (33.3 µM, 0.3% DMSO); (Right) apoptotic HeLa cells 
treated with 2-P1 (33.3 µM, 0.3% DMSO) and inhibitor (Calbiochem # 218826, 33.3 µM) 
mixture. Scale Bar: 20 µm. All images were acquired the same way. (B) Immunofluorescence 
with anti-Caspase 3 antibody. (Left) Apoptotic HeLa cells treated with 2-P1 and primary & 
secondary antibodies. Both 488 and 543 channels were showed strong fluorescent signals and 
could be merged well. (Middle): Apoptotic HeLa cells treated with 2-P1 and secondary 
antibody only. The 488 channel showed the Caspase-3 activities in the cells. The 543 channel 
showed background level of secondary antibody. (Right) Apoptotic HeLa cells only. Both 
488 and 543 channels showed the background levels. Nucleus was stained with Hoechest 
(pseudo-colored in Blue).  
 
      (A) 
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Figure 9-6. (A) Fluorescence microscopic images of Hela cells treated with 2-P5 (20 µM, 1 
hr) and exposed under UV (1000 μJ/cm2) for 10 min. A strong green fluorescence was 
observed when the cells were excited at 488 nm (a-1) comparing with the negative controls: 
2-P5 without UV explosure (a-2), DMSO (a-3) and blank (a-4). All images were acquired the 
same way. (B) Fluorescence microscopic images of 2-P5 and 2-P6 excited at 800 nm. (b-1) 
2-P5 with UV exposure; (b-2) 2-P5 without UV exposure; (b-3) 2-P6 with UV exposure; 




Figure 9-7. (A) Live cell imaging using 2-C1 and 2-C2. The Apoptotic HeLa cells were 
treated with 2-C1 and 2-C2 respectively at 33.3 µM concentration. Both of them showed 








Figure 9-8. The ELF
® 
97 Endogenous Phosphatase Detection Kit (Invitrogen, E6601) was 
used to detect endogenous PTP activity in vivo. Without permeabilizing the cell, ELF
® 
97 was 
incubated with live HeLa cells. The fluorescence signals were monitored by every 20 seconds. 
Results indicated most endogenous PTP activities in live HeLa cells were cytosolic, consistent 























































































































































































Figure 9-9. Graphs for determining IC50
 



































































































































Figure 9-10. Graphs for determining Ki
 
















































     
 
 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































*** Acquisition  Parameters ***
DATE_t : 20:53:17




NS :             16
NUCLEUS : off
O1 :        1853.43 Hz
SFO1 :   300.1318534 MHz
*** 1D NMR Plot Parameters ***
NUCLEUS : off

















































































































































































































































































*** Acquisition  Parameters ***
AQ_mod : qsim
AUNM : au_zg
BF1 :   125.7577890 MHz
BF2 :   500.1300000 MHz
BF3 :   125.7577890 MHz
DATE_t : 00:32:49
DATE_d : Dec 13 2010
DBP07 : edit
INSTRUM : av500
NS :           2608
O1 :       13204.57 Hz
O2 :        2000.52 Hz
PARMODE : 1D
SFO1 :   125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
TE :          300.0 K
*** Processing Parameters ***
AZFW :          0.500 ppm
LB :           1.00 Hz
MAXI :       10000.00 cm
MI :           0.00 cm
PC :           1.40
WDW : EM
*** 1D NMR Plot Parameters ***
Start :         224.36 ppm
Stop :         -14.43 ppm
Hz_cm :        1416.51











































































































































































































































































































































































































*** Acquisition  Parameters ***
AQ_mod : dqd
AUNM : au_zg
BF1 :   300.1300000 MHz
BF2 :   300.1300000 MHz
BF3 :   300.1300000 MHz















DE :            6.0 usec
DECBNUC : off
DECIM :             32
DECNUC : off
DECSTAT : DO










DR :             18
DS :              0
DSLIST : SSSSSSSSSSSSSSS





FL1 :             90 dB
FL2 :             90 dB
FL3 :             90 dB
FL4 :             90 dB
FOV :          20.00 cm
FW :      125000.00 Hz
GRDPROG :
HL1 :              1 dB
HL2 :             35 dB
HL3 :             16 dB
HL4 :             17 dB
INSTRUM : spect
LOCNUC : 2H
NBL :              1
NC :             -2
NS :             16
NUCLEUS : off
O1 :        1853.43 Hz
O2 :        1853.43 Hz
O3 :        1853.43 Hz
PAPS : QP
PARMODE : 1D
PHP :              1




PROBHD : 5 mm QNP 1H/13C/31P/19F Z3246/0214
PROSOL : no
PULPROG : zg30
QNP :              1
RG :   322.5000000
RO :             20 Hz
SEOUT : HR
SFO1 :   300.1318534 MHz
SFO2 :   300.1318534 MHz
SFO3 :   300.1318534 MHz
SOLVENT : DMSO
SW :        17.9519 ppm
SW_h :       5387.931 Hz
TD :          32768










V9 :           5.00 sec
VCLIST : CCCCCCCCCCCCCCC




WBST :           1024
WBSW :      4.0000000 MHz
XL :              0
YL :              0
YMAX_a : 1220306816.0000000
YMIN_a : -924429056.0000000
*** Processing Parameters ***
AZFW :          0.100 ppm
*** 1D NMR Plot Parameters ***
SR :           1.06 Hz
NUCLEUS : off







































































































































































































































































*** Acquisition  Parameters ***
LOCNUC : 2H
NS :          15901
NUCLEUS : off
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :    125.7709936 MHz
SOLVENT : DMSO
SW :       238.7675 ppm
TD :          65536
TE :          300.0 K
*** Processing Parameters ***
LB :           1.00 Hz
SF :    125.7577890 MHz




















































































































































































































































































































































































































































































































































































































































*** Acquisition  Parameters ***
AQ_mod : dqd
AUNM : au_zg
BF1 :   500.1300000 MHz
BF2 :   500.1300000 MHz
BF3 :   500.1300000 MHz
DATE_t : 21:42:55
DATE_d : Dec 18 2010
DBP07 : edit
INSTRUM : av500
NS :             44
O1 :        3088.51 Hz
O2 :        3088.51 Hz
PARMODE : 1D
SFO1 :   500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
TE :          300.0 K
*** Processing Parameters ***
AZFW :          0.100 ppm
LB :           0.30 Hz
MAXI :           4.50 cm
MI :           0.00 cm
PC :           1.00
WDW : EM
*** 1D NMR Plot Parameters ***
Start :          16.48 ppm
Stop :          -4.18 ppm
Hz_cm :         487.29













































































































































































































































*** Acquisition  Parameters ***
AQ_mod : qsim
AUNM : au_zg
BF1 :   125.7577890 MHz
BF2 :   500.1300000 MHz
BF3 :   125.7577890 MHz
DATE_t : 21:45:48
DATE_d : Dec 18 2010
DBP07 : edit
INSTRUM : av500
NS :            824
O1 :       13204.57 Hz
O2 :        2000.52 Hz
PARMODE : 1D
SFO1 :   125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
TE :          300.0 K
*** Processing Parameters ***
AZFW :          0.500 ppm
LB :           1.00 Hz
MAXI :       10000.00 cm
MI :           0.00 cm
PC :           1.40
WDW : EM
*** 1D NMR Plot Parameters ***
Start :         224.26 ppm
Stop :         -14.53 ppm
Hz_cm :        1416.51
















































































































































































































































































































*** Acquisition  Parameters ***
INSTRUM : av500
LOCNUC : 2H
NS :            201
NUCLEUS : off
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :   500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
TD :          32768
*** Processing Parameters ***
LB :           0.30 Hz























































































































































































































































































*** Acquisition  Parameters ***
INSTRUM : av500
LOCNUC : 2H
NS :           1824
NUCLEUS : off
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :   125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
TD :          65536
*** Processing Parameters ***
LB :           1.00 Hz







































































































































































































































































































































































































































*** Acquisition  Parameters ***
BF1 :   300.1300000 MHz
LOCNUC : 2H
NS :             32
O1 :        1853.43 Hz
PULPROG : zg30
SFO1 :   300.1318534 MHz
SOLVENT : CDCl3
SW :        17.9519 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        320.653 degree
PHC1 :          2.436 degree
1H normal range AC300
ag04suy 7






































































































































































































































*** Acquisition  Parameters ***
BF1 :     75.4677490 MHz
LOCNUC : 2H
NS :          13545
O1 :        7924.11 Hz
PULPROG : zgpg30
SFO1 :     75.4756731 MHz
SOLVENT : CDCl3
SW :       238.2968 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         40.610 degree
PHC1 :          1.021 degree
13C Standard AC300
ag04suy 8














*** Acquisition  Parameters ***
BF1 :   121.4948510 MHz
LOCNUC : 2H
NS :             16
O1 :       -6074.78 Hz
PULPROG : zgpg30
SFO1 :   121.4887762 MHz
SOLVENT : CDCl3
SW :       399.5734 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        -78.535 degree
PHC1 :         34.595 degree
31P AC300
ag04suy 6






































































































































































































































































*** Acquisition  Parameters ***
BF1 :   300.1300000 MHz
LOCNUC : 2H
NS :             32
O1 :        1853.43 Hz
PULPROG : zg30
SFO1 :   300.1318534 MHz
SOLVENT : DMSO
SW :        17.9519 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :         58.372 degree
PHC1 :        -10.187 degree
1H normal range AC300



























































































































































































































































*** Acquisition  Parameters ***
BF1 :     75.4677490 MHz
LOCNUC : 2H
NS :           2609
O1 :        7924.11 Hz
PULPROG : zgpg30
SFO1 :     75.4756731 MHz
SOLVENT : DMSO
SW :       238.2968 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :          8.017 degree
PHC1 :        -24.869 degree
13C Standard AC300













*** Acquisition  Parameters ***
BF1 :   121.4948510 MHz
LOCNUC : 2H
NS :              8
O1 :       -6074.78 Hz
PULPROG : zgpg30
SFO1 :   121.4887762 MHz
SOLVENT : DMSO
SW :       399.5734 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        -62.449 degree
PHC1 :         23.903 degree
31P AC300
























































































































































































































*** Acquisition  Parameters ***
BF1 :   500.1300000 MHz
LOCNUC : 2H
NS :             29
O1 :        3088.51 Hz
PULPROG : zg30
SFO1 :   500.1330885 MHz
SOLVENT : MeOD
SW :        20.6557 ppm
*** Processing Parameters ***
LB :           0.30 Hz
PHC0 :        146.720 degree
PHC1 :         -0.006 degree




























































































































































*** Acquisition  Parameters ***
BF1 :   125.7577890 MHz
LOCNUC : 2H
NS :            105
O1 :       13204.57 Hz
PULPROG : zgpg30
SFO1 :   125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :        169.946 degree





















































*** Acquisition  Parameters ***
D[1] :      1.0000000 sec
D[33] :      0.0000000 sec
DATE_t : 05:05:52
DATE_d : Mar 17 2007
NS :              1
O2 :        3088.51 Hz
SFO1 :   500.1330885 MHz
SOLVENT : CDCl3
SW :        20.6557 ppm
SW_h :      10330.579 Hz
*** Processing Parameters ***
LB :           0.30 Hz
*** 1D NMR Plot Parameters ***
Start :           9.00 ppm
Stop :          -1.00 ppm
SR :          12.74 Hz












































































*** Acquisition  Parameters ***
D[1] :      2.0000000 sec
D[33] :      0.0000000 sec
DATE_t : 05:09:58
DATE_d : Mar 17 2007
NS :            300
O2 :        2000.52 Hz
SFO1 :   125.7709936 MHz
SOLVENT : CDCl3
SW :       238.7675 ppm
SW_h :      30030.030 Hz
*** Processing Parameters ***
LB :           1.00 Hz
*** 1D NMR Plot Parameters ***
Start :         224.40 ppm
Stop :         -14.39 ppm
SR :          -0.21 Hz














































































*** Acquisition  Parameters ***
AQ_mod : dqd
AUNM : au_zg
BF1 :   300.1300000 MHz
DATE_t : 05:31:52
DATE_d : Mar 08 2007
NS :             16
O2 :        1853.43 Hz
PARMODE : 1D
RG :   143.6999969
SFO1 :   300.1318534 MHz
SOLVENT : CDCl3
SW :        17.9519 ppm
SW_h :       5387.931 Hz
TE :          300.0 K
YMAX_a : 1220161152.0000000
YMIN_a : -926127360.0000000
*** 1D NMR Plot Parameters ***
SR :          11.64 Hz


































































































*** Acquisition  Parameters ***
AQ_mod : dqd
AUNM : au_zg
BF1 :     75.4677490 MHz
DATE_t : 05:36:09
DATE_d : Mar 08 2007
NS :            212
O2 :        1200.52 Hz
PARMODE : 1D
RG : 32768.0000000
SFO1 :     75.4756731 MHz
SOLVENT : CDCl3
SW :       238.2968 ppm
SW_h :      17985.612 Hz
TE :          300.0 K
YMAX_a : 1221259136.0000000
YMIN_a : -915546560.0000000
*** 1D NMR Plot Parameters ***
SR :           7.70 Hz



































































































































*** Acquisition  Parameters ***
DATE_t : 16:48:09
DATE_d : Aug 30 2007
NS :             16
SFO1 :   300.1318534 MHz
SOLVENT : DMSO
*** Processing Parameters ***
SF :   300.1300011 MHz
*** 1D NMR Plot Parameters ***
Start :          11.00 ppm
Stop :          -0.50 ppm


























































































































*** Acquisition  Parameters ***
DATE_t : 16:54:43
DATE_d : Aug 30 2007
NS :             16
SFO1 :   300.1318534 MHz
SOLVENT : DMSO
*** Processing Parameters ***
SF :   300.1300011 MHz
*** 1D NMR Plot Parameters ***
Start :          11.00 ppm
Stop :          -0.50 ppm













































































































































































































*** Acquisition  Parameters ***
DATE_t : 16:59:33
DATE_d : Aug 30 2007
NS :             16
SFO1 :   300.1318534 MHz
SOLVENT : DMSO
*** Processing Parameters ***
SF :   300.1300010 MHz
*** 1D NMR Plot Parameters ***
Start :          11.00 ppm
Stop :          -0.50 ppm
1H normal range AC300 pdt-25
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